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ABSTRACT 
 
Red blood cells are the most abundant cell type in mammals, although, they are mostly 
described as inert carriers of haemoglobin that function only in gas exchange and transport. 
Evidence is now mounting that these enucleate cells are more complex than previously 
understood. Studies have reported that red blood cells from healthy individuals regulate 
immune cell activity and maturation, but red blood cells from inflammatory disease cohorts are 
dysfunctional. Red blood cells are known to bind a small number of chemokines and have been 
described as a sink for these molecules, and the loss of this activity is correlated with disease 
progression. 
This results of this thesis support a broader role for red blood cells in regulating inflammation 
by acting as a cytokine buffer and modulating cell activity. The aims and hypotheses of this 
thesis were founded on the discovery that red blood cells are a major reservoir for the pro-
inflammatory cytokine, macrophage migration inhibitory factor (MIF); in fact, they contribute 
1000-fold more per millilitre than plasma. Red blood cells were also identified to be a major 
reservoir of 30 additional cytokines, chemokines, and growth factors. Further investigation 
showed that red blood cells bind and release significant quantities of these proteins, a function 
that can be modulated by other cells and by enzyme inhibitors. Incubating red blood cells with 
a cancer cell line (A549 cells) resulted in the significant increase of eight pro-tumorigenic 
cytokines in the red blood cell lysates. These primed red blood cells altered the activity of 
lymphocytes by stimulating the proliferation of T cells compared to controls, and promoted the 
expression of cell activation markers. 
This study supports the hypothesis that red blood cells act as a buffer for cytokines through 
binding and release, and that alterations in red blood cells from cell-to-cell interactions affects 
the activity of T cells. This thesis proposes that red blood cells have multiple functions and the 
results have implications for the study of inflammation, the role of red blood cells in 
diagnostics, and on the development of red blood cell derived therapeutics.  
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MCHC        Mean corpuscular haemoglobin concentration 
MCP‐1        Monocyte chemotactic protein 1 
MCP‐3        Monocyte chemotactic protein 3 
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MIG        Monokine induced by gamma interferon 
MIP‐1α       Macrophage inflammatory protein 1 alpha 
MIP‐1β       Macrophage inflammatory protein 1 beta 
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mRNA        Messenger RNA 
xxiii 
 
MSC        Mesenchymal stem cell 
NaCl        Sodium chloride 
NAP‐2        Neutrophil‐activating peptide‐2 
β‐NGF        Beta nerve growth factor 
PBMC        Peripheral blood mononuclear cell 
PBS        Phosphate buffered saline 
PDGF‐BB      Platelet derived growth factor 
PHA‐P        Phytohemagglutinin‐P 
PI        Propidium iodide 
PLT        Platelet 
pRBC        Primed red blood cells 
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PREAMBLE 
 
The research outlined in this thesis was a result of a discovery whilst investigating macrophage 
migration inhibitory factor (MIF) as a potential biomarker for osteoarthritis. In a double-blind 
placebo controlled trial of stem cell therapy for osteoarthritis, our industry partner (Regeneus 
Pty Ltd) identified that MIF serum levels were significantly reduced over time following stem 
cell treatment. This lead to the hypothesis that MIF may be an optimal biomarker to track 
treatment outcome following stem cell therapy. 
This thesis was initiated to optimise the protocol of blood collection, handling, and processing 
for MIF analysis. The following data was produced by the thesis candidate. In the preliminary 
stages of research for this thesis, initial results found that the method of sample processing 
could result in substantially varied MIF concentrations (Figure X.1.). Blood collected from a 
single individual at one time point could be processed using different methods to produce 
serum or plasma samples that, in turn, produced varied results (Figure X.1.).   
 
Figure X.1. Concentration of macrophage migration inhibitory factor (MIF) in serum and 
plasma samples collected from a single individual produced with a variety of different 
commercially available collection tubes, as measured by enzyme-linked immunosorbent assay 
(n = 1).  
 
 
In an effort to correct for these variations by reducing the time between venepuncture and 
storage, the MIF concentration in whole lysed blood was analysed. For this analysis, whole 
blood was collected and immediately snap frozen to achieve complete cellular lysis. The 
intention of this was to determine the total MIF concentration in whole blood that had not been 
xxvii 
 
subjected to a variety of sample preparation methods or the time required for this processing. 
This whole blood lysate was then analysed using a MIF ELISA (enzyme-linked 
immunosorbent assay). The results of this were unexpected and demonstrated that the 
concentration of MIF in whole blood lysate was approximately 1000-fold higher than plasma 
or serum levels (Figure X.2).  
 
 
Figure X.2. Concentration of macrophage migration inhibitory factor (MIF) in whole blood 
lysate (according to one millilitre of whole blood) or in plasma as measured by ELISA. Data 
are presented as mean ± standard deviation (n = 5).  
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CHAPTER 
  
--------------------------------------------------------------------------- 
 
INTRODUCTION 
 
 
 
This introduction provides an overview of mature red blood cells and the role they play in the 
immune system. The historical view of red blood cells is that, although they are the most 
abundant cell type in humans, they are inert bystanders in inflammatory processes and function 
only in the transport of gas down an oxygen gradient. This chapter introduces the complexity 
of the development, structure, and function of mature red blood cells. The role that red blood 
cells may play in inflammation is also investigated with particular emphasis on the interaction 
between red blood cells and inflammatory molecules (cytokines). Finally, as addressed in the 
aims of this thesis, an outline of the potentially detrimental implications on the quantification 
of these cytokines in samples of blood will be outlined. 
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1.1  BIOLOGY OF RED BLOOD CELLS 
 
Red blood cells are a unique cell type in mammals and they are a crucial component of human 
medical treatment, with over 100 million units of blood collected worldwide every year. When 
mature, these cells lack a nucleus and organelles, and are the most abundant cell type in 
humans. As a result of their seemingly simple structure they were previously believed to have 
a single role, which was the transport of gas. Evidence is now mounting that red blood cells 
are more complicated than once thought and are clearly performing important secondary roles. 
Although these cells lack organelles, they have been shown to contain an antioxidant complex 
which responds quickly to the local environment, are regulated by a rich tapestry of enzymes, 
and contain more than 2000 unique proteins of which a number are still listed as having 
‘unknown functions’. The intricacies of these cells are still being unravelled, even today. 
 
1.1.1   Red blood cell development and death 
Mammalian mature red blood cells are enucleate and are the most abundant cell type in the 
human body with a total of approximately 25 trillion cells, which equates to almost two thirds 
of the total number of cells in the body1,2. Mature red blood cells arise from nucleated erythroid 
progenitor cells in the bone marrow and they survive for approximately 120 days in the 
circulation before being degraded.  
1.1.1.1 Red blood cell development 
The majority of the maturation of red blood cells from progenitor cells occurs in the bone 
marrow, including red blood cell enucleation3. Approximately 2.5 million immature red blood 
cells are released from the bone marrow every second to maintain total red cell number in the 
circulation4. These immature red blood cells are known as reticulocytes and make up 
approximately 1 % of the circulating red cells5. Although reticulocytes lack a nucleus, when 
they are released from the bone marrow they have not yet lost their organelles and thus have 
the capacity to translate protein. The process of reticulocyte maturation to a mature red blood 
cell takes approximately 2 days and includes the elimination of all organelles (with the 
exception of the proteasome) and the restructuring of the cell membrane into the classic bi-
concave shape6–8. The mitochondria from these cells are removed by a combination of 
enzymatic degradation and cell excretion in vacuoles9,10. Less is understood about the 
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elimination of the other organelles, but it has been proposed to include secretion in exosomes 
or autophagy, also known as self-digestion11. Whilst the cells are still nucleated, proteins and 
enzymes integral for red blood cell function such as haemoglobin are produced and remain in 
the cells even after loss of the nucleus and other organelles. 
1.1.1.2 Red blood cell death 
Mature red blood cells survive for approximately 120 days in the circulation before being 
phagocytosed by macrophages in the liver and the spleen12,13. These cells present a ‘self-
maker’, CD47, during their lifespan which prevents engulfment, but as they age they become 
senescent and the level and/or distribution of CD47 on the cell surface can change14,15. This 
alteration in the level of CD47 stimulates the macrophages in the liver and the spleen to remove 
these old cells from the system15,16. 
 
1.1.2   Structure of red blood cells 
In the absence of organelles, the cytoplasm is largely composed of haemoglobin, a 
cytoskeleton, and a 20S proteasome. The haemoglobin is required for the primary role of gas 
exchange, the cytoskeleton maintains the classic bi-concave shape of the cell, and the 
proteasome is tasked with controlled degradation of unwanted or oxidatively damaged 
proteins6,17. Red blood cells, and in particular their membranes, are required to survive repeated 
mechanical stress in their movements through the circulation and the microvasculature18. The 
biconcave shape of these cells and the cytoskeleton enables the required flexibility under these 
sheer forces (Figure 1.1). Unlike the cytoskeletons of most cells, the skeleton of the red blood 
cells sits directly underneath the cell membrane and does not traverse across the cytoplasm19. 
This structure is tethered to the membrane and as such, enables the cells to squeeze through the 
microvasculature at high speeds without permanent damage.  
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Figure 1.1. Illustration of the deformability of a human red blood cell as it moves through 
a microfluidic channel as presented in Li et al.18. 
 
The distinctiveness of red blood cells can be largely attributed to its cellular membrane, the 
most complicated component of red blood cells. The red blood cell membranes have a high 
proportion of membrane-associated enzymes20,21, and they display specific blood group 
antigens. In addition to these unique features, these membranes also contain many of the 
regular components on membranes of nucleated cells, including ligand receptors22 and 
transmembrane transport channels23. Curiously, red blood cell membranes can be isolated by 
centrifugation at approximately 16,000 g24. This number is six times lower than what is needed 
to isolate other cellular membranes which require ultracentrifugation at approximately 
100,000 g25. The reason for this disparity may be a result of the abnormal cytoskeleton tethered 
to the membrane, but this feature is minimally discussed in the literature. Red blood cells are 
also particularly susceptible to osmotic changes in the environment and can be readily 
dehydrated or lysed. Following hypotonic lysis, the red blood cell membranes are capable of 
resealing if the tonicity is restored26. These reformed membranes are referred to as red blood 
cell ghosts. In light of this, lysis has been used as a method to deplete the cells of haemoglobin 
and other intracellular soluble components, and load these empty, theoretically inert, ghosts 
with target molecules such as drugs or cytokines27,28. Slavin et al. demonstrated that bFGF-
loaded red blood cell ghosts promoted wound healing and extended the duration of therapeutic 
benefit compared with application of the recombinant protein alone28. This supposition that red 
blood cell ghosts are inert carriers may not be entirely accurate. Almost all of the enzymatic 
machinery of these cells is located on the red blood cell membrane, so exclusion of the 
cytoplasmic component of the cell is unlikely to render the membrane non-functional. In fact, 
it has been demonstrated that the enzymatic activity of red blood cell membranes is retained as 
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well as the function of the calcium and sodium pumps29,30. Whilst the biological implications 
of this are not understood, it is worthy of further investigation. 
 
1.1.3   Function and activity of red blood cells 
1.1.3.1 Gas exchange and oxidative stress 
The primary documented function of red blood cells is gas exchange wherein they transport 
oxygen from the lungs to oxygen-poor tissues. Intracellular haemoglobin in these cells accounts 
for more than 95 % of the total cellular proteins and the iron core of these molecules enable the 
binding and release of oxygen or carbon dioxide as needed. The limitation of transporting 
oxygen on a regular basis is the resulting exposure to high levels of oxidative stress. Over time, 
haemoglobin is slowly oxidised by the endogenous reactive oxygen species (ROS) into 
methemoglobin at a rate of approximately 4 % per day31. This oxidation damages the protein 
to the point that it can no longer bind oxygen for transport32. Any additional release of ROS 
during this process is readily neutralised by the available intracellular antioxidant factors33. In 
addition to the intracellular oxidative stress pressure, exogenous ROS produced by cells such 
as T cells are also removed from the circulation by red blood cells34. As they can bind and 
readily neutralise these potentially damaging ions, red blood cells have been proposed as an 
oxidative sink for ROS34,35. In order to attenuate oxidative stress-induced damage, the red blood 
cells have a highly complex antioxidant system that encompasses both enzymatic (catalase and 
glutathione peroxidase)33,36 and non-enzymatic factors (glutathione and ascorbic acid)37,38. 
Whilst these processes are highly effective, cell damage occurs over the lifespan of red blood 
cells.  
The antioxidant system in red blood cells is mostly cytosolic, which makes the management of 
oxidative stress on the membrane less efficient. A build-up of ROS at the cell membrane 
typically leads to cell deformability and lipid peroxidation of the membrane, subsequently 
causing haemolysis39. If not managed quickly, oxidative stress-induced haemolysis can cause 
local tissue damage due to the unavoidable release of ROS40. In a healthy system, this is 
typically managed by younger red blood cells which are more readily able to mop up 
exogeneous ROS. However, this system does not work perfectly in inflammatory 
environments. As identified by Castillo et al., open heart surgery can cause further tissue 
damage as a result of ROS release40 and the free ROS observed in the local environment is 
likely a direct result of haemolysis41. Thus, red blood cells play a key role in maintaining 
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oxidative homeostasis, and any dysfunction of that activity is likely to cause detrimental 
downstream effects. 
1.1.3.2 Enzymes in red blood cells 
Enzymes in red blood cells and their membranes are ubiquitous. In the cytosol, enzymes such 
as catalase and glutathione peroxidase minimise the effects of oxidative stress33,36, and a 
protease complex (the 20S proteasome) degrades damaged proteins6. In addition, the red blood 
cell membrane contains a glycolytic enzyme complex that is necessary for cellular 
metabolism20, a number of ATPases to mediate ion transfer across the membrane21, and 
proteolytic enzymes42,43. This diverse group of enzymes is responsible for much of the 
observed activity of red blood cells. Surprisingly, a functional nitric oxide synthase has also 
been identified in both the membrane and the cytosol of red blood cells44. This report is a key 
example of the growing understanding around the complexity of red blood cell enzymes. 
Whilst many of the enzymes mentioned above were identified decades ago, this nitric oxide 
synthase was identified much more recently. Red blood cells have been considered for many 
years as a sink for nitric oxide and due to the high concentration of haemoglobin, have been 
described as metabolisers of this molecule. Contrary to conventional opinion, Kleinbongard et 
al. demonstrated that the red blood cells are not only a sink, but are also actively producing 
functional nitric oxide though a specific synthase44. Thus, the network of enzymes in red blood 
cells is complex and dictates much of the cellular activity in vivo; this points to functions 
beyond conventional red blood cell biology. 
1.1.3.3 Metabolism (glycolysis) 
Although mature red blood cells do not contain any organelles, they still need to metabolise 
glucose to manage their energy requirements and so, in the absence of mitochondria, anaerobic 
glycolysis by the Embden-Meyerhof pathway occurs. A glycolytic enzyme complex located on 
the red blood cell membrane is responsible for this activity20. Pathologies associated with these 
enzymes typically cause non-spherocytic haemolytic anaemia (premature degradation of red 
blood cells), a condition that can be lethal if left untreated45.  
1.1.3.4 Red blood cell proteome and gene expression 
There has been growing interest over the recent years in determining the full proteome of red 
blood cells. Optimising sample preparation techniques and analysis parameters has been 
challenging due to the overwhelming amount of haemoglobin in these cells compared to the 
concentration of all other proteins46. In light of those challenges, the most recent reviews report 
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that 2289 unique proteins have now been identified in red blood cells47. This represents a 
collection of studies that have identified smaller numbers of unique proteins. Pasini et al. 
assessed the structural and functional distribution of the proteins they identified in the red blood 
cell membrane48. As illustrated by Figure 1.2, more than half of the identified proteins were 
directly associated with the membrane or the cytoskeleton. Surprisingly, Pasini et al. identified 
that 6 % of the identified proteins were organellar proteins, including specific transport proteins 
for the Golgi network, the endoplasmic reticulum, and the mitochondria48.  
 
 
Figure 1.2. Subcellular localisation of the identified membrane proteins as illustrated in 
Pasini et al.48.  
 
Similarly, another study identified the presence of translation initiation factors and proteins for 
cellular defence, as well as the expected protein categories49. Of note, this study also reported 
that approximately 24 % of the total observed proteins had unknown functions and could not 
be categorised49. The complexity does not end here, with total RNA transcripts of 1019 genes 
now reported to be present in red blood cells50. These genes were identified as being relevant 
for many normal cellular processes including metabolism (52 %), programmed cell death 
(5 %), and even some genes for translation/transcription of protein (up to 5 %)50. Red blood 
cells contain considerably more active cellular components than their primary role would 
suggest and may be more complex than conventionally described. The complexity of these 
cells and the presence of unknown molecules warrants significant further investigation. 
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1.2  RED BLOOD CELLS AND INFLAMMATION 
 
Red blood cells are the most abundant cell type in the body and are directly exposed to a wide 
variety of tissues on their journey through the circulatory system. For many years, these cells 
have been described to be inert bystanders rather than participants in inflammatory processes. 
However, it is now clear that red blood cells are involved in many pathologies, although the 
specific nature of their involvement for the most part has not yet been elucidated, such as in 
the case of anaemia of chronic inflammation. Red blood cells themselves have also been shown 
to be immuno-stimulatory to specific cellular populations, and can cause cytokine storm events 
following their transfusion. It appears that we are only just scratching the surface of red blood 
cells and their role in inflammation, disease, and repair. 
 
1.2.1   Red blood cells in diagnostics 
Although red blood cells are largely believed to be inert, in regular clinical practice, red blood 
cell characteristics are collected and are used in diagnostics. These diagnostic processes are 
entirely biased towards evaluating the oxygen binding capacity of these cells with a focus on 
diagnosing different types of anaemia. A low red blood cell count, variations in the average 
size of the cells (mean corpuscular volume, MCV), or variations in the average amount of 
haemoglobin in each cell (mean corpuscular haemoglobin concentration, MCHC) can all be 
indicative of anaemia and are all collected as part of the standard full blood count panel. 
Outside of this, there is only one test used regularly that assesses red blood cells and is 
expressive of non-specific inflammation. This simple test has been used since the 19th century 
and it assesses the rate of erythrocyte sedimentation. A very high rate of sedimentation 
(compared to a normal range) indicates broad spectrum inflammation such as an infection or 
an auto-immune condition51,52. However, this is not an optimal biomarker of inflammation, as 
other plasma-derived markers such as C-reactive protein have shown to be more reliable and 
are more responsive to changes in the inflammatory microenvironment53. 
Although not yet used clinically for this purpose, Lippi et al. investigated the analysis of 
another red blood cell characteristic as a diagnostic marker for inflammation54. In this extensive 
study of almost 4000 participants, they identified that red blood cell distribution width (RDW) 
was closely correlated with inflammation as indicated by erythrocyte sedimentation rate and 
level of C-reactive protein. This correlation of RDW with inflammation has received a bit of 
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attention over the last five years. High RDW values have been reported as a risk factor for 
increased mortality in cardiovascular patients55, diabetics56, and patients with chronic 
lymphocytic leukemia57. Curiously, this increased risk of mortality is not isolated to specific 
diseases. Patel et al. demonstrated that high RDW values was a strong predictor of mortality in 
people over the age of 45 and was independent of anaemia and the presence of other diseases58. 
They hypothesised that this observation was a result of increased inflammation and oxidative 
stress58. In light of these results, analysis of red blood cells as an indicator of inflammation or 
overall health is likely a valuable addition to the standard blood analysis panels in clinic. 
 
1.2.2  Anaemia of chronic inflammation 
Anaemia of chronic inflammation is defined as normocytic, normochromatic anaemia, where 
the size and the haemoglobin load of the red blood cells is normal, but the anaemia is caused 
by there being fewer red blood cells in the circulation. The reduced number of red blood cells 
is a result of both increased red blood cell destruction and impaired differentiation of these 
cells59. Anaemia of chronic inflammation presents as a secondary condition to other chronic 
inflammatory diseases such as infection, cancer, or auto-immune conditions60,61. Whilst there 
is still a lot left to understand about this condition, a key molecule in its pathogenesis has now 
been identified62. High levels of this molecule, hepcidin, slows iron export into local tissue, 
thus resulting in lower levels of available iron63. This activity is in turn regulated by the 
presence of pro-inflammatory cytokines such as IL-664. Simultaneously in the pathogenesis of 
anaemia of chronic inflammation, the production of new red blood cells from the bone marrow 
is restricted by low levels of the red blood cell differentiation hormone, erythropoietin65, and 
by inhibiting the maturation of red blood cell progenitors in the bone marrow due to 
inflammatory cytokines59.  
Adequate treatment for the anaemia of chronic inflammation does not yet exist, and the 
recommendation is to focus on treating the underlying condition, as the anaemia typically 
improves once the primary condition is alleviated66. It is not yet understood if this anaemia is 
a result of the chronic inflammation and is a biological response to mediate the inflammation, 
or if the chronic inflammation is in part a result of the anaemia itself, and if the red blood cells 
are playing a role in the modulation of the levels of inflammatory molecules during disease 
progression. 
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1.2.3   Transfusion medicine 
Red blood cell transfusions are the most common blood derived therapeutic and have been used 
widely over the last century. As a transplant, they are generally well tolerated as donor 
matching only needs to be met at the blood type level. Due to its extensive history, the area of 
transfusion medicine has now moved away from optimising the treatment for the patient and 
into optimising the storage parameters for the blood products to extend their use. At the 
moment, red blood cells are stored at 4 °C for up to 42 days before use67. Although there is a 
lot known about the cause of most of the adverse reactions that can occur with red blood cell 
transfusion, there remains the controversial issue of the storage lesion. The storage lesion refers 
to the red blood cell deformability that can occur during long term storage. The debate 
regarding the implications of using these altered cells as a treatment is ongoing68. Whilst there 
are many studies that report a correlation between the transfusion of older (deformed) red blood 
cells and the occurrence of adverse events69,70, there are also studies that report no effect of 
storage duration at all71. This debate has been going on now for decades, and it doesn’t appear 
that an answer will be reached any time soon. 
A lot of analyses have been done in an attempt to determine exactly what occurs in red blood 
cells during storage. The morphology of these cells is known to change substantially over time, 
wherein they become more rigid and are more susceptible to haemolysis72. There are also a 
number of reports that suggest that these cells undergo oxidative damage during storage and 
begin to take on the qualities of senescent red blood cells73. Whilst others have focused more 
on the issue of cytokine release from stored blood74,75. Some adverse events following red 
blood cell transfusion were hypothesised to be a result of contaminating white blood cells 
which secrete a range of inflammatory proteins during storage76. Thus, transfusion of a blood 
pack containing both the contaminating white blood cells and the resulting cytokines could 
elicit a detrimental immune reaction. However, the evidence now suggests that leukodepletion 
does not entirely abolish the cytokine release74 and that in a number of situations it is no 
different to non-depleted red blood cells77,78. Weisbach et al. demonstrated that stored 
leukodepleted red blood cells actually produced significantly more IL-8 than the non-
leukodepleted red blood cells74.  
Regardless of these differences in red blood cell storage, there are longer term effects that have 
been noted as a result of red blood cell transfusions. For example, following hip replacement 
surgery (arthroplasty), 31 % of people who received red blood cell transfusions experienced 
wound healing delays and disruptions; this was significantly higher than the non-transfused 
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group79. Further, people receiving multiple transfusions typically have higher levels of 
circulating CD8+ cytotoxic T cells which has been suggested to be the cause of the 
immunosuppression observed following transfusions80,81. In fact, in a systematic review of the 
literature on the use of red blood cell transfusions, the authors concluded that these transfusions 
were strongly correlated with increased morbidity and mortality, and that on average, the risks 
of transfusion outweighed any potential benefit82. Infection was identified as a primary, 
independent, risk factor for red blood cell transfusion. Of note, this risk of infection was not 
correlated with transfusion-transmitted infections, but instead with transfusion-dependent 
immunomodulation resulting in increased susceptibility to infection82,83. These results and 
other similar studies demonstrate that the red blood cells that are transfused have long term and 
potentially lethal immunological effects, although the mechanisms of such are not well 
understood.  
 
1.2.4   Red blood cells and their interactions with other cells 
Most of the investigation into the activity of immune cells was, and still is for the most part, 
done in single cell cultures containing the target immune cell. The dogma of immunology 
teaches that the other cells of the blood (such as red blood cells or platelets) are inert and would 
not contribute to the overall activity of the immune system. However, all of the recent research 
into red blood cells suggests that this is unlikely to be the case. In response to the changing 
climate around red blood cells and their involvement in inflammatory conditions, a few 
laboratories across the world have started to investigate the specific interaction between red 
blood cells and other cell types. The majority of this investigation has focused on the role red 
blood cells play in altering the function of immune cells. 
1.2.4.1 T lymphocytes 
One of the first reports in this area documented the effect of red blood cells on freshly isolated 
T cells in vivo34. T cells are a subset of lymphocytes, and any increase in proliferation of these 
cells in vitro following stimulation is used as a model of immune activation. This initial paper 
reported that by stimulating T cells and treating them with fresh, autologous red blood cells 
their activity was significantly altered34. Red blood cells stimulated these T cells to proliferate 
more than the untreated control, and were also found to be protective for these cells against 
apoptosis34. These results have since been replicated under similar conditions and does not 
appear to be dependent on the ratio of red blood cells to T cells, but is dependent on the red 
blood cell being intact84–86. These studies have led to the question of whether or not this state 
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of T cell activation is actually its natural state in vivo, as they are always in contact with red 
blood cells. 
In particular disease or inflammatory states, red blood cells have been shown to be dysregulated 
in this activity in that they do not have the same effect on T cells that healthy red blood cells 
do85,87,88. As an example, red blood cells isolated from patients with carotid atherosclerosis 
were found to be no longer protective against T cell apoptosis85, and red blood cells isolated 
after hip arthroplasty were no longer immunogenic to the T cells unlike the cells isolated prior 
to the surgery87. It has been hypothesised that these results are representative of a dysregulation 
of T cell homeostasis that occurs in vivo, and may be involved in potentiating the conditions85.  
1.2.4.2 Dendritic cells 
Red blood cells from healthy donors have been shown to restrict the maturation of dendritic 
cells, and in the process, the secretion of IL-12(p40)89,90. This is proposed to be a mechanism 
for controlling the overstimulation of dendritic cells and the hyper release of pro-inflammatory 
cytokines in vivo90. However, in carotid atherosclerosis this system is dysfunctional similar to 
the observed effects on T cell survival. Red blood cells collected from patients with carotid 
atherosclerosis were less able to prevent the maturation of dendritic cells, and thus the secretion 
of pro-inflammatory cytokines89. 
1.2.4.3 Other immune cells 
There is minimal other literature on the interaction between red blood cells and immune cells 
other than T cells or dendritic cells. A 30 year old study reported that natural killer cells, when 
in the presence of red blood cells, were more cytotoxic towards tumour cells91. Virella et al. 
investigated the effect of autologous red blood cells on B cell activity and they reported a 
significant increase in the secretion of immunoglobulins and of the pro-inflammatory cytokine, 
IFN-γ92. Finally, a recent study reported that red blood cells promoted eosinophil migration 
through endothelial cells by scavenging the chemokine RANTES, thus suggesting a role for 
red blood cells in allergic inflammation93. 
1.2.4.4 Fibroblasts  
The interaction between red blood cells and fibroblasts, a non-immune cell type, has been 
evaluated extensively by one laboratory. This group demonstrated that the presence of red 
blood cells in a culture of fibroblasts alter the function and secretome of these cells. Unlike the 
effect of red blood cells on T cell proliferation and survival, red blood cells suppressed the 
proliferation of fibroblasts and stimulated apoptosis94. Red blood cells also promoted fibroblast 
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mediated contraction of collagen95, the secretion of the chemokine IL-896, and also the secretion 
of matrix metalloproteinases97. This modulation of fibroblast activity illustrates a role for red 
blood cells in the remodelling process of wound healing. 
1.2.4.5 Mechanism of action 
The mechanism of action for this modulation of cellular function by red blood cells has not yet 
been investigated in detail and thus there are multiple theories. Profumo et al. investigated the 
cause of the dysfunction in the red blood cells from carotid atherosclerosis patients that had 
altered T cell activity85. They reported that the result could be replicated in healthy red blood 
cells by subjecting them to oxidative stress, as such they concluded that it was a result of 
oxidative imbalance in the red blood cells85. Similarly, it was reported that treatment with 
healthy red blood cells reduced the level of oxidative stress in the target T cell population34. 
The report by Antunes et al. has been the only study thus far to perform an investigation into 
the factors responsible for the activity of healthy red blood cells on T cells86. In a series of 
experiments, they identified that the causative agent(s) were present in the red blood cell 
conditioned media, and were soluble protein factors that were sensitive to heat86. However, 
they were not able to identify the specific molecule(s) responsible for the activity. In the 
promotion of eosinophil migration, Kanda et al. attributed their results to red blood cells being 
able to bind the chemokine RANTES out of the media and thus play a role in chemotaxis98. 
There is growing evidence that these signalling molecules (cytokines and chemokines) at the 
centre of inflammatory processes may also be interacting with red blood cells, thus giving them 
a role in inflammation. 
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1.3   CYTOKINES IN RED BLOOD CELLS 
 
Cytokines are key mediators and signalling molecules in inflammation. Of the few reports on 
cytokines and red blood cells, the majority are restricted to discussion of the Duffy antigen 
receptor for chemokines (DARC) which is present on red blood cells, and the Gardos channel 
on red blood cells which is regulated by DARC (Figure 1.3). Outside of these areas, there is 
minimal other literature. Although there are some reports on cytokines in red blood cells, no 
study has attempted to quantify these proteins in a unit of these cells. This information is crucial 
for understanding the role of cytokine interactions with red blood cells in blood and the 
implications of haemolysis. 
 
 
 
Figure 1.3. Schematic of the current understanding of the interaction between cytokines and 
red blood cells. 
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1.3.1  Duffy antigen receptor for chemokines (DARC) 
DARC was first identified on red blood cells in 1950 and was described as a new blood group99. 
Since, it has been reported that DARC is not only present on red blood cells but is also 
expressed on some endothelial cells100. Since its identification, the majority of research on this 
receptor on red blood cells has focused on its role in malarial pathogenesis. Plasmodium 
species, the parasites that causes malaria, have been shown to use DARC on red blood cells to 
invade the cells and thus progress the infection101. More than 95 % of West Africans102, and 
68 % of African Americas103 are negative for the Duffy antigen receptor on their red blood 
cells, but are still positive for the receptor on their endothelial cells104. This has likely developed 
as an evolutionary advantage against malaria.  
1.3.1.1 Chemokine binding to red blood cells 
In addition to its role in malaria pathogenesis, another potential role of DARC was identified 
in 1991. Darbonne et al. reported the presence of a receptor on the surface of red blood cells 
that could readily bind IL-8 and implicated red blood cells as a biological sink for this 
chemokine24. Following this report, the same receptor was then described to be promiscuous 
as it was able to bind not only IL-8 but also some C-X-C (IL-8, GRO-α, NAP-2) or C-C 
(RANTES, MCP-1) chemokines105. Further analysis of this receptor identified that it was in 
fact DARC22,106. In the 20 years following these reports, only Eotaxin and MIP-1α have been 
identified as additional ligands for DARC22,107,108. Of the few cytokines that have been 
identified, the concentration of these in the red blood cells from healthy or diseased cohorts 
have never been reported. Due to the broad binding capacity of DARC on red blood cells, they 
have been implicated as sinks for circulating inflammatory markers24,109,110. Although this 
receptor is structurally similar to G-protein-coupled chemokine receptors with its seven 
transmembrane domains, unlike these receptors, ligation of DARC does not appear to activate 
intracellular chemokine signal transduction pathways22. In 1993, Neote et al. reported that 
RBC-bound IL-8 had no effect on mobilising Ca2+ ion stores, which is indicative of signal 
transduction with G-protein-coupled receptors105. Since that report, no other evidence of signal 
transduction has been identified. Similarly, no reference to phosphorylation of the receptor in 
the membrane or its ligand(s) have been reported in the literature. These results have been used 
to support the theory that the primary function of chemokine ligation of DARC is not in 
chemokine signalling, but instead as an inflammatory sink for these markers22,111. Investigation 
into the concentration of these cytokines in the red blood cells of healthy individuals or 
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individuals with inflammatory conditions may provide valuable information regarding disease 
state in the identification of biomarkers.  
Evidence is gathering that DARC on red blood cells, and cytokine ligation of this receptor 
plays a role in inflammatory disease. Whilst DARC negative individuals are less susceptible to 
malarial infection, they have been reported to have a higher risk of developing inflammatory 
conditions such as graft rejection112 or prostate cancer113. This is theorised to be a result of the 
reduced availability of a DARC mediated inflammatory sink114. Although the cytokine binding 
capacity of red blood cells in DARC negative individuals is lost, some capacity to bind excess 
inflammatory markers is retained by the DARC positive endothelial cells. This has been 
evidenced in animal knockout models. In mice lacking DARC from the red blood cells only, 
the overall level of IL-8 and MCP-1 being bound was reduced compared to the DARC positive 
control109. However, binding was still higher than that observed in the complete DARC 
knockout model (no DARC on the red blood cells or the endothelial cells)109. In addition to 
altered binding capacity of the cells, the inflammatory response to stimuli was exaggerated 
when DARC was not present in the animals109. 
Fukuma et al. sought to further investigate the role of DARC on red blood cells as an 
inflammatory sink for cytokines107. In this study, they treated DARC positive and negative 
mice with recombinant protein and monitored the protein half-life. They reported that in DARC 
negative mice, these chemokines were rapidly cleared upon administration. However, the half-
life of the proteins in the peripheral circulation was significantly higher in the DARC positive 
animals due to red blood cell sequestration. With these results, they hypothesised two roles for 
cytokine binding to DARC on red blood cells in managing inflammation. First, that DARC on 
red blood cells acts as an inflammatory sink to remove excess chemokines, and second, that it 
acts as a reservoir of these cytokines to release when they are needed107. The mechanisms 
behind chemokine release from DARC have since been investigated. Release of MCP-1 (a C-
C chemokine) from DARC is activated by two identified mechanisms, (1) clotting or (2) 
treatment with unfractionated heparin115. This discovery supports the hypothesis of Fukuma 
et al., that DARC is involved with both binding and releasing cytokines as needed107. Release 
of chemokines in response to clotting identifies a key role of DARC in inflammation. In vivo, 
clotting occurs at the site of injury or in the case of thrombi, and red blood cells are key to both 
of these processes. Thus, a bolus of chemokines released from red blood cells at the site of 
injury or thrombi may play a role in the resulting inflammatory processes. Humphries et al. 
identified that in a thrombus, MCP-1 levels increase and remain high until resolution and that 
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treatment with MCP-1 leads to accelerated thrombus clearance116. Red blood cells in the 
thrombus are likely to be a major source of this chemokine. Similarly, lung inflammation in 
response to lipopolysaccharide stimulation has been shown to be modulated by DARC. 
Neutrophil migration into the lungs in response to inflammatory stimuli is attenuated and the 
migration of mononuclear inflammatory cells is increased in DARC knockout models109,117,118. 
Local levels of DARC ligand chemokines are also reported to be higher in the lungs of these 
stimulated mice117,118. The results of these studies propose a notable role for cytokines binding 
to red blood cells in modulating immune responses.  
1.3.1.2  Red blood cell microparticles 
Red blood cell derived microparticles have also been demonstrated to be positive for the DARC 
receptor119. This chemokine binding receptor is not only present on the membranes of these 
microparticles, but it also retains its capacity to bind GRO-α out of solution119. Although ligand 
binding to DARC is possible on microparticles, its binding affinity is reduced compared to 
intact red blood cells119. The number of microparticles released from red blood cells increases 
over time with storage and the presence of these microparticles have been implicated as a 
potential risk for red blood cell transfusion120. Interaction with platelets has been demonstrated 
to stimulate the release of GRO-α from allogenic microparticles119. This models a biological 
interaction that may occur in vivo following red blood cell transfusion, which may play a role 
in the observed adverse reactions. 
1.3.1.3 Gardos channel 
The Gardos channel, present on red blood cells, regulates cell volume by transporting 
potassium ions across the cell membrane121 and plays an important role in promoting red blood 
cell dehydration in sickle cell anaemia23. Haemoglobin concentration in red blood cells 
increases as a result of cell dehydration which subsequently enhances the rate of haemoglobin 
polymerisation, a key characteristic of sickled red blood cells122,123. High levels of cytokines 
have been observed in the plasma of sickle cell anaemia patients, and these cytokines have 
been demonstrated to play a role in its pathogenesis124. Rivera et al. reported that the presence 
of select cytokines (including IL-10 and RANTES) at high levels increased the Gardos channel 
activity by up to 80 %125. Further investigation into this interaction identified that this activity 
was mediated, at least in part, by cytokine binding to DARC on red blood cells125,126. DARC 
positive red blood cells were found to be 17x more dense (and thus more dehydrated) than 
DARC negative red blood cells and the density of the DARC positive cells could be modulated 
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with the addition of RANTES or IL-8126. Whilst there are no reported downstream effects of 
cytokine binding to DARC on red blood cells, these studies suggest a functional role of 
cytokines on red blood cells that is additional to its role as a chemokine sink.  
 
1.3.2  Macrophage migration inhibitory factor (MIF) 
Macrophage migration inhibitory factor (MIF) is a pro-inflammatory cytokine and an oxido-
reductase enzyme that was first identified in 1966127. Since its identification, MIF has been 
shown to play a critical role in a wide range of inflammatory conditions. These conditions 
include sepsis, rheumatoid arthritis, and preeclampsia, and patients with these conditions 
typically have higher levels of the protein in their serum or plasma128–130. As such, considerable 
research has focused on MIF as a potential biomarker. However, MIF as a biomarker is 
complicated by the fact that many cells have been shown to produce and secrete MIF. This 
protein was originally identified in lymphocytes127, and has since been identified in 
macrophages and other inflammatory cells98,131, adipocytes132, liver cells133, and many other 
cell types. It is even secreted from the pituitary gland in response to infection134. There are 
reports, although few, that suggest that another source of MIF is mature red blood cells.  
Shortly after its identification, Fox et al. reported in 1974 that the activity of MIF from fetal 
calf serum was attenuated when red blood cells were present135. They hypothesised that this 
loss of activity was indicative of MIF being bound to the red blood cells and becoming 
inactivated. Since that report, red blood cells have been postulated to not only bind, but also 
harbour MIF. A strong correlation between haemoglobin concentration and the concentration 
of MIF in plasma or serum has been observed136,137. This rise in MIF concentration has been 
attributed to red blood cell derived MIF. However, this has been the extent of the investigation. 
Up until this point no study has sought to quantify the concentration of MIF in a unit of red 
blood cells nor to investigate its activity. In fact, it has been recommended to just avoid analysis 
of MIF where red blood cells may be present in order to minimise inference137, but this view 
is particularly short-sighted. Determining the concentration of MIF in red blood cells and its 
chemokine activity is likely to be crucial in understanding the inflammatory processes 
following haemolysis in vivo. MIF has two major documented functions that appear to be 
dependent on its cellular location. Secreted MIF has a primary role as a pro-inflammatory 
cytokine which modulates the migration of inflammatory cells138, and is dependent on its 
tautomerase active site139. Whilst the secondary role of MIF is largely intracellular and is a 
specific oxidoreductase activity which has been demonstrated to regulate cellular oxidative 
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stress140,141, this is likely the primary role that it is playing in red blood cells.  
The value in this analysis is made clearer by looking at a condition where MIF plays a key role, 
such as sepsis. MIF has been reported to be significantly elevated in the plasma of septic 
patients, and high levels of this protein have been correlated with early death in patients with 
severe sepsis142. Similarly, by inhibiting MIF, the survival rate of patients with severe sepsis 
improves signficantly143,144. Haemolysis is a common complication of sepsis, and haemoglobin 
has even been proposed as a potential biomarker for the condition145. In fact, Adamzik et al. 
reported that free haemoglobin levels were twice as high in the non-survivors of severe sepsis 
compared to the survivors145. It is likely that at least some of the MIF detected in the plasma of 
severe septic patients is a result of haemolysis and red blood cell release. Thus, assessment of 
where the MIF has come from and determining what concentration of MIF can be attributed to 
red blood cells could lead to improved therapeutic targets for treating sepsis, a condition with 
very high mortality (approximately 30 %). At the very least, this warrants further investigation. 
 
1.3.3  Other cytokines in red blood cells 
1.3.3.1 D-dopachrome tautomerase (DDT)  
D-dopachrome tautomerase (DDT), also known as MIF-2, has been described as a functional 
homologue of MIF146. Although DDT cannot replicate the same oxido-reductase activity of 
MIF, it shares its tautomerase and cytokine activity147,148. MIF and DDT bind to the same cell 
surface receptor complex formed between CD44-CD74, and ligation of this receptor leads to 
the same downstream effects146. These proteins tend to be localised to the same tissues and 
areas of the body, in fact, DDT has even been identified in red blood cells. Bjork et al. reported 
that red blood cells were responsible for approximately 99 % of the D-dopachrome tautomerase 
activity in whole blood and identified the presence of DDT in these cells149. The reason for its 
localisation in red blood cells is unknown, particularly since it does not share the same oxido-
reductase activities of MIF.  
1.3.3.2 Interleukin 33 (IL-33) 
IL-33 has also been identified in the red blood cell lysates of healthy individuals150. Notably, 
IL-33 is a nuclear protein that is released from dying or dead cells. As such, its presence in red 
blood cells, an enucleate cell, is unexpected. Wei et al. identified that IL-33 was expressed in 
erythroid progenitor cells, thus hypothesising that the protein had been present in the cells since 
they were nucleated150. IL-33 can be released from apoptotic or necrotic cells151 and its release 
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has been shown to stimulate the secretion of TH2 cytokines and play a key role in promoting 
allergic inflammation152. Haemolysis of red blood cells would thus result in a release of this 
cytokine into the soluble fraction of blood. In sickle cell anaemia patients, higher levels of IL-
33 in plasma were observed with increased levels of haemolysis150. This may have implications 
in the pathogenesis of the condition.   
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1.4    CURRENT ANALYTICAL STANDARDS 
 
1.4.1   Analysis and processing of blood 
Plasma and serum are the two most common components of blood analysed in research and 
clinical testing, and soluble disease markers in these fluids are regularly used as indicators of 
immune or disease status153. In the collection of these samples, the integrity of the other blood 
cells needs to be maintained for accurate, reproducible results. However, blood cells are 
particularly susceptible to stress induced by mechanical processing techniques. If blood 
processing takes longer than a few minutes, white blood cells are known to secrete a range of 
factors into the plasma or serum component that can interfere with results154. Similarly, 
excessive centrifugation or sample manipulation can lead to the activation and degranulation 
of platelets also resulting in higher detectable levels of cytokines155. With the knowledge that 
red blood cells may harbour a range of cytokines, careful processing of blood components is 
of paramount importance. As identified by Sobierajski et al., haemolysis in the process of 
isolating serum or plasma can result in high concentrations of detectable MIF137. Although 
panels of cytokines are not monitored on regular basis in clinical diagnostics, their analysis in 
research and clinical trials is becoming common. Thus, any source of interference in the 
quantification of proteins in serum or plasma, such as haemolysis, could confound results. The 
full implications of this however will not be understood until the concentration of these 
cytokines in red blood cells is determined and reported.  
1.4.1.1 Cell washing 
Although red blood cells account for approximately 50 % of the total volume of whole blood, 
in diagnostics they are discarded more often than they are analysed. Outside of the diagnostic 
arena, the protein content of red blood cells does occasionally get evaluated. There is a small 
number of studies that have investigated the proteome of red blood cells and their 
membranes48,49. However, the protocol for red blood cell isolation in these analyses encourages 
excessive washing of the target cells in an isotonic buffer48,49. Extensive washing such as this 
is strongly discouraged in the isolation of other blood cells such as neutrophils to avoid cell 
activation156, yet it is part of regular practice for red blood cell isolation, probably because the 
cells are considered to be transcriptionally and translationally inert and incapable of secretory 
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activity. Optimised methods for gentle isolation of red blood cells is likely to produce cells 
more representative of their native state. 
 
1.4.2   Case study: interleukin-8 
Interleukin-8 (IL-8) is regularly quantified in serum or plasma in clinical research. This protein 
is a chemokine and it is present in plasma at reported concentrations of approximately 7 pg/mL 
in healthy individuals and is associated with a number of conditions such as prostate cancer, 
kidney injury, and coronary syndrome157–159. In 1991, Darbonne et al. identified the presence 
of IL-8 in red blood cells and investigated their capacity to readily bind this protein24. They 
demonstrated that with the addition of IL-8 to the plasma fraction of whole blood, red blood 
cells bound the majority of this protein out of solution24. Whilst this was an interesting finding, 
it highlights an issue in quantifying IL-8 in only plasma or serum. If serum IL-8 levels were 
low, it would not be known if this was a true result or whether the red blood cells had bound 
the excess IL-8 during sample processing, thus creating an artefact. Without knowledge of the 
level of IL-8 bound to the red blood cells, it is difficult to elucidate the true abundance of the 
protein. As an example, people lacking DARC on their red blood cells tend to have higher 
circulating levels of IL-8 than people positive for DARC, which suggests that a fraction of the 
missing IL-8 is likely still there, it is just bound to red blood cells160. This adds variance in IL-
8 quantification even within the healthy population. These confounding factors in IL-8 
quantification in blood is likely to be similar for any other cytokines that are associated with 
red blood cells. Quantification these cytokines in a unit of red blood cells in addition to plasma 
or serum is necessary to elucidate the severity of the issue, and following that, analysis of both 
components may prove to be useful in identifying disease specific biomarkers. 
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1.5    PROJECT DETAILS 
 
1.5.1   Project outline 
There is growing evidence that red blood cells are more complex than was once thought, 
nevertheless, investigation into red blood cells and their response to the inflammatory micro-
environment has not received a lot of attention. There are relatively few publications that have 
investigated the relationship between cytokines and red blood cells, and out of those, none have 
followed up the analysis by investigating the effect of this on immune cell activity. In fact, 
none have sought to quantify these analytes in a unit of red blood cells. Most of the literature 
on cytokines associated with red blood cells is isolated to discussion on cytokine binding to 
DARC, with a small selection of literature that has identified the presence of other cytokines 
in red blood cells not affiliated with DARC. Preliminary data to this thesis identified the 
presence of MIF in red blood cells at 1000-fold higher than the plasma concentration. This 
discovery prompted further analysis into red blood cell derived MIF (Chapter 3), the presence 
of other red blood cell derived cytokines (Chapter 4), and the modulation of the cytokine profile 
of red blood cells and the effect on lymphocyte activity (Chapter 5).  
 
1.5.2   Study hypothesis 
The hypothesis of this study is that red blood cells are a key player in inflammation and that 
this activity is reliant upon their interaction with cytokines. 
 
1.5.3   Study aims 
The overall aim of this thesis was to quantify red blood cell-derived cytokines and to determine 
the role of these cells in the immune response. The specific aims of the study were: 
1. To elucidate the presence and the activity of macrophage migration inhibitory factor in 
red blood cells. 
2. To identify and quantify other cytokines associated with red blood cells. 
3. To modulate the cytokine profile of red blood cells using a variety of techniques 
including incubation with recombinant protein or through cell-to-cell interaction. 
4. To modulate the activity of lymphocytes by using red blood cells with altered cytokine 
profiles. 
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CHAPTER 
  
--------------------------------------------------------------------------- 
 
MATERIALS AND METHODS 
 
 
 
This chapter includes a summary of the materials, equipment, reagents, chemicals, and 
solutions used or referred to in this thesis. This chapter also details the methods that are 
common across multiple chapters. References to the relevant sections of the thesis that detail 
the methods used is also included. 
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2.1   MATERIALS 
 
The materials and equipment that were used to complete the experimental work presented in 
this thesis are outlined in Table 2.1. The reagents, chemicals, and cell lines used to complete 
the experimental work presented in this thesis are outlined in Table 2.2 and Table 2.3. Detail 
on the formulation and storage parameters for the solutions prepared and used for the 
completion of this thesis are outlined in Table 2.4. 
 
Table 2.1. Materials and equipment. 
Materials/Equipment Company 
35 µm nylon cell strainer Becton Dickinson, USA 
Annexin V detection kit BioLegend, USA 
BD Calibrite™ beads Becton Dickinson, USA 
Bio-Plex Pro Human Cytokine 21-plex assay Bio-Rad, USA 
Bio-Plex Pro Human Cytokine 27-plex assay Bio-Rad, USA 
Bio-Plex Pro II Wash Station Bio-Rad, USA 
FACSAria III Cell Sorter Becton Dickinson, USA 
FACScalibur Flow Cytometer Becton Dickinson, USA 
Hematology analyzer, Coulter AcT Diff Beckman Coulter, USA 
IncuCyte™ FLR Essen BioScience, USA 
K2EDTA vacutainers, 3 mL or 9 mL Becton Dickinson, USA 
Luminex® 200 system, Bio-Plex Bio-Rad, USA 
MIF ELISA R&D Systems, USA  
Nuclear Factor Fixation and Permeabilisation Buffer Set BioLegend, USA 
Pierce BCA (bicinchoninic acid) Protein Assay Kit ThermoFisher Scientific, Australia 
Synergy 2 Multi-Mode plate reader BioTek, USA 
Ultra-0.5 Centrifugal Filter Unit, 3K membrane Merck Group, Germany 
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Table 2.2. Reagents and chemicals. 
Reagent/Chemical Supplier 
(S,R)-3-(4-Hydroxyphenyl)-4,5-dihydro-5-isoxazole 
acetic acid (ISO-1) Merck Millipore, Australia 
5(6)-carboxyfluorescein diacetate N-succinimidyl ester 
(CFSE) Sigma Aldrich, USA 
Annexin V-FITC BioLegend, USA 
Antibiotic-antimycotic (100x) Life Technologies, USA 
Bis-Tris Sigma Aldrich, USA 
Bovine serum albumin (BSA) Sigma Aldrich, USA 
Crystal violet Merck Millipore, Australia 
Dextran, molecular weight 450-650 kDa Sigma Aldrich, USA 
Dimethyl sulfoxide (DMSO) Sigma Aldrich, USA 
Dulbecco’s Modified Eagle Medium (DMEM) with 
sodium pyruvate Life Technologies, USA 
Ethylenediaminetetraacetic acid, disodium salt (EDTA)  Sigma Aldrich, USA 
Fetal bovine serum (FBS) AusGeneX, Australia 
Ficoll-Paque GE Healthcare, Australia 
Haemoglobin, human Sigma Aldrich, USA 
Glacial acetic acid ThermoFisher Scientific, USA 
L-3,4 dihydroxyphenylalanine methyl ester ThermoFisher Scientific, USA 
L-glutamine (200 mM) Sigma Aldrich, USA 
Methanol Chem-Supply, Australia 
Mo anti-human CD3-APC antibody, clone: SK7 BioLegend, USA 
Mo anti-human CD3-FITC antibody, clone: UCHT1 BioLegend, USA 
Mo anti-human CD4-APC antibody, clone: RPA-T4 BioLegend, USA 
Mo anti-human CD44-PE antibody, clone: 515 Becton Dickinson, USA 
Mo anti-human CD45-FITC antibody, clone: H130 Affymetrix eBioscience, USA 
Mo anti-human CD74-FITC antibody, clone: MB741 Becton Dickinson, USA 
Mo anti-human CD8a-APC antibody, clone: HIT8a BioLegend, USA 
Mo anti-human GATA-3-PE antibody, clone: 16E10A23 BioLegend, USA 
Mo anti-human T-bet-PE antibody, clone: 4B10 BioLegend, USA 
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Reagent/Chemical Supplier 
Mo IgG1,κ Iso Control-APC, clone: MOPC-21 BioLegend, USA 
Mo IgG1,κ Iso Control-FITC, clone: MOPC-21 BioLegend, USA 
Mo IgG1,κ Iso Control-PE, clone: MOPC-21 BioLegend, USA 
Mo IgG1,κ Iso Control-PE, clone: MOPC-21 Becton Dickinson, USA 
Mo IgG1κ Iso Control-FITC, clone: P3.6.2.8.1 Affymetrix eBioscience, USA 
Mo IgG2a, κ Iso Control-FITC, clone: G155-178 Becton Dickinson, USA 
Mo IgG2b,κ Iso Control-PE, clone: MPC-11 BioLegend, USA 
Penicillin-streptomycin (100x) Sigma Aldrich, USA 
Phosphate buffered saline tablets (PBS) Astral Scientific, Australia 
Phytohemaggultinin-P Sigma Aldrich, USA 
Potassium chloride Sigma Aldrich, Australia 
Protease inhibitor cocktail, mini cOmplete (PrI) Roche, Switzerland 
Recombinant MIF Jomar Bioscience, Australia 
Red blood cell lysis solution Sigma Aldrich, USA 
RPMI-1640 with sodium bicarbonate Sigma Aldrich, USA 
Sodium chloride (NaCl) Sigma Aldrich, USA 
Sodium periodate (NaIO3) VWR Chemicals, Australia 
Trypan blue solution (0.4%) Sigma Aldrich, USA 
TrypLE Life Technologies, USA 
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Table 2.3. Cell lines. 
Cell line Supplier 
A549 cells Bill Walsh research laboratory, Kolling Institute, Australia 
Jurkat cells  Perinatal research laboratory, Kolling Institute, Australia 
 
 
Table 2.4. Solution formulations. 
Solution (concentration) Formulation 
Bis-Tris (200 mM) A 200 mM Bis-Tris solution was prepared by dissolving Bis-
Tris in Milli-Q water 
CFSE (1 mM and 5 µM) A stock solution of 1 mM CFSE was prepared by dissolving 
CFSE in DMSO; stock was stored in aliquots at minus 20 °C; 
as needed, aliquots were diluted further to working 
concentration of 5 µM in PBS 
Dextran solution (6 %) For a 6 % (w/v) dextran solution, dextran powder was 
dissolved in NaCl (0.15 M) and stored at room temperature 
EDTA (5 mM) A 5 mM solution of EDTA was prepared by dissolving EDTA 
in Milli-Q water 
Haemoglobin (25 mg/mL) Solutions of haemoglobin were prepared fresh for calibration 
curves by dissolving haemoglobin in PBS, starting at 
25 mg/mL 
ISO-1 (20 mM and 5 mM) ISO-1 powder was dissolved in DMSO (100 %) to make a 
20 mM stock; stock was stored in aliquots at minus 20 °C; as 
needed, aliquots were diluted further to working concentration 
5 mM in methanol 
L-3,4 
dihydroxyphenylalanine 
methyl ester (400 mM and 
12 mM) 
L-3,4 dihdyroxphenylalanine methyl ester powder was 
dissolved in Milli-Q water to make a 400 mM stock; stock was 
stored in aliquots at minus 20 °C; as needed, aliquots were 
further diluted to working concentration 12 mM in Milli-Q 
water 
Recombinant MIF (1 mM) Recombinant MIF was dissolved in PBS to 1 mM stock; stock 
was stored in aliquots at minus 80 °C 
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Solution (concentration) Formulation 
PHA-P (5 M) A 5 M stock solution was prepared by dissolving PHA-P in 
PBS; stock was stored in aliquots at minus 20 °C 
Potassium chloride, KCl 
(0.6 M) 
KCl was dissolved in Milli-Q water to prepare a 0.6 M solution 
which was stored at room temperature 
Sodium chloride, NaCl 
(0.15 M) 
0.15 M solution prepared by dissolving NaCl in Milli-Q water
Sodium periodate 
(400 mM and 24 mM) 
Sodium periodate was dissolved in Milli-Q water to make a 
400 mM stock; stock was stored in aliquots at minus 20 °C; as 
needed, aliquots were diluted further in Milli-Q water to make 
a 24 mM working solution  
Flow cytometry staining 
buffer 
For a flow cytometry staining buffer, a 0.5 % BSA solution 
was prepared by dissolved BSA in PBS; solution was stored in 
aliquots at 4 °C 
Turks solution Turks solution was prepared by adding glacial acetic acid to a 
final concentration of 1 % (v/v) and crystal violet to a final 
concentration of 0.05% into Milli-Q water; solution was stored 
at room temperature 
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2.2   METHODS 
 
2.2.1   Plasma and blood cell isolation 
Plasma and blood cells were isolated from EDTA anti-coagulated whole blood (k2 vacutainers, 
BD Biosciences) within four hours of collection. After isolation, the blood components were 
either used fresh or were frozen at -80 °C and were subjected to three freeze-thaw cycles at -
80 °C prior to analysis. 
2.2.1.1   Red blood cells (protocol 1) 
Red blood cells were isolated by dextran sedimentation (protocol 1) as in Chapter 3 and 
Chapter 4. Whole blood was added to a dextran solution (6 % w/v in 0.15 M sodium chloride) 
at a ratio of 2:1 in a 15 mL falcon tube. This tube was left upright at room temperature for 
1 hour to enable the red blood cells to sediment to the bottom of the tube (Figure 2.1). After 
the incubation, the upper white blood cell and platelet rich layer was discarded and the top of 
the red blood cell dense lower layer was also discarded to minimise contamination. The 
remaining red blood cell fraction was collected and was washed once in phosphate buffered 
saline (PBS, 500 g, 5 minutes).  
 
 
Figure 2.1. Schematic of dextran sedimentation of red blood cells from whole blood. 
 
2.2.1.2   Red blood cells (protocol 2) 
Red blood cells were isolated by an optimised dextran sedimentation method (protocol 2) as in 
Chapter 5. Whole blood was centrifuged (1500 g, 10 minutes) and the plasma layer was 
discarded. The red blood cell dense pellet was then resuspended in an equal volume of sodium 
Whole blood 
with dextran 
White blood cell 
and platelet rich 
layer 
Red blood cell 
dense layer 
Incubation 
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chloride (0.15 M) in a 15 mL falcon tube. A 6 % solution of dextran (w/v in 0.15 sodium 
chloride) was added to the cell suspension at a ratio of 1:4 (dextran:cells). This cellular 
suspension was then left at room temperature for 30 minutes to enable the red blood cells to 
sediment to the bottom of the tube (Figure 2.1). The upper white blood cell and platelet rich 
layer was discarded along with the top of the lower red blood cell layer to minimise 
contamination. The remaining red blood cell fraction was then collected and washed once in 
phosphate buffered saline (PBS, 500 g, 5 minutes). 
2.2.1.3   White blood cells (total population) 
White blood cells were isolated following dextran sedimentation (protocol 1). A 3 mL aliquot 
of whole blood was added to 1.5 mL of 6 % dextran solution (w/v in 0.15 sodium chloride) in 
a 15 mL falcon tube. This tube was then left to incubate for 60 minutes, after which the white 
blood cell rich fraction was collected (Figure 2.1). The white blood cell suspension was diluted 
in 10 mL of PBS and the cells were then isolated by centrifugation (1000 g, 10 minutes). 
Following isolation, any contaminating red blood cells were lysed by resuspending the cell 
pellet in 3 mL of Milli-Q water for 0.5 minutes. Addition of 1 mL of potassium chloride 
(0.6 M) restored isotonicity to the cell suspension. The remaining white blood cells were then 
pelleted and were washed once in 10 mL of PBS (1000 g, 5 minutes). 
2.2.1.4   Peripheral blood mononuclear cells (PBMCs) 
Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood using density 
gradient cell separation. Whole blood was diluted in an equal volume of PBS and was then 
carefully layered over Ficoll-Paque (2:1 ratio respectively, GE Healthcare). This was then 
centrifuged for 40 minutes (400 g, no brake). After centrifugation, the PBMC layer which had 
formed at the interface between the plasma and the Ficoll-Paque was isolated ( 
Figure 2.2) and was washed once with PBS (500 g, 5 minutes). Any contaminating red blood 
cells in the PBMC fraction were lysed with red blood cell lysis solution (Sigma Aldrich) for 
10 minutes at 37 °C, and the remaining white blood cells were then pelleted and were washed 
once in PBS (1000 g, 5 minutes). 
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Figure 2.2. Schematic of Ficoll-Paque isolation of peripheral blood mononuclear cells 
(PBMCs) from whole blood. 
 
2.2.1.5   Platelets 
Platelet-rich plasma was prepared by slow centrifugation of whole blood (100 g, 20 minutes). 
After this, the upper, platelet rich layer was collected (Figure 2.3) and contaminating cells were 
progressively removed by subsequent cycles of centrifugation of the upper isolated platelet rich 
fraction (100 g, 5 minutes). Platelets were then pelleted by centrifugation and were washed 
twice in PBS (1000 g, 5 minutes).  
 
 
Figure 2.3. Schematic of isolation of platelet rich plasma from whole blood. 
 
2.2.1.6   Plasma 
Plasma was isolated from anticoagulated whole blood by centrifugation at room temperature 
(1500 g, 10 minutes). Samples were stored at -80 °C prior to analysis. 
Centrifugation 
Ficoll-Paque 
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2.2.2   Cell counting 
Blood cells and immortalised cell lines used in analyses were counted by variety of methods. 
White blood cell and platelet depletion of enriched red blood cell populations were also 
quantified. 
2.2.2.1   Haematology analyser  
The cells in whole blood, red blood cell, white blood cell, and platelet populations were 
quantified using a haematology analyser (Coulter Act Diff, Beckman Coulter). Depletion of 
white blood cells and platelets from the enriched red blood cell populations was calculated 
according to the following equation using the values collected from the haematology analyser: 
 
Equation 2.1. Percentage depletion of contaminating cells from purified red blood cells. 
100 െ ቌ
ܽ
ܾ ൈ݀
ܿ ൈ100ቍ ൌ ܲ݁ݎܿ݁݊ݐܽ݃݁	݀݁݌݈݁ݐ݅݋݊ 
Where,  
a = Number of red blood cells in 1 µL of whole blood 
b = Number of red blood cells in 1 µL of the enriched red blood cell sample 
c = Number of white blood cells (or platelets) in 1 µL of whole blood 
d = Number of white blood cells (or platelets) in 1 µL of the enriched red blood cell 
sample  
 
2.2.2.2   Haemocytometer with trypan blue 
An aliquot of cell lines in suspension (A549 cells or Jurkat cells) was diluted in an equal volume 
of trypan blue solution (0.4 %). Of the diluted cell suspension, 10 µL was applied to the 
haemocytometer and the number of live (unstained) and dead (trypan blue stained) cells were 
counted to determine the concentration of cells per mL.  
2.2.2.3   Haemocytometer with Turks solution 
PBMCs were quantified using Turks solution. An aliquot of PBMCs was diluted in Turks 
solution at a ratio of 1:20 (PBMCs : Turks solution). The Turks solution lysed any 
contaminating red blood cells in the sample. Of the diluted cell suspension, 10 µL was applied 
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to the haemocytometer and the number of PBMCs were counted to determine the concentration 
of cells per mL. 
 
2.2.3  Protein quantification 
For the quantification of cytokines, a direct sandwich ELISA was initially utilised to identify 
the concentration of macrophage migration inhibitory factor (MIF) in blood samples. The 
ELISA is one of the most common techniques used to quantify the concentration of a single 
analyte, such as is outlined in Chapter 3. Further experimentation in this thesis introduced a 
need to assess the concentration of a wide variety of cytokines, which was achieved by using a 
multiplex Luminex® assay. This assay uses the same principle as the direct sandwich ELISA 
wherein a capture antibody is used to bind the analyte out of solution, and a subsequent 
detection antibody is added to sandwich the analyte and to enable quantification. The primary 
difference between the two is that the capture antibody in the ELISA is directly bound to the 
well of the plate, whilst the Luminex® capture antibody is bound to a specific colour-coded 
bead. In this assay, the bead colour is specific for an analyte, thus other bead colours can be 
used to differentiate between multiple analytes. Per analyte, these Luminex® kits are 
substantially cheaper, more time efficient, and require lower volumes of sample than ELISAs. 
For this reason, the Luminex® kits were chosen as a preferential technique. For both the ELISA 
and the Luminex® kits, the capture antibodies were human anti-mouse and the detection 
antibodies were human anti-goat. The antibody clones for these kits are unknown as they are 
proprietary. 
2.2.3.1   Multiplex assay – Luminex®  
For cytokine quantification of cell lysates and conditioned media samples, two Luminex® 
multi-plex assays was utilised. The first was the 27-plex human cytokine panel that assays for 
FGF basic, Eotaxin-1, G-CSF, GM-CSF, IFN-γ, IL-1β, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-
8, IL-9, IL-10, IL-12(p70), IL-13, IL-15, IL-17, IP-10, MCP-1, MIP-1α, MIP-1β, PDGF-BB, 
RANTES, TNF-α, and VEGF, and the second was the 21-plex human cytokine panel that 
assays for IL-1α, IL-2Ra, IL-3, IL-12(p40), IL-16, IL-18, CTACK, GRO-α, HGF, IFN-α2, LIF, 
MCP-3, M-CSF, MIF, MIG, β-NGF, SCF, SCGF-β, SDF-1α, TNF-β, TRAIL (Bio-Plex Pro 
27-plex and 21-plex, Bio-Rad). The assays were performed according to manufacturer’s 
instructions as follows. The protocol is summarised in Figure 2.4.  
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Figure 2.4. Schematic of multi-plex assay workflow. 
 
To start, all reagents were brought to room temperature. The Bio-Plex standards were 
reconstituted with 500 µL of the provided standard diluent. This solution was mixed well then 
incubated on ice for 30 minutes. During this time, the 10x magnetic beads were resuspended 
in the provided assay buffer to a 1x concentration. These beads were left to incubate at room 
temperature for 20 minutes. Following incubation of both solutions, the reconstituted standards 
were diluted in the provided standard diluent where 128 µL of the standard was added to 72 µL 
to produce the most concentrated standard. Serial dilution of this standard was then performed 
as a 1:4 dilution series to produce a total of 8 standards for each kit. To each well of the provided 
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96 well plate, 50 µL of the diluted magnetic beads was added and washed twice with the 
provided wash buffer and magnetic wash station (Bio-Plex Pro II wash station). After washing, 
50 µL of the standards, blanks, and samples were added to the relevant wells. This plate was 
then sealed and protected from light during incubation at room temperature on a microplate 
orbital shaker (850 rpm, 30 minutes). Following incubation, the plate was washed three times 
with the provided wash buffer (Bio-Plex Pro II wash station). The 10x detection antibodies 
were diluted 1:10 in the provided detection antibody diluent. Of this solution, 25 µL was added 
to each well. The plate was then sealed and protected from light during incubation at room 
temperature on a microplate orbital shaker (850 rpm, 30 minutes). Following incubation, the 
plate was washed three times with the provided wash buffer (Bio-Plex Pro II wash station). 
The 100x Streptavidin-PE solution was diluted 1:100 in the provided assay buffer. Of the 
diluted Streptavidin-PE solution, 50 µL was added to each well. The plate was the sealed and 
protected from light during incubation at room temperature on a microplate orbital shaker (850 
rpm, 10 minutes). Following incubation, the plate was washed three times with the provided 
wash buffer (Bio-Plex Pro II wash station). The beads in each well were then resuspended in 
125 µL of the provided assay buffer and the plate was sealed and protected from light during 
incubation at room temperature on a microplate orbital shaker (1200 rpm, 1 minute). The plate 
was then read using the Luminex® 200 system (Bio-Plex, Bio-Rad) according to the settings 
outlined in Table 2.5. 
 
Table 2.5. Bio-Plex manager settings for plate analysis. 
Parameter Analysis setting 
Beads per region 50 
Bead map 100 region 
Sample size 50 µL 
DD gates (low) 5,000 
DD gates (high) 25,000 
PMT Low RP1 
 
The calibration curve for each cytokine was analysed with 5 parametric logistic curve 
regression suing Bio-Plex manager software (ver. 5.0, Bio-Rad). Standard values were 
considered acceptable if the points fell within 80 - 120 % of the expected values. 
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2.2.3.2   Haemoglobin quantification 
Concentration of haemoglobin in red blood cell conditioned media samples was quantified by 
assessing absorbance at 414 nm with comparison to a calibration curve (Synergy 2 Multi-Mode 
plate reader). Peaks at this wavelength are indicative of free haemoglobin in the solution. To 
minimise interference, red blood cell membranes were removed by centrifugation of the 
conditioned media samples (16,000 g, 15 minutes, 4 °C). Following centrifugation, 100 µL of 
the membrane-free samples were added to individual wells of a 96-well plate. A calibration 
curve was also prepared by a serial dilution of human-derived haemoglobin (Sigma Aldrich). 
For this calibration curve, 100 µL was also added to wells of the 96-well plate, and the 
absorbance of the plate was read at 414 nm (Synergy 2 Multi-Mode plate reader). 
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2.3   METHODOLOGY INDEX 
 
In this thesis, each results chapter includes a detailed description of all the methods used for 
the outlined experimental work. The location of the detailed methods in the thesis is 
summarised in Table 2.6.  
 
Table 2.6. Reference to methods in thesis 
Method Thesis section reference 
Blood collection 3.2.1, 4.2.1, 5.2.1, B.1.1 
Bicinchoninic acid assay 4.2.5 
Cytokine multiplex assay 4.2.7, 5.2.7 
Enzyme linked immunosorbent assay 3.2.7, B.1.3 
Flow cytometry 3.2.8, 5.2.5 
Haemoglobin quantification 3.2.6, 4.2.6, 5.2.6 
Isolation of red blood cell cytosol and membranes 3.2.3, 5.2.4.3 
Plasma and blood cell isolation 3.2.2, 4.2.2, 5.2.2, B.1.2 
Proliferation assay 5.2.4 
Protein binding to red blood cells 3.2.5, 4.2.4 
Protein recovery efficiency 3.2.4, 4.2.8 
Red blood cell conditioned media preparation 3.2.5, 4.2.3 
Red blood cell isolation (protocol 1) 3.2.2, 4.2.2, B.1.2 
Red blood cell isolation (protocol 2) 5.2.2 
Red blood cell priming 5.2.3 
Tautomerase activity assay 3.2.9 
Statistical analysis 3.2.10, 4.2.9, 5.2.8, B.1.4, E.1.1 
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CHAPTER 
  
--------------------------------------------------------------------------- 
 
IDENTIFICATION OF RED BLOOD CELLS AS THE PRIMARY 
RESERVOIR OF MACROPHAGE MIGRATION INHIBITORY 
FACTOR IN WHOLE BLOOD 
 
 
 
This chapter investigates the presence of macrophage migration inhibitory factor (MIF) in red 
blood cells. Red blood cells are widely accepted to be inert carriers of oxygen and 
haemoglobin, but there is growing evidence that they play a much more critical role in immune 
function. MIF is a key cytokine in disease and aids in managing oxidative stress. In a previous 
study in our laboratory, MIF was identified as a potential biomarker for osteoarthritis. MIF 
levels in plasma decreased significantly after mesenchymal stem cell therapy for this condition 
in a clinical trial. As the number of samples and the number of people processing the samples 
increased, more variability than expected in MIF levels was observed, making statistical 
analysis difficult. In an attempt to determine whether blood processing effects were responsible 
for the differences, a series of experiments with snap-frozen whole blood was completed. The 
discovery that MIF was present in whole lysed blood at concentrations 1000-fold higher than 
plasma led to a series of additional experiments that ultimately produced the work detailed in 
this chapter. As described here, freshly isolated red blood cells from healthy individuals were 
collected and the concentration of MIF was quantified using an enzyme linked immunosorbent 
assay (ELISA). The capacity of cells to bind and release MIF, and investigation into the 
enzymatic activity of MIF was investigated.  
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3.1   INTRODUCTION 
 
Macrophage migration inhibitory factor (MIF) plays a central role in promoting inflammation. 
This 12.5 kDa cytokine is a key component of the early stage inflammatory response that is 
associated with innate immunity. To enable this response, MIF is produced at high 
concentrations and is retained intracellularly for rapid secretion in the active form, a 
homotrimer1. It is secreted by both immune cells (such as macrophages and T cells) and organ 
specific cells (such as hepatocytes and osteoblasts), and unlike other cytokines, it is also 
secreted by the pituitary gland in response to infection2. MIF binds to cells via a cell surface 
receptor complex formed between CD44 and CD74, which initiates a series of signalling 
cascades3. MIF functions, as its name suggests, in preventing the random migration of 
macrophages from the site of inflammation and as a chemokine that recruits other immune 
cells4. In addition, MIF functions to protect cells from apoptosis and oxidative stress5,6. 
Interestingly, the pro-inflammatory function of MIF is dependent on an enzymatic active site 
within its trimeric structure7. As such, its enzymatic and pro-inflammatory activity are closely 
related. 
Interest in MIF has expanded since its discovery in 19668 and it has been implicated in a range 
of acute and chronic inflammatory conditions9–12. For this reason, MIF has been frequently 
proposed as a potential disease biomarker10–14. In a cohort of osteoarthritis patients, Liu et al. 
identified significantly increased levels of MIF in serum and synovial fluid samples when 
compared to healthy controls and also reported a correlation between serum levels of MIF and 
increasing grade severity of osteoarthritis10. Similarly, Todros et al. identified that serum levels 
of MIF were significantly higher in women who had severe preeclampsia when compared to 
women with uncomplicated pregnancies11. However, the involvement of this protein in so 
many biological processes and the wide range of plasma MIF concentrations in healthy 
participants (24.7 ± 13.2 ng/mL)15 makes its use as an independent biomarker challenging16.  
One contributing factor to this variability may be the source of circulating MIF. Levels of MIF 
are most often monitored in serum or plasma collected from peripheral blood and the source is 
typically attributed to white blood cell secretion17,18. More recently, platelets have been 
identified as a previously unrecognised source of MIF which supports the growing literature 
around the involvement of platelets in inflammation19,20. In contrast to white blood cells and 
platelets, there is minimal literature on the cytokines associated with the most common cell 
type in blood, the red blood cell. There are studies indicating that red blood cells bind 
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inflammatory chemokines of the C-X-C or C-C family in addition to MIF30-32. However, no 
information on the concentrations of cytokines associated with red blood cells could be found. 
The preliminary observation that led to the study in this chapter was the quantification of MIF 
at approximately 30 µg/mL in one millilitre of whole blood. The literature on inflammatory 
signalling in disease and injury does not consider red blood cells as a source of cytokines, 
which may need to be re-evaluated in the light of these findings.  
An example of elevated MIF after injury that may be in part a result of red blood cell-sourced 
MIF is post-cardiac arrest syndrome. In healthy volunteers the plasma concentration of MIF is 
typically between 1 and 50 ng/mL21, which is 1000 times higher than most other cytokines. 
Although the plasma level of healthy controls is high compared to other cytokines, after injury 
the MIF level can be significantly elevated. Pohl et al. investigated the role of MIF in post-
cardiac arrest syndrome where patients exhibited return of spontaneous circulation (ROSC)22. 
In patients after ROSC, MIF plasma levels at admission to the intensive care unit were 
significantly higher compared to those in healthy volunteers (173 ± 45 ng/mL vs 
18 ± 2 ng/mL). Red blood cells are susceptible to free radical-induced lipid peroxidation, 
which occurs during ischemia-reperfusion injury as a result of cardiac arrest23. Increased 
haemolysis is observed as a result of ischemic-reperfusion injury and one hypothesis discussed 
is that oxidative stress causes haemolysis24,25. Acute haemolysis would cause a spike in MIF 
levels, which may be interpreted as an inflammatory response when the underlying cause may 
be cellular damage. Pohl et al. found a close relationship between circulating MIF levels and 
cellular damage but not with an inflammatory syndrome22. This result supports the hypothesis 
that the increased MIF observed post-cardiac arrest is a result of haemolysis. 
Red blood cells are the most abundant cell type in the body and are present at upwards of 
5 billion cells per millilitre of whole blood26. Although the conventional view is that red blood 
cells only function in gas exchange, it now appears that the role of this enucleate cell may be 
more complex. Proteomic and transcriptomic analyses have identified 2289 unique proteins in 
red blood cells27 and transcripts of 1019 different genes28. A series of studies on the red blood 
cell soluble proteome over the last decade have classified the majority of identified proteins as 
being involved in either cellular metabolism or regulation of transport29. Within that, the main 
functional areas are catabolism, proteolysis, and energy production (glucose metabolism). 
These functional groups are consistent with the reality that mature red blood cells are actually 
a pool of red blood cells of different ages, on a predominantly destructive pathway. Whilst 
these categories account for much of the red blood cell proteome, approximately one quarter 
of the identified proteins are associated with organelles that are not present in mature red blood 
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cells or are not present in their active form. The presence of such large numbers of transcripts 
and mature proteins in red blood cells raises the question of functionality versus chance. Are 
these proteins present in red blood cells in a functional capacity or as the result of an imperfect 
process during maturation and ejection of the nucleus and other organelles? Red blood cells 
have also been shown to interact with some inflammatory cytokines including IL-8, RANTES, 
and MCP-1 through binding to the Duffy antigen receptor for chemokines (DARC) on the 
surface of red blood cells30–32, as such they may also actually be involved in regulating 
inflammation.  
D-dopachrome tautomerase (DDT), or MIF-2, is an active enzyme that has been identified 
within red blood cells33. The structural similarities between DDT and MIF have been 
researched extensively, and it has been reported that these proteins share 34 % amino acid 
sequence identity in humans34–36. DDT is encoded by a gene adjacent to MIF and has an 
overlapping functional spectrum with MIF. The DDT protein and MIF share the same cell 
surface receptor complex, CD74-CD44, and induce similar cell signalling and effector 
functions. Furthermore, an analysis of the signalling properties showed that they work 
cooperatively, and that neutralisation of DDT in vivo significantly decreases inflammation34. 
In fact, these proteins appear to be localised to the same areas throughout the body, with the 
testis being the only organ studied thus far that has a significant difference in expression 
levels34. It is likely that DDT and MIF are both present in red blood cells, however, their 
intracellular function remains unknown. Although there is minimal literature on this point, 
Mizue et al. suggested that MIF is indeed present in red blood cells after seeing an increase in 
MIF levels which correlated to the concentration of haemoglobin21. In order to explore this 
further, the aims and hypothesis of the study presented in this chapter were as follows. 
 
3.1.1   Chapter hypothesis 
It is hypothesised that red blood cells are the primary reservoir for MIF in whole blood and that 
this MIF is enzymatically active. 
 
3.1.2   Chapter aims 
1. To quantify MIF in human red blood cells. 
2. To investigate the role of MIF in red blood cells, particularly its enzymatic activity. 
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3.2   METHODS 
 
3.2.1  Blood collection 
This study was approved by the Macquarie University Human Research Ethics Committee 
(5201100827) and by the Northern Sydney Coast Human Research Ethics Committee of 
NSLHD and CCLHD (1201-046M). Written informed consent was obtained from all 
participants before enrolment.  
Whole blood was collected from healthy volunteers by venepuncture (n = 10; female: 3, 
male: 7). The age range of these participants was 21 - 47 years. Blood was combined with 
EDTA (ethylenediaminetetraacetic acid) for anticoagulation (K2EDTA vacutainers, Becton 
Dickinson). Blood and blood components were isolated at room temperature within four hours 
of collection. All samples were subjected to three freeze-thaw cycles at -80 °C prior to analysis 
to ensure complete cellular lysis. Samples were stored at -80 °C until analysis. 
 
3.2.2  Plasma and blood cell isolation 
The components of whole blood were isolated using a range of techniques. Collected cell 
populations (whole blood, red blood cells, white blood cells, and platelets) were isolated and 
frozen immediately for analysis of cell lysates or were used fresh for storage experiments 
(Section 3.2.5). Concentration and purity of whole blood, red blood cell, white blood cell, and 
platelet populations were determined using a haematology analyser (Coulter AcT Diff, 
Beckman Coulter).  
3.2.2.1 Whole blood and plasma 
Whole blood was separated into aliquots and frozen at specific concentrations directly after 
anticoagulation. Plasma was isolated from anticoagulated whole blood by centrifugation 
(1500 g, 10 minutes, 23 °C) and was frozen at -80 °C. 
3.2.2.2 Red blood cells and white blood cells 
For isolation of the blood cells, whole blood was added to dextran solution (6 % w/v dextran 
in 0.15 M sodium chloride) at a 2:1 ratio (blood:dextran). This solution was gently mixed and 
left upright for 60 minutes at 23 °C for red blood cell sedimentation. After sedimentation, two 
layers formed and were collected and transferred into individual tubes. The lower, red blood 
cell dense layer, was washed once in phosphate buffered saline (PBS, 500 g, 5 minutes) and 
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the red blood cell pellet was isolated. The upper layer, rich in white blood cells, was washed 
once in PBS at 1000 g for 10 minutes. Any contaminating red blood cells were lysed by the 
addition of excess Milli-Q water (MQ-H2O, 6:1 original whole blood volume) for 0.5 minutes. 
Isotonicity was restored by the addition of potassium chloride (0.6 M, 1:3 potassium 
chloride:MQ-H2O). Remaining cells were pelleted and washed in PBS at 1000 g for 5 minutes.  
3.2.2.3 Platelets 
For isolation of platelets, platelet rich plasma was prepared by centrifugation of whole blood 
(100 g, 20 minutes, 23 °C). The upper, platelet dense layer was collected and contaminating 
cells were removed by two subsequent cycles of centrifugation of the platelet rich plasma and 
collection of the upper soluble fraction (100 g, 20 minutes, 23 °C). Platelets were then pelleted 
and washed twice in PBS (1000 g, 5 minutes, 23 °C). 
 
3.2.3  Isolation of red blood cell cytosol 
Red blood cell membranes were removed from cell lysates of purified red blood cells to collect 
the cytosolic fraction (after three freeze-thaw cycles). The cell membranes were isolated by 
centrifugation (16,000 g, 15 minutes, 4 °C) after which the upper, cytosolic fraction was 
collected and was stored at -80 °C until analysis.  
 
3.2.4  Recovery efficiency 
Recombinant MIF (rMIF, 50 ng/mL, R&D Systems) was spiked into red blood cell lysates 
immediately prior to analysis of samples on the MIF ELISA. A control sample was also 
analysed to factor in any dilution effect. For the controls, the sample diluent (MIF ELISA 
sample diluent, R&D systems) was added into the corresponding red blood cell lysates at the 
same volume as the recombinant MIF spike. The recovery efficiency of recombinant MIF was 
calculated using the following equation: 
 
Equation 3.1. Recombinant protein recovery efficiency. 
ܣ ൅ ܤ
ܥ ൈ100 ൌ ܲ݁ݎܿ݁݊ݐܽ݃݁	ݎ݁ܿ݋ݒ݁ݎݕ 
Where, 
A = Concentration of un-spiked control 
B = Concentration of recombinant protein (spiked) 
C = Final assayed concentration of sample 
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3.2.5  Red blood cell conditioned medium and binding of MIF  
To evaluate red blood cell release of MIF and protease activity during incubation, purified red 
blood cells were suspended in PBS (200 x 106 cells/mL) with or without protease inhibitors 
(PrI, mini cOmplete protease inhibitor cocktail tablets, Roche) and were incubated for 24 hours 
(5 % CO2, 37 °C). After incubation, the red blood cells were removed by centrifugation (500 g, 
5 minutes). The red blood cell pellet and the conditioned PBS were collected and frozen 
separately at -80 °C. Purified red blood cells were also incubated in the presence of 
recombinant MIF (2 ng/mL, Jomar Bioscience) as above in PBS and with or without protease 
inhibitors (24 hours, 5 % CO2, 37 °C). After incubation, the red blood cell pellet and the 
conditioned PBS was collected and frozen separately at -80 °C. The ‘in silico’ spike was 
calculated according to the following equation: 
 
Equation 3.2. Calculation of concentration of in silico spike. 
ܣ ൅ ܤ ൌ ܫ݊	ݏ݈݅݅ܿ݋	ݏ݌݅݇݁ 
Where, 
A = Concentration of MIF secreted in un-spiked control 
B = Concentration of recombinant protein (spiked)  
 
3.2.6  Haemoglobin quantification 
Levels of free haemoglobin in plasma and red blood cell conditioned media were measured by 
spectrophotometric analysis as previously described37 on a Synergy 2 plate reader (BioTek). 
Absorbance peaks at 414 nm are indicative of free haemoglobin. A standard curve of 
haemoglobin (Sigma Aldrich) at known concentrations was analysed at 414 nm. 
 
3.2.7  Enzyme-linked Immunosorbent Assay (ELISA) 
Concentrations of MIF were measured using a MIF ELISA (R&D Systems) which was run 
according to manufacturer’s instructions. The absorbance data for the MIF ELISA were 
collected with a Synergy 2 plate reader (BioTek) at 450 nm with absorbance correction at 
570 nm. The calibration curve was analysed using a log/log curve fit using GraphPad Prism 
software (ver. 6, USA). 
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3.2.8  Immunophenotyping 
Immunophenotyping of the purified red blood cell population was performed by flow 
cytometry on a FACSCalibur flow cytometer with a 488 nm argon laser (Becton Dickinson) 
with data collection using CELLQuest Pro software (ver. 5.2.1). Sample preparation proceeded 
as follows. Fresh purified red blood cells were diluted in PBS and this solution was passed 
through a 35 µm cell strainer (Becton Dickinson) to produce a single cellular suspension. This 
cell suspension was then equally divided up into six flow cytometry tubes such that each 
contained at least 100,000 cells. Following this, the cells were washed twice in PBS with 
2 % FBS (fetal bovine serum, 5 minutes, 1000 g, 23 °C). The resulting cell pellet was 
resuspended in 50 µL of PBS with 2 % FBS (v/v) and 5 µL of the isotype controls, or the 
monoclonal antibodies for CD45, CD44, or CD74 (Table 3.1). This solution was incubated at 
room temperature for 10 minutes. After incubation, the cells were washed twice in PBS 
(5 minutes, 1000 g, 23 °C). Cells were resuspended in 100 µL of PBS and were immediately 
analysed by flow cytometry. A minimum of 10,000 events were counted per sample. 
  
Table 3.1. Monoclonal antibodies for immunophenotyping of red blood cells. 
Antibody Fluorochrome Clone 
Mouse anti-human CD44 PE 515 
Mouse anti-human CD45 FITC HI30 
Mouse anti-human CD74 FITC M-B741 
Mouse IgG1,κ Iso Control  PE MOPC-21 
Mouse IgG1κ Iso Control FITC P3.6.2.8.1 
Mouse IgG2a, κ Iso Control FITC G155-178 
 
3.2.9  MIF tautomerase activity  
Red blood cell derived MIF was tested for dopachrome tautomerase activity as previously 
described38. Briefly, L-dopachrome methyl ester was prepared shortly before use by adding 
100 µL of L-3,4 dihydroxyphenylalanine methyl ester (12 mM; Thermo Fisher Scientific) and 
100 µL of sodium periodate (24 mM, AnalaR) to 3800 µL of reaction buffer (50 mM Bis-Tris, 
1 mM EDTA, pH 6.2). This solution was used immediately. Immediately prior to analysis, 
200 µL of the reaction buffer was added to 20 µL of 40 nM MIF in a 96-well plate. In this 
assay, a decrease in absorbance is indicative of enzymatic activity and was monitored at 
475 nm over 10 minutes. A negative control (no MIF) was included in this assessment to 
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monitor any non-enzymatic decrease in absorbance over the 10-minute period. For analysis of 
enzymatic activity, the following solutions were tested: 1) recombinant MIF, 2) whole red 
blood cell lysate (including membranes), and 3) the red blood cell cytosolic fraction. For MIF 
inhibition, 10 µL of the MIF solutions (80 nM) were incubated with 10 µL of ISO-1 ((S,R)-3-
(4-Hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid, 5 mM in methanol, Merck Millipore), 
or 10 µL of the vehicle (methanol 75 % v/v in DMSO, dimethyl sulfoxide) for 15 minutes at 
room temperature before analysis. ISO-1 was reconstituted in DMSO to 20 mM, it was then 
diluted to 5 mM in 100 % methanol (v/v). This was optimised for MIF inhibition of red blood 
cell lysates as DMSO negatively interfered with the samples.  
 
3.2.10  Statistical analysis  
Data were evaluated using two-tailed, paired t-tests to assess statistical significance between 
groups with significance levels of p < 0.05. For comparison of three or more groups, a one-
way ANOVA was used with Geisser-Greenhouse correction for sphericity and correction for 
multiple comparisons was performed (Sidak correction) with significance levels of p < 0.05. 
Statistical analysis and graphing of results was performed using GraphPad Prism software (ver. 
6, USA). Flow cytometry results were analysed and illustrated using Flowing Software 2 (ver. 
2.5.1, Finland). Where relevant, fold change after treatment was determined and presented as 
mean ± confidence interval (CI), and concentration values were presented as mean ± standard 
deviation (SD). Data analysed in this study were assessed as normally distributed according to 
the Kolmogorov-Smirnov test. The concentration of cytokines in blood components was 
presented according to the relative contribution in one millilitre of whole blood. This 
calculation was performed for each cell population according to the following equation:  
 
Equation 3.3. Concentration of protein in one millilitre of whole blood. 
ܣ
ܤ	ൈ		ܥ ൌ ܥ݋݊ݐݎܾ݅ݑݐ݅݋݊	ݐ݋	ݓ݄݋݈݁	ܾ݈݋݋݀ 
Where, 
A = Original cell number of population in 1 mL of whole blood 
B = Number of cells assayed per mL 
C = Concentration of analyte per mL 
 
For the remainder of this chapter, the term ‘significant’ will be used to indicate a statistically 
significant result of p < 0.05 unless otherwise specified.  
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3.3   RESULTS 
 
3.3.1  Red blood cell purity 
The purity of enriched red blood cell fractions was calculated by comparing the ratio of white 
blood cells or platelets to red blood cells in the whole blood sample and to the enriched sample. 
Following dextran sedimentation, white blood cells were depleted by approximately 80 % and 
platelets were depleted by approximately 97 % (Table 3.2). Thus, for every one million red 
blood cells there were 210 white blood cells and 4,050 platelets. 
 
Table 3.2. Purity assessment of enriched red blood cell fractions. 
RBC purity (%)* WBC depletion (%)* PLT depletion (%)* 
99.97 ± 0.01 79.0 ± 5.1 97.3 ± 2.9 
*Data are presented as mean ± standard deviation (n = 10) 
 
 
 
3.3.2  Distribution of MIF between blood components  
Red blood cells contribute the highest concentration of MIF to one millilitre of whole blood 
when compared to the other major components (Table 3.3). Red blood cells contribute 
127 ± 19 % of the total MIF in whole blood, whilst white blood cells, platelets, and plasma 
contribute approximately 1.7 % combined. Although white blood cells contain the highest 
concentration of MIF per cell (34.1 ± 9.8 fg/cell), the prevalence of red blood cells is 1000 
times higher than white blood cells. Thus, they are the primary reservoir for MIF in peripheral 
blood.  
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Table 3.3.  Distribution of MIF across major components of blood and corresponding 
average concentration per cell. 
Blood Fraction 
Percentage of 
MIF 
contribution 
(%) * 
Total MIF 
contribution to 
1 mL whole blood
(ng/mL) * 
Measured 
MIF/cell 
(fg/cell) * 
Previously 
reported 
MIF/cell 
(fg/cell) 
Whole blood 100 23,678 ± 4,365 n/a n/a 
Red blood cells 127 ± 19 31,241 ± 9,129 5.6 ± 0.9 n/a 
White blood cells 1.1 ± 0.8 251 ± 173** 34.1 ± 9.8 3.9-1000# 
Platelets 0.4 ± 0.2 92 ± 14** 0.3 ± 0.2 0.3## 
Plasma 0.1 ± 0.1 26 ± 26** n/a n/a 
*Data are presented as mean ± standard deviation (n = 5) 
**Data are significantly different from whole blood (p < 0.05) 
#Intracellular concentration of macrophages17,19 
##Intracellular concentration of platelets19 
 
 
 
3.3.3  Recovery efficiency 
To investigate the extent of sample interference by factors such as haemoglobin, red blood cell 
lysates were spiked with recombinant MIF (final concentration of 2 ng/mL) immediately prior 
to analysis by ELISA to determine recovery efficiency. Recombinant MIF recovery was 
between 90 - 105 % (97 ± 7 %) for the red blood cell lysates. These results are similar to the 
reported recovery of recombinant MIF from EDTA plasma (80 - 108 %) and serum 
(94 - 104 %) (R&D systems, MIF ELISA product validation).  
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3.3.4  Location of MIF on red blood cells 
The MIF concentration of the cytosolic fraction of red blood cells was compared to the whole 
red blood cell lysate. To isolate the cytosolic fraction, the red blood cell membrane was 
removed by centrifugation from the lysate. There was a significant decrease in the 
concentration and the fold change of the MIF measured in the cytosolic fraction compared to 
the whole lysate (Figure 3.1). There was an average fold change of 0.89 in the concentration 
of MIF between the lysate and the cytosol samples. This indicates that approximately 10 % of 
the MIF was bound to or was associated with the red blood cell membrane. 
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Figure 3.1. MIF concentration in whole red blood cell lysate (per 10 million cells) and the 
concentration of MIF in the cytosolic fraction of the lysate (per 10 million cells) as measured 
by ELISA. Data are presented as mean fold change ± 95% CI, n = 5, statistically significant (*) 
if p < 0.05. 
 
 
3.3.5  MIF receptors 
Immunophenotyping of red blood cells was performed to investigate the presence of CD44 and 
CD74 receptors on red blood cells. These results demonstrate that whilst the red blood cells 
were positive for half of the MIF receptor complex, CD44, and that they were negative for the 
other half of the complex, CD74 (Figure 3.2). As anticipated, the analysed red blood cells were 
also negative for CD45, a leukocyte specific marker (Figure 3.2). 
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Figure 3.2. Fresh red blood cells collected from healthy volunteers were stained for the 
presence of CD markers and the immunophenotype was determined by flow cytometry. A 
comparison of antibody labelled red blood cells (filled histogram) and the respective IgG 
negative controls (empty histogram) demonstrates that the red blood cells were positive for the 
presence of (A) CD44 and were negative for the presence of (B) CD74 and (C) CD45. Data are 
presented as overlay histograms. 
 
 
3.3.6  Red blood cell incubation and MIF release (conditioned media) 
MIF was released from red blood cells after overnight incubation at 37 °C in PBS 
(6.5 ± 1.4 ng/mL). The addition of protease inhibitors during incubation did not have a 
significant effect on the release of MIF or on the red blood cell lysates. After incubation, 
approximately 1 % (control: 1.1 ± 0.3 %; PrI: 1.3 ± 0.4 %) of the original intracellular 
concentration of MIF (control, T0) was released into the PBS (Figure 3.3). 
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Figure 3.3. Red blood cells were incubated for 24 hours at 37 °C in 5 % CO2 
(200 x 106 cells per mL) in the presence of PBS alone (control) or PBS with protease inhibitors 
(PrI). After incubation the conditioned PBS (conditioned media, ●) and remaining whole cells 
(lysate, ■) were separated and frozen to lyse all intact cells. Samples were analysed by ELISA. 
Conditioned media samples (●) are presented against the left y-axis, and lysate samples (■) are 
presented against the right y-axis. Data are presented mean ± SD, n = 5, data are statistically 
significant (*) if p < 0.05. 
 
 
3.3.7  Red blood cell binding of MIF 
Recombinant MIF was added to suspensions of red blood cells which were then incubated at 
37 ºC for 24 hours. The ‘in silico’ spike refers to the expected MIF concentration in the 
supernatant with the addition of rMIF. There was no significant difference between the 
concentration of MIF in the spiked sample and the predicted concentration (in silico spike) in 
the conditioned media or lysates of the control (Figure 3.4a and Figure 3.4c). However, with 
the addition of protease inhibitors during incubation there was significantly less (p = 0.036) 
MIF measured in the conditioned media fraction of the spiked sample when compared to the 
‘in silico’ spike (Figure 3.4b). Assay controls were run which demonstrated that the protease 
inhibitors themselves did not bind MIF out of solution (2.4 ± 0.7 ng/mL vs 2.2 ± 0.3 ng/mL, 
for rMIF vs rMIF + PrI respectively). As such, the results indicate that the cells were directly 
involved in the reduced levels of MIF. This difference was not mirrored in the corresponding 
protease inhibitor treated lysates (Figure 3.4d). 
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Figure 3.4. Red blood cells were incubated for 24 hours at 37 °C in 5 % CO2 
(200 x 106 cells per mL) in the presence of PBS alone (control), PBS with protease inhibitors 
(PrI), or PBS with recombinant MIF (rMIF) spiked in at a final concentration of 2 ng/mL to 
solutions with or without protease inhibitors (RBC + rMIF (PrI) or RBC + rMIF respectively). 
The expected concentration after spike is represented as ‘in silico spike’. After incubation the 
conditioned PBS (conditioned media, A and B) and remaining whole cells (lysate, C and D) 
were separated and frozen to lyse all intact cells. Samples were analysed by ELISA. Data are 
presented as the fold change from the PBS control (A and C) or the PBS + PrI control (B and 
D) with mean fold change ± 95% CI, n = 5. Data are statistically significant (*) if p < 0.05. 
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3.3.8  Concentration of haemoglobin in red blood cell conditioned media 
The concentration of haemoglobin in plasma samples and in red blood cell conditioned media 
was quantified by monitoring absorbance at 414 nm. The level of haemoglobin in red blood 
cell conditioned media samples was significantly less than that measured in plasma with means 
of 0.2 mg/mL and 0.6 mg/mL respectively (Figure 3.5). There was no significant difference 
between the concentration of haemoglobin in red blood cell conditioned media with or without 
protease inhibitors (Figure 3.5). 
 
 
 
Figure 3.5. Concentration of haemoglobin in plasma and the red blood cell conditioned 
media (200 x 106 cells per mL) incubated in PBS with and without protease inhibitors (RBC-
CM + PrI and RBC-CM respectively) over 24 hours at 37 °C. Haemoglobin concentration was 
measured by absorbance at 414 nm. Data are presented as mean ± SD, n ≥ 5, statistically 
significant (*) if p < 0.05. 
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3.3.9  MIF tautomerase activity 
Consumption of the substrate L-dopachrome methyl ester in the presence of MIF is indicative 
of the tautomerase activity of the protein and is represented by a decrease in measured 
absorbance. The addition of red blood cell lysates and cytosol (containing 10 ng of MIF) to the 
substrate steadily decreased the measured absorbance over the 10-minute period indicating 
enzymatic activity (Figure 3.6). This reaction progressed at a comparable rate to the 
recombinant protein. There was no significant difference between the rate of substrate 
breakdown between the red blood cell cytosol and the whole lysate. 
 
 
Figure 3.6. Dopachrome tautomerase activity of MIF was monitored in solutions of 10 ng 
of MIF and (black) an assay blank containing no MIF. A decrease in absorbance over 
10 minutes was indicative of enzymatic consumption of the substrate L-dopachrome methyl 
ester as seen with (blue) recombinant MIF, (red) red blood cell lysate, and (green) red blood 
cell cytosol. Data are presented as mean ± SD, n = 5, statistically significant (*) if p < 0.05.
  
 
The addition of the MIF inhibitor, ISO-1, to recombinant MIF resulted in an inhibition of the 
tautomerase activity (Figure 3.7a). For recombinant MIF, the vehicle caused little interference 
with the assay, however this was not the case for the red blood cell samples. Although the 
chosen vehicle was optimised for the red blood cell samples, the addition of the vehicle without 
the inhibitor caused notable interference (Figure 3.7b and Figure 3.7c). After monitoring the 
absorbance for 10 minutes in the lysates, the PBS control had decreased to 24 % ± 8.3 
compared to 44 % ± 12.4 for the vehicle control (Figure 3.7b). Despite the interference, there 
was a significant difference between the vehicle control and the inhibitor samples at the 
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conclusion of the assay for both the lysate and the cytosol (lysate: p = 0.036; 
cytosol: p = 0.005). This difference was more prominent in the cytosol samples. This indicates 
that there had been inhibition of MIF in red blood cell samples although it was not complete 
under the conditions tested. 
 
 
Figure 3.7. Dopachrome tautomerase activity of MIF and its inhibition using ISO-1 was 
monitored for (A) recombinant MIF, (B) red blood cell lysate, and (C) red blood cell cytosol. 
MIF samples were incubated with PBS (green), 5mM ISO-1 in vehicle (blue), or vehicle (red) 
prior to analysis. A decrease in absorbance was monitored at 450 nm and was indicative of 
enzymatic consumption of substrate. An assay blank (black) which contained no MIF was also 
monitored to determine level of non-enzymatic loss of absorbance. Data are presented as mean 
± SD, n = 5, statistically significant compared to the ISO-1 sample (*) if p < 0.05. 
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3.4  DISCUSSION 
 
The purpose of this study was to assess the distribution of MIF across the components of 
peripheral blood to identify potential reservoirs that may alter serum levels during blood 
processing. In investigating this, the red blood cell component of blood was identified as a 
major source of MIF. Although others had previously identified that MIF was associated with 
red blood cells, a crucial aspect of this study was the quantification of this protein, which 
revealed the dominant role of red blood cells as a MIF reservoir. In conventional biomarker 
research, MIF is monitored in the plasma fraction of blood, and white blood cells have been 
attributed as the primary reservoir for this protein17,18. More recently, platelets were also 
reported to contain MIF and MIF mRNA19. The research in this chapter demonstrates that the 
other major component of blood, red blood cells, not only contains a store of MIF but that they 
account for the majority of MIF that is present in whole blood (Table 3.3). By using blood 
collected from healthy volunteers, red blood cells were isolated and were identified to contain 
90 % of red blood cell derived MIF in the cytosol and that the remaining 10 % was associated 
with the red blood cell membrane (Figure 3.1). An activity assay was performed to assess if 
the MIF inside red blood cells was in its active state or if it required modification upon release 
and it was demonstrated to be enzymatically active within the cell (Figure 3.6). It was also 
identified that red blood cells release approximately 1 % of their total MIF into the surrounding 
solution when incubated at 37 °C for 24 hours (Figure 3.3).   
The results of this study indicate that red blood cells are likely to have functions beyond gas 
exchange, particularly in the inflammatory process. This study showed that red blood cells can 
release MIF into solution, however, the factors that may influence this were not explored in 
detail. In the subsequent chapters, some of the stimuli that can affect release from red blood 
cells were tested.  
 
3.4.1  MIF in red blood cells 
In a report aiming to optimise blood collection techniques for MIF analysis, Sobierajski et al. 
demonstrated that as haemolysis occurred over time, levels of MIF also increased at a linear 
rate15. They concluded that red blood cell associated MIF may be the cause of this artefact. 
Confirming this observation in our study, high levels of MIF associated with red blood cells 
were identified (Table 3.3). It was also demonstrated that the recovery efficiency of 
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recombinant MIF from red blood cell lysates was as good, if not slightly better than the reported 
recovery efficiencies in serum and plasma (R&D systems, MIF ELISA product validation). 
This result indicates that there were no additional interfering factors (such as haemoglobin) in 
red blood cell lysates which may compromise MIF detection.  
3.4.1.1 MIF on the red blood cell membrane 
The concentration of MIF, on a per cell basis, for white blood cells and platelets was consistent 
with reports from the literature17,19. Although red blood cells contain at least 8-fold less MIF 
per cell than white blood cells, the abundance of red blood cells in whole blood means that 
their contribution of MIF outweighed any other component by more than 100-fold (Table 3.3). 
Analysis of the MIF concentration in the cytosolic fraction compared to the total cell lysate 
(which included red blood cell membranes) indicated that approximately 10 % of the detectable 
MIF may actually reside on the red blood cell membrane (Figure 3.1). In order to further 
investigate this, immunocytochemistry would be a beneficial technique in identifying the 
localisation and distribution of MIF in and/or on red blood cells. If MIF does reside on the red 
blood cell membrane, its binding receptor(s) at this stage are unknown. Using 
immunophenotyping, it was observed that the most well-known MIF receptor complex (CD44-
CD74) does not exist on the membrane (Figure 3.2). MIF has been reported to bind to other 
receptors including CXCR24, however there is no literature on the presence of CXCR2 on red 
blood cells. Interestingly the Duffy antigen receptor for chemokines (DARC), which is 
abundant on the red blood cell surface, shares a number of binding partners with the MIF 
receptor CXCR239. These shared binding partners include a number of cytokines such as IL-8, 
GRO-1, and GRO-339. This study has shown that the primary receptor for MIF is not present 
on red blood cells, thus it is hypothesised that MIF, like other cytokines, is also a shared binding 
partner of CXCR2 and DARC. This hypothesis was not in the scope of this current study, but 
future research into the MIF content of red blood cells in DARC knockout models may be 
useful to test this hypothesis. 
 
3.4.2   MIF release and binding: a passive or active process 
3.4.2.1 MIF release from red blood cells 
In this study, it was observed that approximately 1 % of red blood cell associated MIF was 
released when incubated at 37 °C (Figure 3.3). In these conditioned media samples, the amount 
of haemoglobin detected accounts for approximately 750,000 red blood cells per millilitre, 
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which is approximately 0.4 % of the starting cell number (Figure 3.5). Therefore, over half of 
the MIF detected in the conditioned media was released from intact red blood cells.  
In other cells, MIF is secreted by non-classical pathways, which are not well understood in the 
protein secretion literature. One proposed pathway utilises the ATP binding cassette transporter 
subfamily 1 (ABCA1)40. When the transporter was inhibited on monocytes, the secretion of 
MIF after lipopolysaccharide stimulation was significantly attenuated40. This transporter 
primarily regulates cellular cholesterol and phospholipid homeostasis, and is present on red 
blood cells41,42. In red blood cells, it is unclear whether active protein release occurs, or whether 
MIF is released from intact red blood cells via a passive system. However, if active release of 
MIF occurs from red blood cells, the ABCA1 mechanism may enable it. 
3.4.2.2 Red blood cell binding of MIF 
Red blood cells have been described as an inflammatory sink for chemokines to regulate 
circulating levels32,43. In this thesis, it was hypothesised that red blood cells perform a similar 
role for MIF; acting as a buffer to regulate free cytokine in plasma. An earlier report proposed 
that red blood cells could bind exogenous MIF, thereby removing the inhibition of macrophage 
migration44. They demonstrated that after red blood cells were incubated with FBS, MIF 
activity in the serum, as measured by migration inhibition, decreased. They postulated that this 
decrease was a result of MIF being bound to the red blood cells. To further explore the potential 
binding of MIF, the study in this chapter incubated red blood cells with recombinant MIF for 
24 hours and then assayed the solution for extracellular MIF. Red blood cell binding of 
exogenous MIF should have decreased the media concentration, however it was not 
significantly different to the expected levels in the control samples (in silico spike). In a 
variation of the experiment, the addition of protease inhibitors during incubation did have an 
effect (Figure 3.4). There was significantly less MIF in the conditioned media in comparison 
to the ‘in silico’ spike after incubation in the presence of protease inhibitors, indicating either 
an attenuation in MIF release or an increase in MIF binding to the red blood cells. Discussion 
on the possible causes of this will follow in the next section (Section 3.4.2.3). 
3.4.2.3 Proteases and red blood cells 
Proteases play a key role in the binding and secretion of cytokines in other cell types through 
processing of pro-proteins to active cytokines and in modulating the activity of receptors45. 
Red blood cells do not have protease activated receptors, which are a sub-family of G-protein 
coupled receptors46. However, receptors such as DARC have the 7-transmembrane structure 
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associated with G-protein coupled receptors, without the intracellular signal transduction 
domain47. Proteases and enzymes play a crucial role in red blood cells in the absence of 
organelles. Red blood cells utilise enzymes for a variety of functions including the production 
of prostaglandins as well as their inactivation, and the production of nitric oxide using 
endogenous nitric oxide synthases48–50. By incubating red blood cells with protease inhibitors, 
some enzyme activity may have been suppressed causing the observed reduction in exogenous 
MIF (Figure 3.4). The protease inhibitors used in this study are a cocktail of broad spectrum 
inhibitors, that act on serine-, cysteine-, and metalloproteases. Future work in this area would 
benefit from studying the effect of individual inhibitors on the binding and release activity of 
red blood cells. In order to investigate this further, use of stable isotope labelled or xeno-protein 
would provide valuable information. These techniques could be used to track the movement of 
the protein and to determine whether or not it was internalised or modified by protease activity.   
3.4.2.4 Red blood cell depletion 
Although it was not investigated in this study, one area of interest for further research may be 
the effect of depleting the cells of MIF. One hypothesis for the lack of binding observed in this 
study (Figure 3.4) was that the cells may already be saturated with MIF, which may also induce 
feedback inhibition. Depleting the cells of this protein may enable MIF to bind more readily to 
the red blood cells. Specific methods of depletion have not been investigated in detail in this 
project, but it has been observed that methods involving extensive washing of the cells may 
result in this type of depletion (Appendix B). If depleting the cells did result in a higher binding 
capacity for MIF, there is a possibility that the cells could be depleted in vitro and then used as 
a therapeutic for diseases associated with excess levels of MIF such as sepsis or rheumatoid 
arthritis7,9. This type of therapy may have utility as an alternative to anti-MIF treatments.  
 
3.4.3  Evidence for a dual role 
MIF is a unique cytokine that functions both as an inflammatory chemokine and as an enzyme. 
The inflammatory activity of MIF is dependent on the enzymatic active site, thus these two 
functions are linked51. Swope et al. showed that by blocking the enzymatic active site, MIF 
had a reduced capacity to activate neutrophils51. Most studies that investigate the activity of 
MIF use protein that has been secreted from white blood cells. The study in this chapter 
investigated the activity of intracellular MIF. A key finding, that has relevance to the capacity 
of red blood cells to affect the immune response, was that intracellular MIF is enzymatically 
active and thus likely to be functional as a chemokine (Figure 3.6). 
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3.4.3.1 Intracellular: Oxidoreductase activity 
The less frequently discussed enzymatic function of MIF is its thiol-oxidoreductase activity 
and its ability to scavenge reactive oxygen species52,53. This study demonstrated that there is a 
high concentration of MIF in red blood cells, which may be explained by assuming that the 
primary function is intra-cellular oxidoreductase activity. The chemokine activity of MIF from 
red blood cells is likely to be observed by either release from intact cells or in much higher 
concentrations after red blood cell lysis. Nguyen et al. identified that the oxidoreductase 
activity is retained in a specific peptide fragment of MIF which is independent of its 
tautomerase activity52. This activity has since been demonstrated in a number of cell types. 
MIF deficient fibroblasts contained 2.3-fold more intracellular reactive oxygen species (ROS) 
than the MIF-positive controls53 and in neurons the increase in ROS after stimulation was 
decreased by intracellular administration of rMIF54. The effect of MIF on oxidative stress has 
also been demonstrated on whole organisms. Recently, MIF has been shown to play a crucial 
role in healthy lung development in neonates55. Hyperoxia-induced lung injury (HALI) is lung 
damage that can result from exposure to high levels of oxygen such as in a neonatal intensive 
care unit. In a recent article, Sun et al. identified that MIF plays an important regulatory role 
in dealing with high levels of oxygen56. When MIF was knocked down, there was a higher 
level of mortality among the mice. Similarly, altered expression of MIF in pre-term infants was 
associated with the incidence of bronchopulmonary dysplasia57. For premature mouse pups, 
only 8 % of MIF deficient mice survived compared to 75 % of the wild type mice55. The low 
mortality rate of MIF deficient mice was closely correlated with less mature lungs than the 
control group. 
Red blood cells are burdened with substantial oxidative stress due to their primary oxygen-
carrying function. To combat this, they contain a number of known mechanisms, such as the 
20S proteasome, to deal with this stress and catabolise damaged proteins. Intracellular MIF is 
likely to be another part of the red blood cell stress mechanism. Investigation in the activity of 
MIF as an oxidoreductase in red blood cell lysates was complicated by the fact that red blood 
cells contain a variety of different oxidoreductase enzymes. Thus, investigation into this 
activity would require protein purification to isolate the red blood cell derived MIF in its native 
form. Quantifying the oxidoreductase activity of red blood cell derived MIF would be 
interesting, but was not in the scope of this study. 
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3.4.3.2 Extracellular: Cytokine activity 
MIF has also been described to have a number of roles in inflammation. It was originally 
identified as the factor that inhibited macrophages from migrating away from the site of 
inflammation8. Since then, it has been identified as a chemotactic attractant for monocytes, a 
modulator of glucocorticoid activity, and involved in neutrophil activation17,19,51. Since MIF 
has multiple enzymatic and chemotactic functions, studying the cytokine activity in isolation 
is not straightforward. Glucocorticoid regulation by MIF is associated with its oxidoreductase 
activity and the leukocyte activation is associated with its tautomerase activity51,52. The 
migration assay used to measure MIF activity involves the quantification of cell migration in 
the presence of MIF compared to controls. Numerous problems have been reported with the 
assay due to cell aggregation, surface adhesion, and passive migration, which lead to high 
standard deviations and only semi-quantitative results58. In addition, there have been reports of 
difficulty in purifying active MIF, which have led to suggestions that tertiary structural changes 
or an unknown co-factor affects the activity58.  
The data presented in this chapter indicate that MIF is present at a concentration of 
approximately 30 µg/mL in whole blood, which is one million times higher than the pg/mL 
levels usually reported for cytokines in plasma. Given that acute injury events, such as those 
reported by Pohl et al.22 can cause the release of high quantifies of MIF locally and 
systemically, it seems likely that a mechanism for the attenuation of MIF chemokine activity 
would exist. 
3.4.3.3 Other: Tautomerase activity 
Substantial research has been done on investigating the tautomerase activity of MIF with a 
particular emphasis on the development of MIF inhibitors7,59. In spite of this, its biological 
substrate is yet to be identified and the reason for MIF having this activity remains unknown. 
A number of chemical substrates for MIF tautomerase activity have been identified (such as 
D-dopachrome, L/D-dopachrome methyl ester, or p-hydroxyphenyl-pyruvate) and are used to 
quantify the level of activity in vitro. D-dopachrome tautomerase (DDT), or MIF-2, catalyses 
the same substrates in vitro, but its activity is not inhibited by the same chemical, ISO-135. 
This study identified that red blood cell lysates and cytosols are enzymatically active and are 
active at a rate that is comparable to recombinant MIF. Considering that the majority of MIF 
is present in the cytosolic fraction of red blood cells (Figure 3.1) it is not surprising that there 
was not a significant difference in the rate of substrate degradation between the whole lysate 
Chapter 3 – Identification of RBCs as the primary reservoir of MIF in whole blood 
77 
 
and the cytosol (Figure 3.6). Inhibition of recombinant MIF, lysate derived MIF, and cytosolic 
MIF using ISO-1 resulted in a significant attenuation of the breakdown of the substrate (Figure 
3.7). However, it was difficult to quantify how effective this inhibition was in red blood cells 
samples. For ISO-1 to act effectively as an inhibitor of MIF activity, it required a high 
concentration (~50 %) of organic solvent to be present. The most widely reported solvent for 
ISO-1 is DMSO. Although the presence of DMSO did not affect recombinant MIF, it interfered 
with the red blood cell samples and the addition of the DMSO vehicle alone turned the solutions 
opaque. This interference has been documented in the literature60, so to circumvent this, the 
effects of a range of other organic solvents were tested and methanol was chosen as the optimal 
solvent. Methanol did not impede the inhibitory effect of ISO-1 and it had the lowest 
background interference for red blood cell samples. The background effect of methanol as a 
vehicle on the samples was less for the cytosolic fraction (Figure 3.7c) than for the lysates 
(Figure 3.7b) as some precipitation was observed in the lysate samples at the conclusion of the 
incubation with the sample. 
Although MIF inhibition did occur, it was not possible to quantify the level of inhibition with 
the current assay and the complex nature of the red blood cell lysate. It is not clear if the 
tautomerase activity was a result of MIF enzymatic activity alone, or if it was a combination 
of MIF and D-dopachrome tautomerase enzymatic activity. Future studies should target the 
identification of MIF inhibitors that are compatible with complex protein solutions such as cell 
lysates. 
 
3.4.4   Implications in disease 
High plasma levels of MIF are often correlated with increased inflammation. A key aspect to 
consider, regarding the microgram quantities of MIF residing in red blood cells, is the 
implications of cell lysis in disease or injury. Red blood cell lysis can occur following injury, 
which would release high concentrations of enzymatically and chemotactically active MIF. 
This immediate release of high levels of MIF may actually play a role in the early stages of the 
immune response to injury. There is considerable literature on the protective effects of MIF 
and a recent paper on an animal model of ischemia reperfusion injury after myocardial 
infarction demonstrated that MIF exerts both pro-inflammatory effects and protective effects 
in cardiomyocytes61. 
It is important to note that the data enclosed in this chapter was collected using blood from 
healthy volunteers, and as such, analysis of blood isolated from specific disease cohorts in the 
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future would be of value. MIF is frequently cited as being present at increased concentrations 
in the plasma of diseased cohorts when compared to the healthy controls10-12. It is not 
unreasonable, therefore, to hypothesise that the concentration of MIF in, or being released by, 
red blood cells may also differ in these groups. Further research in this area should seek to 
determine if there is any correlation between red blood cell associated MIF and the initiation, 
progression, or the protection against inflammatory disease.   
MIF in red blood cells is likely present for a number of reasons. It is part of the mechanism by 
which the red blood cell manages oxidative stress, and it is able to exert its pro-inflammatory 
and protective functions upon lysis. Like MIF, red blood cells too are playing multiple roles. 
Whilst their primary role is in a gas transport and exchange, they are also likely to be involved 
in the immune response. Further investigation into this alternative role for red blood cells will 
be outlined in Chapter 4. 
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3.5   CONCLUSION 
 
The results of this chapter demonstrate that in vivo haemolysis would result in the release of 
high concentrations of active MIF. Unless this excess MIF is modulated or deactivated in other 
ways, this released MIF would exert its pro-inflammatory signalling activity on surrounding 
cells. MIF has been described as an important factor in a wide variety of diseases and a review 
of the literature presents a rich tapestry of its interactions in many cell types, including both 
pro-inflammatory and protective effects in the same injury model. The identification and 
quantification of this cytokine in its active form in the most abundant cell type in the body (red 
blood cells) is likely to contribute to the understanding of a number of these MIF associated 
conditions. MIF is present in whole blood in microgram quantities per millilitre, however, 
during normal function, over 90 % is sequestered in the red blood cell cytosol. The release of 
MIF in microgram per millilitre concentrations after injury suggests that highly effective 
mechanisms are present to suppress its chemokine activity. Given the literature on the 
protective functions of MIF, an alternative hypothesis is that extracellular MIF has a cell and 
tissue protective function that may be its primary role after acute injury62.  
This discovery could have implications on conditions such as haemolytic anaemia, wound 
healing and clot formation, sepsis, and adverse events following red blood cell transfusions. 
More research is required to elucidate the involvement of red blood cell derived MIF in a 
variety of processes, but this discovery may change the way that disease is researched, 
including its progression and the involvement of the immune system. Just as ‘junk DNA’ was 
discovered to be anything but ‘junk’, so too are red blood more active than was once thought. 
Subsequent chapters in this thesis investigate the presence of other cytokines and growth 
factors in red blood cells that may be working in concert with MIF to communicate with the 
immune system. 
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CHAPTER 
  
--------------------------------------------------------------------------- 
 
INVESTIGATION AND QUANTIFICATION OF A PANEL OF 
CYTOKINES IN RED BLOOD CELLS 
 
 
 
This chapter investigates the presence of a panel of 48 cytokines in red blood cell lysates 
isolated from healthy volunteers. The previous chapter of this thesis demonstrated that red 
blood cells are the primary reservoir for macrophage migration inhibitory factor in whole 
blood and that this protein was enzymatically active. Upon the discovery that this pro-
inflammatory protein was present in red blood cells at 1000-fold the concentration that is 
detected in plasma, it was desirable to know if this was to be observed for any other 
inflammatory cytokines. This chapter will expand on that investigation by quantifying the levels 
of 47 additional cytokines in red blood cells and in plasma using multi-plex technology. In 
addition, the binding and release of these cytokines from red blood cells will be assessed with 
consideration of the role of proteases in these activities. This investigation is based on the 
premise that red blood cells are able to act as a buffer in the blood for inflammatory molecules 
by binding and releasing these proteins as needed. 
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4.1    INTRODUCTION 
 
Analysis of clinical blood samples is typically one of the first steps in diagnosing disease and 
is an important part of the research process of seeking new diagnostic markers. Monitoring the 
level of markers such as liver enzymes or C-reactive protein in the plasma component of blood 
can be indicative of inflammatory changes that occur in a wide range of conditions. Testing 
only plasma or serum simplifies the analysis by removing the cellular components of the blood. 
This is valuable, but it represents an incomplete profile of the relevant markers. The plasma is 
only one part of a much more complex, living tissue that rapidly responds to stress by altering 
the levels of signalling proteins that are also commonly studied markers1. After blood is 
collected for analysis, the sample must be stabilised to avoid changes in the plasma levels of 
disease markers. A number of factors, such as choice of anticoagulant, temperature, time, cell 
lysis, or platelet activation can result in release of cytokines and other proteins into the plasma 
thus invalidating the resulting analysis2. In the previous chapter, macrophage migration 
inhibitory factor (MIF) was shown to be present in red blood cells at levels 1000-fold higher 
than the typical plasma concentration (Chapter 3). After blood collection, the plasma level of 
MIF could be significantly altered by relatively low levels of haemolysis or by release of MIF 
by intact red blood cells. In this chapter, the analysis of potential biomarkers associated with 
red blood cells was widened to include 47 additional cytokines, chemokines, and growth factors 
that are commonly studies as biomarkers of disease. Importantly, the analysis included the total 
concentration in red blood cell lysates and the concentration released by intact red blood cells. 
Blood is composed of three main cell types (white blood cells, red blood cells, and platelets) 
suspended in plasma. An understanding and analysis of the other components of blood can 
provide some critical information in disease populations. Differential white blood cell counts 
and morphological changes in leukocytes can provide valuable diagnostic information that 
supplement other tests and clinical assessments3. These cells are known to produce and respond 
to a number of cytokines to either promote or suppress inflammatory processes4,5 and more 
recent research into white blood cells has revealed that they have significant roles in some 
diseases and would potentially have value in diagnostics6,7. Platelets are specialised, enucleate, 
cellular components of blood that function in the coagulation cascade to stop bleeding by 
aggregating and clotting blood vessel injuries. The role of platelets in signalling, has been the 
subject of recent research and they have been demonstrated to contain mRNA and a range of 
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inflammatory signalling proteins, which may play a role in inflammatory diseases such as 
atherosclerosis8–10. Platelets are an easily harvested source of cytokines and growth factors and 
have been harnessed as a therapeutic for inflammatory conditions, such as the use of platelet 
rich plasma for osteoarthritis11. Red blood cells on the other hand are understudied and are 
generally understood to be primarily involved in respiratory gas exchange. As a result of this 
and their extremely high haemoglobin content, which is considered a contaminant in biomarker 
studies, red blood cells are discarded more often than they are analysed. The use of red blood 
cells for diagnostics is typically limited to monitoring cell number, concentration of 
haemoglobin, and erythrocyte sedimentation rate12. Although red blood cell research has been 
relatively slow, some studies have shown that red blood cells are multifunctional and may be 
more complex than previously understood.  
Red blood cells can enhance cytotoxicity mediated by natural killer cells against tumour cells 
in vitro in a dose-dependent manner13. Red blood cells, or soluble factors released by these 
cells, can also stimulate the secretion of pro-inflammatory markers from lung fibroblasts14. 
These studies demonstrate that red blood cells may be an important component of the immune 
system and are capable of signalling or receiving signal from other cell types. In 1974, 
Fox et al. reported that red blood cells could ‘mop up’ endogenous macrophage migration 
inhibitory factor (MIF)15, which they postulated was due to red blood cell binding and others 
have reported similar activity with the Duffy antigen receptor for chemokines (DARC). DARC 
is a receptor on the surface of most red blood cells and has been studied as the primary binding 
site for the pathogen Plasmodium vivax16. However, as Neote et al. identified, this receptor is 
“promiscuous” and has a number of binding targets17. These targets include some chemokines 
from the C-X-C or C-C cytokine families including IL-8, RANTES, and MCP-1. They 
proposed that the role of this receptor may be to act as a chemokine sink for modulating 
inflammation. Since this report in 1993, few additional cytokines and inflammatory proteins 
have been identified on or in red blood cells18–20.  
The previous chapter of this thesis demonstrated that red blood cells are the primary reservoir 
of the pro-inflammatory cytokine MIF in whole blood (Chapter 3). This cytokine is present in 
red blood cells in its active pro-inflammatory state within the cell cytosol, suggesting that it is 
primed for activity upon red blood cell lysis. This further supports the theory that the red blood 
cells may in fact play an important role in inflammation. Red blood cells are devoid of 
organelles, but they have developed alternative processes to continue functioning throughout 
their lifetime. MIF is just one of the many active enzymes within red blood cells. Red blood 
cells contain an enzymatic structure known as the 20S proteasome21. This proteasome is crucial 
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for managing oxidative stress and protein damage within the cell in concert with other enzymes 
such as catalase and glutathione peroxidase22,23. Membrane bound enzyme complexes regulate 
glycolysis24, and intracellular enzymes function in protein and molecule modification within 
red blood cells25. Oonishi et al. reported that mechanical stress stimulated the red blood cells 
to produce more cytosolic PGE1 and PGE225. They postulated, with support from previous 
literature26,27, that enzymes were responsible for modifying the molecules into their active, 
detectable state when stressed. 
Previous studies have identified a small number of chemokines associated with red blood cells, 
however, the role of red blood cells in signalling remains poorly understood. In this chapter, 
the analysis of purified red blood cells was widened to include 47 additional cytokines, 
chemokines, and growth factors that are commonly studied as biomarkers of disease. In 
addition, the analysis explored factors that may affect the binding and release of cytokines from 
red blood cells, including enzymatic control. It is of interest to understand how red blood cells 
may be involved in the homeostasis of whole blood by releasing and binding of signalling 
proteins. 
 
4.1.1   Chapter hypothesis 
It is hypothesised that red blood cells are associated with more cytokines than MIF alone, and 
that red blood cells can bind and release these cytokines in response to their environment. 
 
4.1.2   Chapter aims 
1. To quantify the levels of a panel of 48 inflammatory cytokines, chemokines, and growth 
factors in human red blood cells. 
2. To investigate the capacity of red blood cells to bind and release these cytokines. 
3. To determine the role of proteases in cytokine binding and release. 
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4.2   METHODS 
 
4.2.1   Blood collection 
Whole blood was collected from healthy volunteers by venepuncture (n = 10; female: 6, 
male: 4) directly into EDTA vacutainers (K2EDTA vacutainers, BD Biosciences). The age 
range of these participants was 23 - 47 years. All fractions of blood were collected and 
processed at room temperature within four hours of collection. All samples were stored at -
80 °C and were subjected to three freeze-thaw cycles at -80 °C to ensure complete cellular lysis 
prior to analysis. 
This study was approved by the Macquarie University Human Research Ethics Committee 
(5201100827) and by the Northern Sydney Coast Human Research Ethics Committee of 
NSLHD and CCLHD (1201-046M). Written consent was collected from all participants before 
participation in this study. 
 
4.2.2   Plasma and blood cell isolation 
Plasma and blood cells were isolated from EDTA anti-coagulated whole blood. Plasma and 
white blood cells at known concentrations were collected and frozen immediately for future 
analysis. Red blood cells were collected and were either frozen immediately or were used fresh 
for storage and protein binding experiments (Section 4.2.3 and 4.2.4). Cell number and purity 
was determined using a haematology analyser (Coulter AcT Diff, Beckman Coulter). 
4.2.2.1 Plasma 
Plasma was isolated by centrifuging whole, anticoagulated blood at 1500 g for 10 minutes at 
room temperature. The plasma fraction was collected and stored at -80 °C.  
4.2.2.2 Red blood cells and white blood cells 
Red blood cells and white blood cells were isolated using dextran sedimentation as follows. 
Whole blood was added to a 6 % solution of dextran (w/v in 0.15 M sodium chloride.) at a 2:1 
ratio. This solution was left at room temperature for 1 hour for the red blood cells to sediment 
to the bottom of the tube. After this time the upper white blood cell rich layer and the lower 
red blood cell fraction were separated and added into individual tubes. The lower red blood 
cell fraction was washed once in phosphate buffered saline (PBS, 500 g, 5 minutes) and the 
remaining red blood cell pellet was either frozen (-80 °C) or used fresh. The upper, white blood 
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cell rich layer was washed once in PBS (1000 g, 10 minutes). The supernatant was discarded, 
and any contaminating red blood cells were lysed by hypotonic shock by resuspending the cell 
pellet in 3 mL Milli-Q water for 30 seconds. After this time, isotonicity was restored by adding 
1 mL potassium chloride (0.65 M) and the solution was diluted up to 15 mL with PBS. The 
remaining cells were pelleted and washed twice in PBS (1000 g, 5 minutes) and the remaining 
cell pellet was resuspended in PBS and frozen immediately at -80 °C. 
 
4.2.3   Red blood cell conditioned medium 
After isolation, red blood cells were either frozen immediately in PBS (400 million cells per 
mL) to produce red blood cell lysates (T0) or they were incubated for 24 hours in PBS (T24, 
200 million cells per mL, 37 °C, 5 % CO2). Red blood cells were incubated with or without 
protease inhibitors (1x, mini cOmplete protease inhibitor cocktail tablets, Roche). After 
incubation, the conditioned media was collected by centrifugation (500 g, 5 minutes), and the 
remaining red blood cell pellet was resuspended to a concentration of 400 million cells per mL. 
All samples were stored at -80 °C, and were subjected to three freeze/thaw cycles before 
analysis. 
 
4.2.4   Red blood cell protein binding 
To assess whether or not red blood cells could bind exogenous protein out of solution, they 
were incubated for 24 hours (T24, 37 °C, 5 % CO2) in the presence of Bio-Plex recombinant 
protein standards reconstituted and diluted in PBS (27-plex and 21-plex human cytokine 
panels, Bio-Rad). Recombinant protein standards (25 µL, Bio-Plex standard-3) were diluted in 
175 µL of PBS with or without protease inhibitors (1x, mini cOmplete protease inhibitor 
cocktail tablets, Roche). Red blood cells were incubated at 200 million cells per mL according 
to the conditions outlined in Table 4.1. An aliquot of untreated red blood cells was also frozen 
prior to incubation (T0) in PBS (400 million cells per mL). 
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Table 4.1. Incubation conditions for red blood cell (RBC) protein binding analysis at 
37 °C, 5 % CO2. 
RBCs  
(200 million cells per mL) PBS  
Recombinant 
Protein 
Protease 
Inhibitors 
Condition 1 (Control)    
Condition 2 (BP)    
Condition 3 (PrI)    
Condition 4 (BP-PrI)    
 
After incubation, the resulting conditioned media was isolated by centrifugation (500 g, 
5 minutes), and the remaining red blood cell pellet was resuspended to a concentration of 
400 million cells per mL. All samples were stored at -80 °C, and underwent three freeze/thaw 
cycles before analysis. 
 
4.2.5   Bicinchoninic acid assay 
To evaluate the amount of protein that was released by the red blood cells, the red blood cell 
conditioned media was analysed using the bicinchoninic acid (BCA) assay (Pierce BCA 
Protein Assay Kit, Thermo Fisher Scientific) according to the manufacturers instructions. 
Standards were prepared for the calibration curve by serial dilution of bovine serum albumin. 
To run the assay, 25 µL of the sample, standard, or blank controls were incubated with 200 µL 
of the assay kit reagent solution (50:1, Reagent A:B) in a clear flat-bottom 96 well plate. This 
solution was briefly mixed using an orbital shaker (500 rpm, 0.5 minutes), after which the plate 
was covered and incubated at 37 °C for 30 minutes. Following incubation, the absorbance was 
measured at 562 nm on a plate reader (Synergy 2 plate reader, BioTek). The calibration curve 
was analysed using four-parameter curve fit on GraphPad Prism software (ver. 6, USA).  
 
4.2.6   Haemoglobin quantification 
Levels of free haemoglobin in plasma samples and red blood cell conditioned media samples 
were monitored by assessing absorbance at 414 nm (Synergy 2 plate reader, BioTek) as 
previously described28. Peaks at this wavelength are indicative of free haemoglobin. Red blood 
cell membranes were removed from the conditioned media samples prior to analysis by 
centrifugation at 16,000 g for 15 minutes. A haemoglobin calibration curve was prepared using 
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purified haemoglobin (Sigma Aldrich) and the resulting data were analysed on GraphPad Prism 
software (ver. 6, USA). 
 
4.2.7   Cytokine multiplex assay 
Two multiplex assays were used in this study, the first was the 27-plex human cytokine panel 
that assays for FGF basic, Eotaxin-1, G-CSF, GM-CSF, IFN-γ, IL-1β, IL-1ra, IL-2, IL-4, IL-
5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12(p70), IL-13, IL-15, IL-17, IP-10, MCP-1, MIP-1α, MIP-
1β, PDGF-BB, RANTES, TNF-α, and VEGF, and the second was the 21-plex human cytokine 
panel that assays for IL-1α, IL-2Ra, IL-3, IL-12(p40), IL-16, IL-18, CTACK, GRO-α, HGF, 
IFN-α2, LIF, MCP-3, M-CSF, MIF, MIG, β-NGF, SCF, SCGF-β, SDF-1α, TNF-β, TRAIL 
(Bio-Plex Pro 27-plex and 21-plex, Bio-Rad). The assays were performed according to 
manufacturer’s instructions using an automated magnetic wash station (Bio-Plex Pro II, Bio-
Rad) for the washing steps. The assays were run on the Luminex® 200TM system (Bio-Rad) 
and fluorescence values were collected. The calibration curve for each cytokine was analysed 
with 5 parametric logistic curve regression using Bio-Plex manager software (ver. 5.0, Bio-
Rad, USA). Standard values were considered acceptable if the points fell within 80 - 120 % of 
the expected values.  
 
4.2.8   Recovery efficiency 
To assess any signal interference in the red blood cell lysates, the Bio-Plex recombinant protein 
standards were spiked into the lysates (25 µL of Bio-Plex standard-3 into 75 µL of lysate). A 
control was also run, wherein the sample diluent was added at the spiking volume to the red 
blood cell lysates to account for any dilution effect. These samples were analysed using the 27-
plex and 21-plex human cytokine panels (Bio-Plex Pro, Bio-Rad). The recovery efficiency for 
each cytokine was determined using the following equation: 
 
Equation 4.1.  Recombinant protein recovery efficiency. 
ܣ ൅ ܤ
ܥ ൈ100 ൌ ܲ݁ݎܿ݁݊ݐܽ݃݁	ݎ݁ܿ݋ݒ݁ݎݕ 
Where, 
A = Concentration of un-spiked control 
B = Concentration of recombinant protein (spiked) 
C = Final assayed concentration of sample 
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4.2.9   Statistical analysis 
The multiplex assay data are presented as either concentration or fold change of fluorescence. 
Protein concentration (BCA assay) and haemoglobin concentration of plasma and conditioned 
media samples were statistically evaluated using two-tailed, paired t-test to assess statistical 
significance (p < 0.05) between groups. Graphing of results was performed using GraphPad 
Prism software (ver. 6, USA). The concentration of cytokines in blood components was 
presented according to the relative contribution in one millilitre of whole blood. This 
calculation was performed for each cell population according to the following equation: 
 
Equation 4.2. Concentration of protein in one millilitre of whole blood. 
	ܣܤ	ൈ		ܥ ൌ ܥ݋݊ݐݎܾ݅ݑݐ݅݋݊	ݐ݋	ݓ݄݋݈݁	ܾ݈݋݋݀ 
Where, 
 A = Original cell number of population in one millilitre of whole blood 
 B = Number of cells assayed per millilitre 
 C = Concentration of analyte per millilitre 
 
Statistical analysis of raw fluorescence responses from cytokine data were performed using ‘R’ 
version 3.2.3 (2015-12-10, R: A Language and Environment for Statistical Computing). 
Mixed-effects modelling was done using lmer29. The significance of interaction terms and 
interaction means and their associated standard errors were obtained using the Phia package30, 
for post-hoc analysis. Multiple test correction was done according to Holm’s method31. To 
analyse the fluorescence response, the following mixed-effects model, in R notation, was used:  
 
Equation 4.3. Mixed-effects model for statistical analysis of cytokine data. 
log2ሺFIሻ~Fluid ∗ Cytokine ൅ Treatment ∗ Cytokine ൅ Treatment: Fluid
൅ ሺ1|IDሻ ൅ ሺ1|Treatment: Fluid: Plateሻ 
 
Where the log2 of fluorescence responses (Fl) was modelled using 3 fixed effects, (1) Fluid (2 
levels, lysate and secretion), (2) Cytokine (either 27 or 21 levels), and (3) Treatment (4 levels, 
Control, PrI, BP, BP-PrI) plus their 1st degree interactions, together with two random effects 
defined as (1:ID), where ID represented subject identifier, and (1|Treatment:Fluid:plate) and  
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where plate was a factor containing 2 levels. The random effects account for patient-to-patient 
variability and for differences with respect to Treatment and Fluid groupings across the 2 
cytokine plates.  
For the remainder of this chapter, the term ‘significant’ will be used to indicate a statistically 
significant result of p < 0.05 unless otherwise specified.  
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4.3   RESULTS 
 
4.3.1   Red blood cell purity  
The purity of the enriched red blood cell populations was calculated according to the efficiency 
of white blood cell and platelet depletion from whole blood samples. Dextran sedimentation of 
whole blood resulted in depletion of approximately 82 % of white blood cells and 98 % of 
platelets from the enriched red blood cell fractions (Table 4.2). Thus, for every one million red 
blood cells there were approximately 175 contaminating white blood cells and 3,450 
contaminating platelets. 
 
Table 4.2. Purity assessment of enriched red blood cell (RBC) fractions (n = 10). 
RBC purity (%) White blood cell depletion (%) Platelet depletion (%) 
99.97 ± 0.01 82.5 ± 6.8 97.7 ± 3.0 
*Data are presented as mean ± SD 
  
  
4.3.2   Cytokine profile of plasma and red blood cells 
The cytokine profile of red blood cells, white blood cells, and plasma was analysed by using 
an antibody-mediated multiplex bead array. White blood cell correction for red blood cell 
cytokine concentration was achieved by determining the cytokine load of a known number of 
white blood cells and then calculating the load of the contaminating white blood cells. Of the 
48 cytokines that were assayed for, 44 were present in the plasma fraction and 35 were present 
at detectable levels in the red blood cells of one or more biological replicate after correction 
for white blood cell contamination (Table 4.3). When calculated back to the relative 
contribution of the plasma and red blood cells in one millilitre of whole blood, the red blood 
cells represented the largest reservoir for 69 % of the cytokines (33 in 48) compared to the 
plasma. Across the 48 cytokines analysed, there were 31 where the level of the cytokine in red 
blood cells substantially exceeded the plasma level (> 2-fold increase). In these proteins, the 
range of fold increase in red blood cells versus plasma was 3.6 to 3970 (i.e. the red blood 
cell:plasma ratio). In these 31 cytokines, the median fold change was 11.3. Two cytokines, 
MIG and SCGF-β, were higher in plasma than in the red blood cell population (Table 4.3).  
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There were three cytokines that were present at high levels in white blood cells but returned 
anomalous results in the purified red blood cells (IL-1ra, PDGF-bb, SCGF-β). For these 
cytokines, the expected concentration for white blood cell contamination in red blood cell 
populations was more than what was detected. The concentration of IL-1ra in white blood cells 
(when corrected to the number of white blood cells contaminating the red blood cell 
populations) was predicted to be present at a mean of 1572.8 pg/mL across all six biological 
replicates. However, in the purified red blood cells, IL-1ra was detected in only one biological 
replicate at 299.6 pg/mL, which is 5-fold lower than predicted. Similar discrepancies were 
observed with SCGF-β and IL-2 (Table 4.3). The mean depletion of white blood cells and 
platelets were 83 % and 98 % respectively. The small number of contaminating cells may not 
be representative of the whole heterogeneous population, which may account for the anomalous 
results. 
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Table 4.3. Concentration of cytokines in EDTA plasma and red blood cells (RBCs) in one millilitre of whole blood with correction for white 
blood cell contamination (n = 6). 
Cytokine 
Plasma* RBCs* White blood cell (WBC) contribution 
No. of 
subjects 
pg/mL of whole blood No. of 
subjects 
pg/mL of whole blood Corrected for WBC contamination (pg/mL) pg/mL of total No. of subjects Concentration SD Concentration SD Concentration SD Concentration SD 
Pro-inflammatory 
IFN-α2 6 8.9 2 6 256.2 130 256.2 130.0 - - 0 
IFN-γ 6 17.7 9.5 5 106.4 56.5 105.3 56.2 1.2 0.2 6 
IL-1α 2 2.5 0.3 0 - - - - 3.8 0.6 2 
IL-1β 5 0.4 0.1 0 - - - - 1.2 0.2 6 
IL-5 5 2.5 1.8 3 28.2 12.6 28.2 12.6 - - 0 
IL-9 2 2 1.5 0 - - - - 1.1 1.2 3 
IL-12(p70) 5 2.5 1 3 19.8 15.4 15.0 16.3 3.9 1.4 6 
IL-15 0 - - 0 - - - - 3.0 1.4 2 
IL-17 3 7.5 1.8 3 87.9 50.2 70.1 46.6 23.0 6.5 6 
IL-18 6 6.2 3.2 6 505.4 251.5 488.2 247.9 17.2 7.9 6 
MIF 6 28.1 3.8 6 111,633 56,912 111,545 56,954 87.9 64.7 6 
TNF-α 6 7.1 3.3 2 79.7 62.5 54.3 76.5 21.4 8.4 6 
TNF-β 3 3.1 0.9 2 31.7 11.4 31.7 11.4 - - 0 
TRAIL 6 25.2 11.7 4 262.6 63.2 247.8 66.0 20.9 8.0 4 
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Cytokine 
Plasma* RBCs* White blood cell (WBC) contribution 
No. of 
subjects 
pg/mL of whole blood No. of 
subjects 
pg/mL of whole blood Corrected for WBC contamination (pg/mL) pg/mL of total No. of subjects Concentration SD Concentration SD Concentration SD Concentration SD 
Anti-inflammatory 
IL-1ra 5 20.8 6.6 1 299.6 - - - 1572.8 252.7 6 
IL-2ra 6 29.3 5.3 3 282.6 31.7 280.9 28.8 6.2 5.3 3 
IL-4 4 0.4 0.2 2 4.6 0.8 3.3 0.9 1.4 0.2 6 
IL-10 1 1.4 - 0 - - - - - - 0 
IL-13 5 2.0 1.0 3 2.3 2.3 1.4 2.3 0.9 0.1 6 
Chemokines 
CTACK 6 36.3 9.3 5 222.2 85.7 131.4 100.5 93.28 33.6 6 
Eotaxin-1 5 6.4 2.2 6 79.3 38.4 74.6 38.4 4.8 0.9 6 
GRO-α 3 6.0 1.7 4 187.3 47.8 184.0 54.3 4.8 0.9 6 
IL-8 5 1.5 0.3 1 25.4 - - - 24.6 15.7 6 
IL-16 6 46.6 11.2 5 2904.9 3231.7 2904.9 3231.7 - - 0 
MCP-1 0 - - 2 55.0 6.8 36.1 7.7 15.5 4.9 6 
MCP-3 4 23.4 5.5 0 - - - - - - 0 
MIG 6 70.2 34.5 0 - - - - 3.7 0.7 3 
MIP-1α 6 0.5 0.3 4 5.2 2.3 3.9 2.1 1.5 0.4 6 
MIP-1β 6 6.3 3.5 2 42.7 56.3 25.7 48.9 9.4 7.3 6 
RANTES 6 510.7 268.5 6 8744 11,785 5618 10,489 3125.8 1488.3 6 
SDF-1α 6 121.9 11.3 6 872.4 206.2 811.8 193.4 60.5 34.0 6 
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Cytokine 
Plasma* RBCs* White blood cell (WBC) contribution 
No. of 
subjects 
pg/mL of whole blood No. of 
subjects 
pg/mL of whole blood Corrected for WBC contamination (pg/mL) pg/mL of total No. of subjects Concentration SD Concentration SD Concentration SD Concentration SD 
Growth Factors 
bFGF 6 4.8 2.0 6 197.1 72.4 147.2 87.3 49.9 18.2 6 
G-CSF 6 5.3 3.6 3 148.8 79.0 131.1 79.1 16.0 3.1 6 
GM-CSF 0 - - 5 939.7 460.2 772.3 538.5 185.3 85.1 6 
HGF 6 39.8 7.8 6 800.3 490.5 691.2 500.3 109.1 31.5 6 
IL-3 6 18.1 2.0 6 345.8 209.7 334.2 217.6 17.4 6.8 4 
IL-7 5 1.7 0.9 2 34.6 5.2 34.0 6.2 1.2 0.2 2 
IP-10 6 132.5 142.7 4 147.8 87.1 134.0 83.3 15.0 3.5 6 
M-CSF 6 4.3 3.2 3 115.6 7.9 99.5 13.2 17.0 4.3 5 
β-NGF 5 1.2 0.2 0 - - - - - - 0 
PDGF-bb 6 20.3 17.4 5 1073.5 2004.9 115.4 2095.6 1018.9 353.1 6 
SCF 6 6.5 1.5 1 54.1 - 51.9 - 1.9 0.6 4 
SCGF-β 3 944.3 563.9 0 - - - - 118.7 69.2 4 
VEGF 5 2.1 0.8 6 113.9 50.3 82.8 53.7 31.1 7.5 6 
Cytokines with multiple functions 
IL-2 0 - - 0 - - - - 15.9 6.6 6 
IL-6 2 0.5 0.1 0 - - - - 1.6 0.7 4 
Il-12(p40) 1 44.5 - 3 1914.7 357.9 1693.7 254.7 301.1 130.9 6 
LIF 6 5.7 3.2 3 119.5 27.5 119.5 27.5 - - 0 
*Data are presented as mean ± SD 
**Cytokines in bold are ≥ 2 fold higher in the red blood cell lysates (corrected for WBC contamination) compared to plasma
Chapter 4 – Investigation and quantification of a panel of cytokines in RBCs 
101 
 
 
4.3.3   Recovery efficiency 
To assess whether there was any interfering factors in red blood cell lysates that may confound 
quantitative results, the recovery efficiency of recombinant protein in red blood cell lysates 
was determined. A recovery efficiency of < 100 % indicated that the assay was not detecting 
all of the available cytokines, and a recovery efficiency of > 100 % indicated that the assay was 
reporting more cytokine than was actually present. For this study, the mean recovery efficiency 
in red blood cell lysates for 42 of 48 of the cytokines fell between 70 and 120 % (Table 4.4). 
For approximately 75 % of the cytokines, the available protein was below 100 % mean 
recovery. There were four cytokines (mostly chemokines) that had mean recovery efficiency 
of over 120 %, including IFN-α2 (166.6 ± 34.2 %), GRO-α (225.1 ± 177.3 %), SDF-1α 
(364.9 ± 401.9 %), and MCP-3 (369.8 ± 326.3 %). Quantitative data collected for these 
cytokines will need to be used with caution. The recovery efficiency of MIF, as determined by 
Bio-Plex, was 91.0 ± 10.4 % (Table 4.4). This recovery efficiency was consistent with the 
results obtained using the MIF ELISA in Chapter 3, which reported a recovery of 97 ± 7 % 
(Section 3.3.3). 
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Table 4.4. Percentage of protein recovery after recombinant protein spike into red blood 
cell lysates as measured by fluorescence (n = 5, mean ± SD). 
 
Cytokine Protein recovery after spike
* 
% Standard deviation 
Pro-inflammatory 
IFN-α2 166.6 34.2 
IFN-γ 94.7 28.7 
IL-1α 77.4 21.2 
IL-1β 77.5 2.6 
IL-5 75.5 3.1 
IL-9 75.2 3.6 
IL-12(p70) 76.3 33.8 
IL-15 67.1 3.9 
IL-17 76.1 3.4 
IL-18 89.7 29.4 
MIF 91.0 10.4 
TNF-α 81.9 6.1 
TNF-β 93.6 34.7 
TRAIL 101.8 19.3 
Anti-inflammatory 
IL-1ra 82.7 16.7 
IL-2ra 110.3 14.9 
IL-4 86.5 10.4 
IL-10 75.2 14.1 
IL-13 83.3 8.1 
Cytokines with multiple functions 
IL-2 78.2 4.7 
IL-6 70.2 16.9 
IL-12(p40) 111.6 77.9 
LIF 80.5 6.2 
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Cytokine Protein recovery after spike
* 
% Standard deviation 
Chemokines 
CTACK 119.0 15.9 
Eotaxin-1 86.3 23.9 
GRO-a 225.1 177.3 
IL-8 72.3 17.5 
IL-16 117.0 30.0 
MCP-1 68.6 28.1 
MCP-3 369.8 326.3 
MIG 105.1 94.1 
MIP-1α 88.7 15.4 
MIP-1β 93.2 61.0 
RANTES 86.4 15.9 
SDF-1α 364.9 401.9 
Growth factors 
bFGF 94.7 48.2 
G-CSF 75.2 14.5 
GM-CSF 81.0 9.4 
HGF 103.7 14.7 
IL-3 114.4 26.2 
IL-7 81.7 3.1 
IP-10 75.8 7.4 
M-CSF 98.9 6.5 
Β-NGF 75.3 29.4 
PDGF-bb 71.3 18.4 
SCF 95.5 36 
SCGF-β 92.1 26.2 
VEGF 79.5 6.6 
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4.3.4   Cytokines in red blood cell conditioned media 
Red blood cell conditioned media was prepared by incubating red blood cells in a protein free 
media (PBS) for 24 hours at 37 °C and the resulting conditioned media was assayed for levels 
of inflammatory markers. The concentration of red blood cells used to produce the conditioned 
media was approximately 25x lower than the concentration of cells in whole blood (whole 
blood contains approximately 5 billion red blood cells/mL). Even so, detectable levels of 40 of 
the 48 cytokines were present in the conditioned media for one of more biological replicates 
(Table 4.5). There were 18 cytokines that were released at concentrations higher than what was 
detected in plasma. For example, TNF-α was present at 61.5 ± 50.6 pg/mL in conditioned 
media (Table 4.5) and 7.1 ± 3.3 pg/mL in plasma (Table 4.3). IL-8 was also detected at high 
concentrations in the conditioned media compared to circulating plasma levels (979.6 ± 873.6 
vs 1.5 ± 0.3 respectively). The detectable concentration of IL-8 varied substantially between 
biological replicates; the range of IL-8 in the conditioned media was 291 - 2641 pg/mL (Table 
4.5). This variability was also observed for a number of other cytokines including RANTES 
(86 - 502 pg/mL), TNF-α (8 - 127 pg/mL), and MIF (688 - 2597 pg/mL) (Table 4.5). Although 
the absolute concentration differed depending on the assay used, similar variability between 
biological replicates was observed for the release of MIF from red blood cells as measured by 
ELISA in Chapter 3 (4519 - 8177 pg/mL, Figure 3.3). For eight of the cytokines, including IL-
2 and IL-6, levels were undetectable in red blood cell lysates (Table 4.3), but were detected in 
the red blood cell conditioned media (6.9 ± 2.6 pg/mL for IL-2 and 5.5 ± 3.4 pg/mL for IL-6). 
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Table 4.5.  Cytokines in red blood cell (RBC) conditioned media after 24 hours at 37 °C 
(200 million cells/mL) (n = 6, mean ± SD). 
 
Cytokine RBC secretion Concentration (pg/mL) Standard deviation No. of subjects 
Pro-inflammatory 
IFN-α2 18.8 3.5 5 
IFN-γ 3.7 2.2 4 
IL-1α 8.6 3.5 6 
IL-1β 25.1 21.2 6 
IL-5 0.2 0.2 2 
IL-9 0.9 1.0 2 
IL-12(p70) 1.0 - 1 
IL-15 9.9 4.6 6 
IL-17 11.0 3.1 2 
IL-18 3.4 1.4 5 
MIF 1496.2 753.2 6 
TNF-α 61.5 50.6 6 
TNF-β - - 0 
TRAIL 21.2 7.1 4 
Anti-inflammatory 
IL-1ra - - 0 
IL-2ra 12.2 5.7 6 
IL-4 0.5 0.2 5 
IL-10 0.3 - 1 
IL-13 0.4 0.4 2 
Cytokines with multiple functions 
IL-2 6.9 2.6 5 
IL-6 5.5 3.4 5 
IL-12(p40) 80.5 40.9 5 
LIF - - 0 
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Cytokine RBC secretion Concentration (pg/mL) Standard deviation No. of subjects 
Chemokines 
CTACK 2.7 1.7 2 
Eotaxin-1 7.3 - 1 
GRO-a - - 0 
IL-8 979.6 873.6 6 
IL-16 17.5 7.4 5 
MCP-1 7.9 2.3 5 
MCP-3 - - 0 
MIG 5.5 4.5 6 
MIP-1α 2.2 2.7 6 
MIP-1β 30.7 35.2 6 
RANTES 303.5 173.0 6 
SDF-1α 67.2 26.7 6 
Growth factors 
bFGF 35.5 9.6 6 
G-CSF 10.2 2.9 5 
GM-CSF 78.0 30.7 6 
HGF 38.3 17.3 6 
IL-3 24.6 11.8 6 
IL-7 0.2 - 1 
IP-10 11.0 12.3 2 
M-CSF 4.9 3.5 5 
Β-NGF - - 0 
PDGF-bb 32.6 57.9 6 
SCF - - 0 
SCGF-β - - 0 
VEGF 17.1 6.2 6 
 
   
Chapter 4 – Investigation and quantification of a panel of cytokines in RBCs 
107 
 
4.3.5   Concentration of haemoglobin in red blood cell conditioned media 
The concentration of haemoglobin in red blood cell conditioned media was quantified by 
monitoring the absorbance of plasma and red blood cell conditioned media samples at 414 nm. 
The level of haemoglobin in the conditioned media samples were significantly lower than the 
haemoglobin concentration of the plasma samples (Figure 4.1). There was no significant 
difference in the concentration of haemoglobin for any of the conditioned media samples. The 
mean concentration of haemoglobin in the conditioned media samples corresponds to 
approximately 0.5 - 1.5 % of the original red blood cell number.  
 
   
Figure 4.1. Concentration of haemoglobin in plasma and the conditioned media of red 
blood cells (2 x 108 cells per mL) incubated in PBS with and without protease inhibitors (RBC-
CM + PrI and RBC-CM respectively) or with Bio-Plex standard recombinant protein with or 
without protease inhibitors (RBC-CM + BP + PrI and RBC-CM + BP) over 24 hours at 37 °C. 
Haemoglobin concentration was measured by absorbance at 414 nm. Data are presented as 
mean ± SD, n ≥ 5, statistically significant (*) if p < 0.05. 
 
 
4.3.6   Modulation of red blood cell cytokine profile and conditioned media 
To assess the effect of protease inhibitors on the cytokine profile of red blood cells, purified 
red blood cells were incubated with and without protease inhibitors (PrI) for 24 hours at 37 °C. 
The cytokine profile of each fraction was assessed and the fold change between the control and 
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the PrI treatment was determined. The fold change of a selection of cytokines is presented in 
Figure 4.2; the data for the remaining cytokines can be found in Appendix C.  
A downward trend in the concentration of cytokines was observed in both the conditioned 
media and the red blood cell lysate following PrI treatment (Appendix C). When corrected for 
the conditioned media and the lysate, the adjusted means and standard errors from the fitted 
fixed-effect statistical model showed that the level of IL-1b, IL-8, and MIF were significantly 
reduced with PrI treatment. Treatment of red blood cells with PrI resulted in less IL-8 in both 
the conditioned media and in the red blood cell lysate after incubation (fold change of 
0.1 ± 0.07 and 0.2 ± 0.1 for each respectively). A decrease in TNF-α was observed in both the 
conditioned media and the lysate (fold change of 0.5 ± 0.3 and 0.7 ± 0.2 respectively) and the 
same was observed for IL-6 (fold change of 0.7 ± 0.3 and 0.8 ± 0.1 respectively). An increase 
in the concentration of detectable cytokines after PrI treatment was not common, but was 
observed for IL-16 in the lysate of red blood cells (fold change of 2.2 ± 0.6). The effect of PrI 
treatment on the red blood cells was variable between biological replicates for each cytokine. 
For GM-CSF, there was minimal variability between replicates with a fold change and standard 
deviation of 1.02 ± 0.05 for PrI conditioned media. Whereas, the effect of PrI on RANTES 
concentration in conditioned media varied substantially between each biological replicate with 
a corresponding fold change and standard deviation of 1.51 ± 1.25.  
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Figure 4.2. Summary of cytokines released from red blood cells into PBS over 24 hours and 
in the corresponding red blood cell lysate at 37 °C with or without protease inhibitors (PrI) as 
measured by Bio-Plex and reported as fluorescence (100 million cells in 1 mL PBS). Data are 
presented as mean fold change after addition of PrI ± 95% CI, where  represents fold change 
in conditioned media of PrI treatment compared to the no PrI control, and  represents fold 
change in fluorescence in lysate of red blood cells treated with PrI compared to the no PrI 
control (n = 6). 
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4.3.7  Total protein in red blood cell conditioned media 
The amount of protein present in red blood cell conditioned media with and without protease 
inhibitors was quantified using the BCA assay. The mean concentration of protein in the 
conditioned media was slightly higher in the protease inhibitor treated samples when compared 
to the untreated controls (114.1 ± 38.7 µg/mL and 106.9 ± 49.4 µg/mL respectively). 
However, there was no significant difference between the amount of protein in conditioned 
media with and without protease inhibitor treatment. 
 
 
4.3.8   Red blood cell protein binding and modulation 
Red blood cells were incubated with recombinant protein (Bio-Plex kit standards) in PBS for 
24 hours at 37 °C. To assess if any recombinant protein bound to the red blood cells, the 
concentration of cytokines in the lysate was assessed after incubation. The fold change of a 
selection of cytokines is presented in Figure 4.3, the data for the remaining cytokines can be 
found in Appendix D. The level of a number of cytokines in the red blood cell lysates increased 
after incubation with recombinant protein (Figure 4.3). The red blood cell lysate had 3-fold 
more IL-1ra (fold change of 2.9 ± 1.6) in the recombinant protein treated samples when 
compared back to the control, and 12-fold more β-NGF (fold change of 12.1 ± 4.2). The 
concentration of IL-12(p70) also increased with the addition of recombinant protein, it had a 
fold change of 2.8 ± 0.8 for the control and 3.7 ± 0.5 for the protease inhibitor treated samples. 
Treatment with protease inhibitors had variable effects depending on the cytokine. There was 
a significant difference between the control sample and the protease inhibitor treated samples 
for IL-8, GRO-α, and MIG. Treatment with protease inhibitors resulted in more IL-8 detected 
in the lysate, and less GRO-α and MIG compared to the untreated control (Figure 4.3). For six 
of the cytokines, including MIF and SDF-1α, there was no change in the lysate concentration 
following the addition of recombinant protein with or without protease inhibitors (Figure 4.3). 
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Figure 4.3. Summary of cytokines in red blood cell lysate after incubation into PBS over 
24 hours at 37 °C with or without recombinant protein and protease inhibitors (PrI) as measured 
by Bio-Plex and reported as fluorescence (100 million red blood cells in 1 mL PBS). Data are 
presented as fold change after addition of recombinant protein ± 95% CI, where  represents 
fold change in cytokine profile of lysate with exogenous recombinant protein compared to 
control, and  represents fold change in cytokine profile of lysate with PrI, with addition of 
exogenous recombinant protein compared to control (n = 5). 
 
 
4.3.9   Red blood cell cytokine binding 
Red blood cells were incubated at 37 °C for 24 hours in the presence of protease inhibitors 
and/or recombinant protein (Bio-Plex standards in PBS). Individual cytokine data for the 
resulting red blood cell lysates are outlined in Section 4.3.8. For analysis of treatment effect on 
red blood cell lysates, the cytokine data were analysed using fixed-effects statistical models 
Chapter 4 – Investigation and quantification of a panel of cytokines in RBCs 
112 
 
across pairwise comparisons between treatments (Section 4.2.9). There was no significant 
difference in cytokine concentration between the untreated control and protease inhibitor 
treated control on either the 27-plex or 21-plex panel. However, a downward trend in the 
cytokine levels in red blood cell lysates was observed with the addition of protease inhibitors 
(Figure 4.4). Red blood cells that were incubated with recombinant protein had significantly 
higher cytokine concentration across both panels when compared to the controls (Table 4.6). 
The increase in lysate cytokine concentration was consistent in both untreated and protease 
inhibitor treated red blood cells for the 27-plex panel and the 21-plex panel (Table 4.6).  
 
 
 
Figure 4.4. Boxplot summaries of cytokine log2 transformed raw fluorescence response 
data for red blood cell lysates collected using (A) the Bio-Plex human 27-plex panel and (B) 
the Bio-Plex human 21-plex panel (n = 5). Cells were incubated for 24 hours (37 °C, 5 % CO2) 
with or without protease inhibitors (PrI) and with or without recombinant protein (BP). The 
conditions are presented from left to right as control, PrI, BP, and BP-PrI. Data are statistically 
significantly different (*) if p < 0.05, (**) if p < 0.01, or (***) if p < 0.001. 
  
log
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Table 4.6. Statistical analysis of the effect of treatment according to sample type (red blood 
cell lysate) with pairwise treatment comparison for red blood cells incubated for 24 hours 
(37 °C, 5 % CO2) with or without protease inhibitors (PrI) and with or without recombinant 
protein (BP)# (n = 5). 
Comparison Sample type Pr(>Chisq) Significance## 
27-plex 
Control vs PrI Red blood cell lysate 0.642  
Control vs BP Red blood cell lysate 0.038 * 
PrI vs BP-PrI Red blood cell lysate 0.003 ** 
BP vs BP-PrI Red blood cell lysate 1.000  
21-plex 
Control vs PrI Red blood cell lysate 0.265  
Control vs BP Red blood cell lysate 8.58x10-9 *** 
PrI vs BP-PrI Red blood cell lysate 1.66x10-12 *** 
BP vs BP-PrI Red blood cell lysate 0.719  
# Analysis performed on cytokine log2 transformed raw fluorescence data 
## For Pr(>Chisq): * ≤ 0.05; ** ≤ 0.01; *** ≤ 0.001  
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4.4    DISCUSSION 
 
In the previous chapter of this thesis, MIF was detected in red blood cells at high concentrations 
and in its active form. This discovery prompted the aim of this current study, which was to 
investigate whether more cytokines than MIF alone were associated with red blood cells. The 
results of this study revealed that 35 of the 48 cytokines assayed were present in red blood cell 
lysates of healthy volunteers (Table 4.3) and for the 31 of these cytokines that were higher in 
the red blood cell lysates than in the plasma, there was a median fold increase of 11.3 (range 
3.6 to 3970-fold). Unlike any other study to date, the concentrations of these cytokines in red 
blood cell lysates were quantified and were reported according to their relative abundance in 
whole blood (Table 4.3). The panel of cytokines identified in red blood cells cover a range of 
pro- and anti-inflammatory factors, chemokines, and growth factors. A number of these 
cytokines are regularly monitored in plasma or serum for biomarker studies1 and the expression 
and secretion of these cytokines are thought to be limited to specific subsets of white blood 
cells32. The identification of these cytokines associated with red blood cells indicates that an 
additional, previously unknown, level of cytokine interactions may exist in blood. This study 
also showed that red blood cells are not only reservoirs for cytokines, but that they may also 
release and bind them in a process that is independent of haemolysis, however further 
investigation is required to confirm this (Table 4.5 and Figure 4.1). After storage in a protein 
free solution, red blood cell conditioned media contained a broad range of pro- and anti-
inflammatory factors, chemokines, and growth factors. When exogenous cytokines were 
spiked into red blood cell storage media, the resulting cell lysates had significantly increased 
cytokine concentrations indicating cell binding (Figure 4.3). Finally, treatment with protease 
inhibitors, resulted in modulation of the concentration of these cytokines in the conditioned 
media and in the red blood cell lysates (Figure 4.2 and Figure 4.3). The results of this study 
further demonstrate that, alongside its gas exchange function, red blood cells may play a role 
in cytokine signalling. Red blood cells are associated with a variety of cytokines and are able 
to secrete or bind these cytokines when exposed to different stimuli.  
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4.4.1   Cytokines in red blood cells 
4.4.1.1 Classes of cytokines identified in red blood cells 
Red blood cells have been identified in the literature as a reservoir for a small number of 
cytokines. In 1991, red blood cells were reported to be a chemotactic sink for IL-8, and in 1993 
the C-X-C class chemokines MGSA (aka GRO-α), NAP-2, and IL-8 were reported to bind to 
red blood cells17,33. In the study outlined in this chapter, of the 17 C-X-C chemokines in the 
family, three (18 %) were identified in the lysates of red blood cells after correcting for white 
blood cell contamination, specifically GRO-α, IP-10, and SDF-1α (Table 4.3 and Table 4.7).  
Neote et al. also reported the presence of RANTES and MCP-1 of the C-C chemokine family17, 
and Fukuma et al. reported the presence of Eotaxin18. These findings were confirmed by the 
current study, which also identified RANTES, Eotaxin, and MCP-1 in red blood cell lysates. 
In addition, five more C-C chemokines were also identified out of a total of 27 chemokines in 
the family which adds up to 30 % C-C chemokines being associated with red blood cells (Table 
4.3 and Table 4.7). The study in this chapter has revealed other classes of cytokines that are 
also associated with red blood cells as outlined in Table 4.7. In a recent study, red blood cells 
were identified as a major source of the nuclear protein IL-33, which is part of the IL-1 cytokine 
superfamily34. They found that levels of IL-33 increased in the plasma of sickle cell patients 
who had experienced varying levels of haemolysis. The study in this chapter identified IL-18 
in red blood cells, which represents 6 % of the IL-1 superfamily (Table 4.3 and Table 4.7). In 
addition to those already mentioned, a range of growth factors (including bFGF, GM-CSF, and 
VEGF), chemokines (IL-16), and pro- and anti-inflammatory cytokines (including IFN-γ, 
TNF-α, and IL-2ra) were also identified.  
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Table 4.7. Families of cytokines that were identified in red blood cell lysates (n = the 
number of proteins in each family and b = the number of analytes available on the assayed Bio-
Plex kits). 
Family Cytokine 
C-C chemokines  
(n = 27; b = 7) 
CTACK 
Eotaxin 
MCP-1 
MCP-3 
MIP-1α 
MIP-1β 
RANTES 
CSF family  
(n = 3; b = 3) 
G-CSF 
GM-CSF 
M-CSF 
C-X-C chemokines 
(n = 17; b = 5) 
GRO-α 
IP-10 
SDF-1α 
FGF growth factors 
(n =22; b = 1) 
bFGF 
GM-CSF/IL-5/IL-3 
family 
(n = 3; b = 3) 
GM-CSF 
IL-3 
IL-5 
IFN family (Type I) 
(n = 17; b = 1) 
IFN-α2 
IFN family (Type II) 
(n = 1; b = 1) 
IFN-γ 
 
IL-1 superfamily 
(n = 11; b = 4) 
IL-18 
Family Cytokine 
IL-6 family 
(n = 11; b = 3) 
G-CSF 
LIF 
IL-12 family 
(n = 5; b = 2) 
IL-12(p40) 
IL-12(p70) 
IL-17 family 
(n = 6; b = 1) 
IL-17 
MIF family 
(n = 2; b = 1) 
MIF 
PDGF growth 
factors 
(n = 10; b = 2) 
PDGF-bb 
VEGF 
TNF superfamily 
(n = 19; b = 3) 
TNF-α 
TNF-β 
TRAIL 
Unclassified HGF 
IL-2ra 
IL-4 
IL-7 
IL-13 
IL-16 
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4.4.1.2 Red blood cell contribution to whole blood cytokine level 
In clinical studies, optimal sample preparation is crucial for reproducible results35. These 
techniques generally focus on minimising white blood cell and platelet activation during 
plasma or serum isolation. The results of this study highlight that haemolysis can too cause 
interference. Even minimal haemolysis that may not be macroscopically detectable 
(haemolysis of ≥ 0.125 % of red blood cells in whole blood)28 could interfere with the results 
of the clinical study. For example, IL-16 was present at 62 times the concentration in red blood 
cells when compared to plasma. Haemolysis of 0.125 % of red blood cells (releasing 
approximately 0.19 mg/mL of haemoglobin) could release approximately 5 pg/mL of IL-16, 
which is 10 % of the mean plasma concentration (46.6 pg/mL). This undetectable amount of 
haemolysis could quickly confound results.  
Although the cytokine concentration in red blood cells identified in this study indicates that 
they are a major reservoir in blood, the full range of cytokines associated with red blood cells 
remains to be determined. In addition, the non-denaturing red blood cell lysis method (freeze-
thaw cycles) used to ensure compatibility with the antibody assay, may not have produced 
accurate results for every cytokine. An example of this phenomenon is IL-8 which has been 
reported in multiple studies as being associated with red blood cells. It was observed in this 
study that with correction for white blood cell contamination, the levels of IL-8 in red blood 
cell lysates were not detectable (Table 4.3). However, after red blood cell incubation in protein 
free media, IL-8 levels increased significantly in the red blood cell lysates and red blood cell 
conditioned media (Table 4.5). Discussion on why this may have occurred will be continued 
in Section 4.4.2.1.  
4.4.1.3 Assay and sample validity 
The recovery efficiencies reported here are similar to reported values for plasma assayed on 
the Luminex platform36,37, with the exception of the cytokines with very high recovery 
efficiencies including IFN-α2, GRO-α, SDF-1α, and MCP-3 (Table 4.4). Belabani et al. 
reported on the accuracy of Luminex based multiplex assays and their acceptance criteria for 
recovery efficiencies was determined to be between 75 -125 %36. Using that criteria, 39 of the 
48 cytokines analysed in this study fell within the acceptable range for red blood cell lysates.  
To correct for any white blood cell contamination in the enriched red blood cell samples, white 
blood cells were isolated and the concentration of cytokines per cell was determined. Using 
these data, the theoretical white blood cell contribution to the total concentration for each 
cytokine was calculated according to the number of remaining white blood cells (Table 4.3). 
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This enabled an estimate of the red blood cell cytokine contribution to whole blood. For some 
cytokines, the white blood cell contamination was negligible. For example, the total 
concentration of MIF in the red blood cell lysate was 111,633 ± 56,912 pg/mL, whilst the white 
blood cell contribution was 87.9 ± 64.7 pg/mL. This correction calculation had a more 
substantial effect on other cytokines. For example, the white blood cells contributed a third of 
the total CTACK measured in the red blood cell lysates (total concentration: 222.2 pg/mL; 
corrected concentration: 131.4 pg/mL). The validity of this correction mechanism was brought 
into question with the results of cytokines such as IL-1ra. The theoretical white blood cell 
contribution of IL-1ra was calculated to be 1572.8 ± 252.7 pg/mL and IL-1ra was detectable in 
the white blood cell lysates of all six biological replicates. However, the actual measured 
concentration of IL-1ra in the red blood cell lysates (with white blood cell contamination) was 
far below this. In fact, IL-1ra was only detectable in one biological replicate of the red blood 
cell lysates, and was present at 5-fold less than the white blood cell mean (Table 4.3). So, where 
did the IL-1ra go and why was it not detected? One possible reason for this involves the chosen 
cell isolation method in this study. The process of isolating the white blood cells was 
approximately 30 minutes longer than the isolation of the red blood cells and involved 
additional steps. During this process, additional cell activation and/or communication between 
the components may have occurred to stimulate the expression of IL-1ra and possibly other 
cytokines. The white blood cell population also contained higher numbers of platelets than that 
present in the red blood cell isolates. Platelets are a source of some cytokines and this may have 
resulted in artificially high concentrations detected in the white blood cell lysates, such as that 
observed for PDGF-bb (Table 4.3). The percentage of contaminating white blood cells after 
dextran fractionation is very low and it may be that these cells are a specific cell type and not 
representative of the whole heterogenous white blood cell population. If this is the case it may 
also be that the cytokine concentration in the contaminating cells is different from the whole 
white blood cell population, which could account for the discrepancy in analytes such as IL-
1ra. The low concentration of white blood cells in the purified red blood cells was insufficient 
for flow cytometry analysis and this type of analysis could only be achieved on much larger 
blood samples than were available for this study. 
At this point, it is clear that signalling between the components of blood is more complex that 
previously understood. In addition, fractionation of blood into its elements is not as 
straightforward as once thought. Collecting, anticoagulating, and isolating individual 
components will inevitably introduce artefacts especially if major reservoirs of analytes are 
perturbed during the processing. An optimal cell isolation methodology, which produces 
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biologically relevant plasma and blood cells, will require rapid sample processing and minimal 
manipulation. 
4.4.1.4 Assay dependent discrepancy in MIF concentration 
The concentration of MIF in red blood cells was the subject of Chapter 3. Levels were measured 
using an R&D Systems MIF ELISA and were reported as 31,241 ng in one millilitre of whole 
blood (Chapter 3, Table 3.3). In this chapter, MIF was one of a number of cytokines measured 
using a multiplex bead-based array (Bio-Plex, Bio-Rad) and levels were reported as 112 ng in 
one millilitre of whole blood (Table 4.3). This is a discrepancy of approximately 280x between 
the two assay types. An even larger discrepancy of 929x was observed for the MIF plasma 
levels according to each assay (26 ng/mL vs 0.028 ng/mL for the ELISA and Bio-Plex 
respectively). According to the manufacturers of each kit, the antibody pair for each assay 
(capture antibody and detection antibody) is sourced from the same supplier (R&D Systems) 
and despite experimentation, the reason for this difference remains unknown. Although the 
antibodies are from the same species and are sourced from the same supplier, the specific 
antibody clones in each assay are proprietary and thus it is impossible to know at this stage if 
they are the same. It is well accepted in the literature that using different antibodies will result 
in different concentrations of the analyte being detected38, however differences of up to 1000-
fold are not typical even with different antibodies.  
The discrepancies observed for MIF is supported by the literature in plasma or serum collected 
from healthy volunteers, but is never discussed in detail. In the published literature, MIF 
concentration measured using MIF ELISAs are reported in ng/mL39–41, and pg/mL for Luminex 
bead-based arrays42–44. The potential reasons for this are numerous. For instance, the chemistry 
required to bind the antibodies to the plate for the ELISA is different than what is required to 
bind to the magnetic beads (hydrophobic interactions vs covalent bonding respectively). This 
may have resulted in altered binding capacity and strength between the two kits, and thus 
differing results. Additionally, the physical availability of the antigen binding site of the 
antibody is likely to be different in each assay. Attaching antibodies to a spherical bead may 
have resulted in reduced availability of the binding site to the protein in comparison to the 
ELISA, particularly for the larger forms of MIF such as the homotrimer. At this stage, the cause 
of the discrepancy remains unknown, however it was not in the scope of this study to resolve 
these technical issues. Although there is a discrepancy in MIF levels between assays, the trends 
between groups are consistent. For both assays the difference in MIF concentration between 
plasma and red blood cell lysates (according to contribution to one millilitre of whole blood) 
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is between 1000x - 5000x (Table 3.3 and Table 4.3). As such, any in depth analysis of MIF 
should still be valid if comparisons are done using the same assay type. From a review of the 
literature, MIF appears to be the only cytokine on the Bio-Plex panel that is reported at such 
vastly different concentrations between assay types.  
 
4.4.2   Red blood cell conditioned media 
Analysis of red blood cell conditioned media has not been widely reported in the scientific 
literature. Out of six publications, the effect of red blood cell conditioned media on a number 
of cell types has been investigated. One study reported that T cell proliferation was stimulated 
in the presence of red blood cell conditioned media which was comparable with intact red blood 
cell-mediated proliferation44. Whilst Fredriksson et al. observed that culturing fibroblasts in 
the presence of intact red blood cells or red blood cell conditioned media stimulated the 
secretion of IL-8 and the expression of the corresponding mRNA14. They were able to replicate 
this effect by culturing fibroblasts in the presence of TNF-α and IL-1β, both of which were 
cytokines detected in the red blood cell conditioned media in this chapter (Table 4.5). 
Interestingly, the cytokine profile of the conditioned media was not investigated in any of these 
studies. In contrast, an evaluation of the cytokine profile of red blood cell conditioned media 
was the focus of this chapter.  
After incubation in PBS without serum, a wide range of cytokines were detected in the 
conditioned media of red blood cells (Table 4.5). The concentration of haemoglobin in the red 
blood cell conditioned media indicated lysis of 0.5 - 1.5 % of the original number of red blood 
cells. For 40 cytokines, the concentration in the conditioned media was higher than what could 
be attributed to the red blood cell lysis. For IL-16, the concentration in the conditioned media 
was 10 % of the cell lysate concentration prior to culture and for IFN-γ, 88 % of the initial 
lysate concentration was measured in the conditioned media. This suggests that the proteins 
were being released or shed in a mechanism that is independent of haemolysis. 
4.4.2.1 Concentration of cytokines in conditioned media 
When normalised for cell number, the concentration of 32 of the cytokines in the conditioned 
media were higher than that detected in the red blood cell lysate prior to incubation (Table 4.5). 
IFN-α2 was detected at approximately 180 % of the initial lysate concentration, and VEGF was 
detected at 500 % of the initial lysate concentration. The cytokine with the largest difference 
between pre-culture lysate concentrations and the concentration in the conditioned media was 
IL-8 (Table 4.3 and Table 4.5). With white blood cell correction, IL-8 was below the limits of 
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detection for red blood cells lysates prior to incubation. After incubation at 37 °C for 24 hours, 
979.6 ± 873.6 pg/mL of IL-8 was released in the red blood cell conditioned media. The lack of 
detectable IL-8 in the red blood cell lysates was unexpected as it is one of the few cytokines 
that has been identified by multiple reports as being present in and released from red blood 
cells33,45,46. The cytokines that exhibit this increase in concentration may have been bound to 
chaperones or to a complex prior to incubation. The limitations of immunoassays in detecting 
complex bound cytokines have been previously described47–49. The goal of this chapter was to 
determine which cytokines were present in red blood cells and additionally which cytokines 
were bound or released by red blood cells. The methods were chosen to maintain biological 
activity rather than an attempt to obtain absolute quantification. In the next chapter, the effect 
of red blood cells on other cell types is explored and so, the purpose of this chapter was to 
provide some insight into which cytokines may be involved in signalling. An extensive survey 
of sample preparation methods aimed at dissociating cytokines to enable absolute 
quantification was beyond the scope of this study. 
An increase in secreted cytokines from stored red blood cells is generally attributed to white 
blood cell contamination, but a 1999 study suggested otherwise45. That study compared the 
cytokine release after storing whole blood for 42 days to red blood cells and leukodepleted red 
blood cells45. They reported that the storage of whole blood resulted in the lowest concentration 
of secreted IL-8 (1.7 ± 7.0 pg/mL) and that the leukodepleted red blood cells secreted the 
highest concentration of IL-8 (26.8 ± 31.0 pg/mL). Further to that, warming the leukodepleted 
red blood cells to room temperature for 24 hours during the 42-day period resulted in even 
higher IL-8 release (125.8 ± 158.6 pg/mL). These results suggest that perturbation of these 
cells stimulated the release of IL-8. In light of this study, it is likely that the reason for the 
increased cytokine concentration in the stored red blood cell conditioned media is not simply 
white blood cell contamination, but possibly also the presence of chaperones or else a result of 
cell activation. Further research in this area is required to elucidate whether some red blood 
cell-associated cytokines are bound and therefore inaccessible to the immuno-assay. Further to 
this, a study that explores potential binding partners and the conditions that promote binding 
and release of cytokines would be valuable in situations where stored red blood cells are used 
clinically. 
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4.4.3   Modulation of the red blood cell cytokine profile 
4.4.3.1 Binding of recombinant protein 
Red blood cells have been described as potential sinks for inflammatory cytokines33,50,51. In 
support of this hypothesis, there was a significant increase in the concentration of cytokines in 
the red blood cells lysates after incubation with recombinant protein (Figure 4.4), with lysate 
levels increasing in 41 of the 48 cytokines (Appendix D). These results suggest that the red 
blood cells bound the cytokines out of solution. Red blood cells have been observed to 
inactivate and sequester IL-8 out of whole blood until cellular saturation through ligation of 
the Duffy antigen receptor for chemokines (DARC)33. Similar reports have been made for 
MCP-1 and MIP-1α52,53. Although there is some literature around cytokine binding to DARC, 
there is surprisingly little reference to the implications of this for red blood cells. DARC is 
present in abundance on red blood cells, endothelial cells, and on platelets and yet, most reports 
focus on the implications of this binding partnership on endothelial cells. It is not clear what 
receptors or molecules the other red blood cell-associated cytokines identified in this chapter 
may be binding to or if they are being internalised as a result. Future, more targeted studies are 
required to identify these binding sites. 
4.4.3.2 Protease inhibitor treatment 
Proteases and protease inhibitors play an important role in blood. For example, one of the most 
abundant proteins in plasma, alpha-2-macroglobulin, is a pan-inhibitor that acts to bind and 
inhibit proteases. Red blood cells are a rich source of a range of proteases and enzymes and 
this study has indicated that enzymes may play a role in cytokine binding and release21,54. The 
addition of a cocktail of protease inhibitors (Roche cOmplete cocktail) to red blood cells during 
incubation altered the cytokine profile of the resulting conditioned media and lysate (Figure 
4.2). The Roche cOmplete cocktail inhibits serine-, cysteine-, and metallo-proteases all of 
which have been reported in red blood cells55–57. This treatment resulted in an overall reduction 
in the level of detectable cytokines in both the conditioned media and the lysates (Figure 4.4). 
This modulation was most notable with IL-8, wherein the concentration of detectable cytokine 
in both the conditioned media and lysate was 5-fold lower than the untreated control (Figure 
4.2). In 1991 it was observed that IL-8 bound reversibly to red blood cells via the DARC33. It 
was reported that brief incubation (15 minutes) with a cocktail of proteases prevented cellular 
binding by 100 %33. Treatment with protease inhibitors in this chapter resulted in the inverse, 
where cellular binding increased by 3-fold (Figure 4.3). An increase in binding with protease 
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inhibitors was also observed for IL-1β and IL-5 (Appendix D), and a decrease in protein release 
into the conditioned media was observed for MIF and TNF-α (Appendix D). 
Red blood cells are devoid of the classic secretion pathways that are well documented in other 
cells types due to the lack of membrane bound organelles. As a suggestion for alternative 
mechanisms, Schnabel et al. observed that coagulation and treatment with heparin drove MCP-
1 release from DARC on red blood cells52. At this point, the exact mechanism of binding or 
release of these cytokines is not clear, but the results of this study suggest that proteases and 
protease inhibitors amongst other factors may be involved. The Roche cOmplete cocktail 
contains serine-, cysteine-, and metallo-protease inhibitors, however, it is not clear whether 
they were internalised or not. For this reason, future investigation in this area will require 
analysis of the effect of individual enzyme inhibitors. 
 
4.4.4   Clinical significance 
The results of this study may have implications on understanding the pathology of haemolytic 
conditions such as sickle-cell disease and paroxysmal nocturnal haemoglobinuria. In these 
disorders, the increase in free haemoglobin in the plasma has been attributed to causing 
complications such as platelet activation and inflammation58,59. In the light of these results, 
haemolysis would also lead to the release of a range of cytokines into the plasma that may have 
down-stream effects on neighbouring cells. These results also suggest that red blood cells may 
play a crucial role in blood in regulating circulating cytokine levels by binding and releasing 
signalling proteins and the cells may be contributing to blood homeostasis. If red blood cells 
are actively binding circulating proteins out of plasma, then they may too be representative of 
the inflammatory state of the participant which has potential implications in diagnostics. 
 
  
Chapter 4 – Investigation and quantification of a panel of cytokines in RBCs 
124 
 
4.5   CONCLUSION  
 
The results of this study may be from in vitro experiments on isolated blood components, but 
they make one thing quite clear. The locations and total quantities of signalling molecules such 
as cytokines are different to those described in the literature and as such, the signalling 
processes in blood are probably more complex. In one aspect, the conclusion from these 
experiments is that a reductionist biomarker discovery approach of analysing plasma or serum 
in isolation may be limiting, and a large piece of the puzzle may be lost in the process. 
Techniques such as monitoring the relative levels of panels of cytokines between the cell types 
and plasma in blood may prove to be more beneficial in disease research as opposed to 
determining the absolute concentrations in plasma or serum alone. In addition, analysis of 
overall trends and patterns in the cytokine data in this study is a valuable way to examine this 
type of analysis (Figure 4.4). Blood and its signalling network is highly complex, and analysis 
of individual cytokines may not be representative of the whole picture. 
This study demonstrated that red blood cells have an extensive cytokine profile and that said 
profile can be modulated by adjusting their local environment, such as with the introduction of 
extracellular recombinant protein or with the inhibition of proteases. This raises the question 
of what may be modulating the cytokine profile of red blood cells in vivo. This list is potentially 
endless, but the effect of different cell types in the local vicinity is particularly interesting. 
More investigation into this will follow in Chapter 5. 
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CHAPTER 
  
--------------------------------------------------------------------------- 
 
MODULATION OF RED BLOOD CELL CYTOKINE PROFILE AND 
THE EFFECT ON IMMUNE CELL ACTIVITY 
 
 
 
This chapter investigates the effect of cell-to-cell interactions on the red blood cell cytokine 
profile and activity. The previous chapter of this thesis demonstrated that the cytokine profile 
of red blood cells could be modulated under certain conditions, with the addition of exogenous 
protein and/or protease inhibitors. This chapter will expand on that investigation by assessing 
another mechanism by which the cytokine profile of red blood cells can be modulated. Red 
blood cells were incubated with a proliferating intact cancer cell line (red blood cell priming 
with a cancer cell line). Any changes in the red blood cell or the red blood cell conditioned 
media as a result of priming were evaluated by monitoring how these components altered the 
activity of immune cells. Although the effect of protease inhibitors on cytokine binding and 
release from red blood cells was discussed in Chapter 3 and Chapter 4, they were not included 
in this study. The aim of this chapter was to model biological interactions between cells that 
may occur in vivo. As such, the inclusion of protease inhibitors in this model would not have 
been representative of in vivo conditions. 
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5.1   INTRODUCTION 
 
Red blood cells are emerging as an important regulator of cell function and survival. A small, 
but important body of literature has demonstrated that the inclusion of red blood cells in culture 
with other cell types can initiate changes in the secretion profile and in the activity of those 
cells. Red blood cells have been shown to interact in vitro with fibroblasts to stimulate the 
secretion of IL-81 and matrix metalloproteinases2, and to modulate the growth and apoptosis 
of those cells3. Red blood cells can also bind RANTES secreted by endothelial cells, and by 
doing so, regulate the migration of eosinophils4. This interaction between red blood cells and 
inflammatory cells has been studied, however, binding and release of cytokines by red blood 
cells are not usually discussed as potential mechanisms of action. In 1988, it was observed that 
the presence of red blood cells was required to enhance natural killer cell cytotoxicity against 
tumour cells5. Similarly, red blood cells have been shown to suppress dendritic cell maturation 
and excess secretion of pro-inflammatory cytokines6, and to play a role in B cell activation7. 
Particular emphasis has been placed on the role of red blood cells in T cell proliferation and 
survival8–10. Incubation of T cells or mixed lymphocyte populations with red blood cells can 
result in a reduction of apoptosis and a promotion of lymphocyte proliferation, in particular 
proliferation of cytotoxic T cells (CD8+ cells)10–12. Red blood cells also stimulate the release 
of inflammatory cytokines including TNF-α and IFN-γ in a dose dependent manner13. It has 
been suggested that this activity is dependent on red blood cell derived-protein factors that may 
be haemoglobin or peroxiredoxin II9. Whilst other groups hypothesise that this activity is a 
result of red blood cells reducing oxidative stress and damage in T cells by protecting cell 
membrane integrity14. This protection is dependent on the red blood cells being intact and in 
close proximity to the T cells. 
In recent years, the dysregulation of red blood cells in inflammatory conditions has been 
investigated and it has been reported that red blood cells isolated from participants with carotid 
atherosclerosis have an attenuated capacity to protect T cells from apoptosis15. This result was 
also replicated by subjecting healthy red blood cells to excessive oxidative stress. Red blood 
cells isolated from the same disease group were also unable to regulate dendritic cell 
maturation16 and the result of this has been directly correlated with atherosclerotic plaque 
progression17. In other study, following hip arthroplasty, red bloods were less able to stimulate 
proliferation of T cells when compared to the samples collected before the surgery18. Similarly, 
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storage of red blood cells for 2-3 weeks produced this same, suppressive effect on both 
autologous and allogeneic T cells19. A reduction in IL-2 was observed with red blood cell 
treatment, however the proliferation could not be rescued by addition of recombinant IL-2. The 
implications of these results are not currently understood, but it was hypothesised that the 
dysregulation of the interaction between red blood cells and T cells may interfere with T cell 
homeostasis in vivo15. Dysregulated immune activity and chronic inflammation can promote 
tumour development and protection from apoptosis20. A549 cells are a human non-small cell 
lung carcinoma cell line that has been investigated extensively due to its capacity to suppress 
an immune response. The literature has reported that this activity is modulated at least in part 
by tumour-derived cytokine release. It was demonstrated that this cell line, amongst others, 
expressed the toll-like receptor TLR421. Ligation of this receptor induced the release of a range 
of immunosuppressive and proangiogenic cytokines (TGF-β, VEGF, and IL-8) which 
promoted cell growth and resistance to apoptosis21. 
As outlined in the previous chapter (Chapter 4), red blood cells are capable of both binding and 
releasing cytokines in response to their local environment. This result was induced by 
incubation with a known cocktail of recombinant proteins. The study outlined in this chapter 
aimed to investigate a biological interaction of inducing cytokine binding to red blood cells. In 
vivo, red blood cells come into contact with a wide array of cell types and the proteins that they 
secrete. In capillaries, red blood cells are forced to deform in order to pass through the 
microvasculature, and direct cell-to-cell contact occurs with endothelial cells and other tissue 
cells in the process22. In the lungs, gas exchange occurs across the capillary and alveolar walls, 
however, gases are not the only molecules transported and exchanged by red blood cells. Red 
blood cells are carriers of drugs, such as steroids and anticonvulsants, that partition between 
plasma protein binding and red blood cells23. Exchange of protein-binding molecules occurs 
between red blood cells and other cells in the restricted confines of capillaries23. Molecules, 
including proteins, bound to the surface of red blood cells appear to play a key role in cell 
function and are likely to modulate exchanges with other cells. Washed red blood cells have 
altered functions24,25 and may have diminished levels of cytokine (Appendix B). On this basis, 
the hypothesis of the chapter was that interaction with other cell types would modify the red 
blood cell cytokine profile and subsequently those cell-contact primed red blood cells would 
have an altered effect on immune cells. 
In this study, the effect of priming red blood cells with A549 cancer cells on lymphocyte 
proliferation, survival, and function was investigated. The experimental ratios of A549 cells to 
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red blood cells were based on literature describing the structure and cellular makeup of lung 
capillaries26,27. Red blood cell speed, flux, and density in capillaries have been published for 
humans, as well as rodents and amphibians and these datasets were used to approximate the 
number of cells for the priming experiments26. The total capillary surface area has been 
estimated, using morphometric assessment, to range from 0.01 m2 in a mouse lung28 to 126 m2 
in a human lung29. The surface area of endothelial cells is approximately 1100 µm2 per cell, 
which is consistent across species26; this demonstrates that the increased capillary surface area 
is a direct result of increased numbers of endothelial cells. This is relevant to the priming 
experiments conducted in this chapter because a growing tumour is made of proliferating cells 
and neovascularisation. For the purposes of the experiments in this chapter, it was assumed that 
the A549 cells were structurally similar to endothelial cells, which they can mimic30. 
Endothelial cells that are seeded at 1.8 million cells per T75 culture flask (as in this study), 
provided stable growth, would be the equivalent of an endothelial surface area of 20 cm2, which 
represents 0.0015 % of the total lung capillary surface area. 
In the analysis of peripheral blood mononuclear cells (PBMCs), the response of the T cell 
population (CD3+ cells) was of particular interest. Subsets of this population was also analysed 
with focus on the response of CD4+ cells and CD8+ cells. CD4+ cells in a lymphocyte group 
are described as T helper cells, whilst CD8+ cells in a lymphocyte group are referred to as 
cytotoxic T cells.  
 
5.1.1   Chapter hypothesis 
It is hypothesised that priming red blood cells with a cancer cell line will change the cytokine 
profile of these red blood cells and that these cells will alter immune cell activity. 
 
5.1.2   Chapter aims 
1. To investigate if the cytokine profile of red blood cells would change following 
incubation with a cancer cell line. 
2. To evaluate the activity of peripheral blood mononuclear cells in response to treatment 
with naïve red blood cells. 
3. To determine if priming red blood cells with a cancer cell line would induce altered 
activity in the peripheral blood mononucleated cells.  
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5.2   METHODS 
 
 
 
Figure 5.1. Overview of experimental design. 
 
 
5.2.1   Blood collection 
Whole blood was collected from healthy volunteers by venepuncture (n = 12; female: 7, 
male: 5) directly into EDTA vacutainers (K2EDTA vacutainers, BD Biosciences). The age 
range of these participants was 25 - 48 years. All fractions of blood were collected and 
processed at room temperature within four hours of collection. For multiplex analyses all 
samples were stored at -80 °C and were subjected to three freeze-thaw cycles at -80 °C prior 
to analysis to ensure complete cellular lysis. 
This study was approved by the Northern Sydney Coast Human Research Ethics Committee of 
NSLHD and CCLHD (1201-046M). Written consent was collected from all participants before 
participation in this study. 
(Sec 5.2.4.1) 
(Sec 5.2.3.1) 
(Sec 5.2.2) 
(Sec 5.2.3.2) 
(Sec 5.2.7) 
(Sec 5.2.7) 
(Sec 5.2.4) 
(Sec 5.2.5) 
(Sec 5.2.2) 
(Sec 5.2.1) 
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5.2.2   Blood cell isolation 
Red blood cells and peripheral blood mononucleated cells (PBMCs) were isolated from EDTA 
anti-coagulated whole blood. Red blood cells were collected and were either frozen 
immediately or were used fresh for priming experiments (Section 5.2.3.2). PBMCs were used 
fresh for proliferation experiments (Section 5.2.4). A haematology analyser (Coulter Act Diff, 
Beckman Coulter) was used to determine cell number and purity of populations. 
5.2.2.1 Red blood cell isolation 
Red blood cells were isolated using dextran sedimentation as follows. Whole blood was 
centrifuged (1500 g, 10 minutes) and the upper plasma layer was discarded. The remaining cell 
pellet was resuspended in an equal volume of sodium chloride (0.15 M). Dextran (6 % w/v in 
0.15 M sodium chloride) was then added to this cellular suspension at a 1:4 ratio (dextran:cell 
suspension). This solution was left at room temperature for 30 minutes for red blood cells to 
sediment to the bottom of the tube. After this time the upper white blood cell rich layer was 
discarded and the lower red blood cell fraction was isolated. The red blood cell fraction was 
washed once in phosphate buffered saline (PBS, 500 g, 5 minutes) and the remaining red blood 
cell pellet was either frozen (-80 °C) or used fresh (Section 5.2.3.2). 
5.2.2.2 Peripheral blood mononucleated cells (PBMCs) 
PBMCs were isolated from whole blood using density gradient separation. Whole blood diluted 
in an equal volume of PBS was carefully layered on top of Ficoll-Paque (2:1 ratio respectively, 
GE Healthcare) and was centrifuged without a brake (400 g, 40 minutes). After centrifugation, 
the PBMC layer at the interface between the plasma and the Ficoll-Paque was isolated and 
washed once with PBS (500 g, 5 minutes). Any contaminating red blood cells were lysed with 
red blood cell lysis solution (Sigma Aldrich) for 10 minutes at 37 °C. 
 
5.2.3   Priming red blood cells with A549 cells 
5.2.3.1 A549 cell culture 
A549 cells were expanded in A549 culture media (DMEM with 10 % FBS and 1 % antibiotic-
antimycotic, v/v) at 37 °C and 5 % CO2. Cells were passaged twice a week with TrypLE when 
the cells reached confluence. Cells were counted using a haemocytometer and viability was 
determined by trypan blue staining. 
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5.2.3.2 Priming conditions 
To prime the red blood cells, A549 cells were seeded into T25 flasks and T75 flasks at a 
concentration of 0.1 x 106 cells per mL of ADSC culture media (total volume: 6.25 mL and 
18 mL for T25 and T75 flasks respectively) and were incubated for 24 hours to ensure 
adherence to the plate (37 °C, 5 % CO2). After incubation, the following conditions were 
prepared using freshly isolated red blood cells (Table 5.1). For red blood cell priming, the total 
volume of culture media in the T75 flasks was 18 mL and in the T25 flasks was 6.25 mL. 
 
Table 5.1. Red blood cell (RBC) priming conditions with red blood cells at ratios of 1:100 
and 1:1000 at 37 °C, 5 % CO2 for 72 hours. 
Condition Label Flask size  
A549 cells 
number 
Red blood cell 
number 
A549 cells - T75 1.8 x 106 - 
A549 cells - T25 0.625 x 106 - 
A549 cells:RBCs (1:100) Primed (pRBC-L) T75 1.8 x 106 180 x 106 
A549 cells:RBCs (1:1000) Primed (pRBC-H) T25 0.625 x 106 625 x 106 
RBCs Unprimed (upRBC-L) T75 - 180 x 106 
RBCs Unprimed (upRBC-H) T25 - 625 x 106 
 
 
Cells were then incubated for 72 hours at 37 °C with 5 % CO2. Following incubation, the 
conditioned media with the red blood cells in suspension was collected and the red blood cells 
were isolated by centrifugation out of the conditioned media (500 g, 10 minutes). Any 
remaining particulates in the conditioned media were removed by centrifugation (2000 g, 
10 minutes) after which it was stored at -80 °C. The red blood cells were washed once with 
PBS and counted using a haematology analyser (Coulter Act Diff, Beckman Coulter). The red 
blood cells were then either used intact for proliferation assays (Section 5.2.4), or were frozen 
at -80 °C to produce red blood cell lysates.  
5.2.3.3 A549 cell imaging 
A549 cells were seeded into 12-well plates at 0.025 x 106 cells per well. These cells were 
incubated for 24 hours (37 °C, CO2), after that point A549 cells were either treated with red 
blood cells at a ratio of 1:100 or 1:1000, or left untreated (A549 culture media, 1.5 mL per 
Chapter 5 – Modulation of RBC cytokine profile and the effect on immune cell activity 
138 
 
well). After incubation for a further 72 hours (37 °C, CO2) the red blood cells and conditioned 
media were discarded, and the adherent A549 cells were washed well with PBS. Images of the 
A549 cells were collected using the IncuCyte FLR, and the level of confluence for each well 
was calculated using IncuCyte image analysis software (ver. 2011A Rev2) using the mean of 
the well (9 images collected per well). 
 
5.2.4   Proliferation assay 
5.2.4.1 Jurkat cell culture 
Jurkat cell culture media consisted of RPMI-1640 with FBS (10 % or 2.5 %, v/v), penicillin 
and streptomycin (1 % v/v), and L-glutamine (200 mM solution, 1 % v/v). Cells were 
maintained at a concentration between 0.2 x 106 and 1 x 106 cells/mL in culture. Jurkat cells 
were expanded with 10 % FBS (v/v) and were sub-cultured into 2.5 % FBS six days prior to 
initiation of the proliferation assay. Dead cells were removed using Ficoll-Paque once a week 
by layering 5 mL of the cell suspension over 5 mL of Ficoll-Paque. This was then centrifuged 
with no brake (400 g, 40 minutes), and the live cells at the interface of the PBS layer and the 
Ficoll-Paque layer were collected, washed twice with PBS and returned to culture. Cells were 
counted using a haemocytometer and viability was determined with trypan blue staining. 
5.2.4.2 PBMC cell culture 
After isolation, PBMCs were put into culture for 3 days until initiation of the proliferation assay 
(37 °C, 5 % CO2). PBMCs were cultured in RPMI-1640 with FBS (10 % v/v), penicillin and 
streptomycin (1% v/v), and L-glutamine (200 mM solution, 1 % v/v). After culture, only the 
cells still in suspension were collected, thus depleting the PBMC population of monocytes 
(which are plate adherent). An aliquot of the cells was diluted in Turks solution (1:20) and 
counted using a haemocytometer.  
5.2.4.3 Preparation of red blood cell lysates, cytosol, and membranes 
Frozen primed (pRBC) and unprimed (upRBC) red blood cells (Section 5.2.3) were subjected 
to three freeze-thaw cycles to ensure complete cellular lysis, thus producing red blood cell 
lysates. The lysates were clarified by centrifugation to remove particulates (2000 g, 5 minutes). 
The red blood cell cytosolic fraction was isolated by removing the cellular membranes from 
the red blood cell lysates by centrifugation (16,000 g, 20 minutes). The resulting membranes 
were washed twice with Milli-Q water (16,000 g, 20 minutes) before being resuspended in 
RPMI-1640 media. 
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5.2.4.4 CFSE labelling 
Jurkat cells or PBMCs (1 million cells per mL) were stained with CFSE (5(6)-
carboxyfluorescein diacetate N-succinimidyl ester) at a final concentration of 5 µM in PBS for 
10 minutes at 37 °C. After staining, the cells were washed once with FBS to quench the excess 
CFSE. Immediately after labelling, the cells were analysed by flow cytometry and staining 
efficiency was determined to be greater than 99 %.  
5.2.4.5 Proliferation assay conditions 
Proliferation assays were performed with CFSE stained Jurkat cells or PBMCs for up to 6 days 
with low serum media (RPMI-1640, 1 % FBS, 1 % penicillin/streptomycin, 1 % L-glutamine, 
v/v). Jurkat cells (0.25 x 106) were cultured in 12-well plates, with a total culture media volume 
of 2.5 mL for 6 days (37 °C, 5 % CO2). PBMCs (1.5 x 106) were cultured in 6-well plates, with 
a total culture media volume of 5 mL for 5 days. For analysis of apoptosis and expression of 
transcription factors, unstained PBMCs were cultured under the same conditions. PBMCs were 
stimulated with PHA-P (Phytohemagglutinin-P, 5 µg/mL), and Jurkat cells were left 
unstimulated. Jurkat cells and PBMCs were cultured with or without autologous red blood cells 
at a ratio of 1:10 (Jurkat/PBMCs to red blood cells). As outlined in Section 5.2.3.2, the red 
blood cells had been either primed (incubated with A549 for 72 hours) or unprimed (incubated 
alone for 72 hours). In variations of the proliferation assay, Jurkat cells were treated with red 
blood cell lysates, cytosols, or membranes (from primed or unprimed cells) at concentrations 
equivalent to 2.5 x 106 cells per well. Additionally, Jurkat cells were treated with conditioned 
media (undiluted) from red blood cell priming conditions (Section 5.2.3.2).  
At the conclusion of the culture period, the conditioned media from each sample was collected 
and stored at -80 °C for future analysis. The PBMCs and Jurkat cells were isolated and 
processed for flow cytometry analysis as outlined below (Section 5.2.5). 
 
5.2.5  Cell staining and flow cytometry 
Following cell culture, the PBMCs and Jurkat cells were isolated by centrifugation (1000 g, 
10 minutes). The resulting conditioned media was collected and stored (-80 °C) and the 
remaining cells were prepared for flow cytometry analysis. For each sample, 1 x 104 events of 
the stained target population were acquired and analysed by flow cytometry using Cell Quest 
Pro software (ver. 5.2.1) and Flowing Software (ver. 2.5.1). 
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5.2.5.1 Jurkat cell analysis 
Following culture, Jurkat cells were isolated by centrifugation (1000 g, 10 minutes). In red 
blood cell treated conditions, the red blood cells were lysed with red blood cell lysis buffer 
(10 minutes, 37 °C). The Jurkat cells were then washed in PBS before being analysed by flow 
cytometry (FACScalibur) to monitor level of CFSE fluorescence.  
5.2.5.2 PBMC analysis 
Following culture, PBMCs were isolated by centrifugation (1500 g, 10 minutes). In red blood 
cell treated conditions, the red blood cells were lysed with red blood cell lysis buffer 
(10 minutes, room temperature). The PBMCs were then washed once in PBS before 
commencing staining with the following antibodies (Table 5.2). Cells stained with CFSE were 
only co-stained with APC conjugated antibodies. 
 
Table 5.2. Antibodies and proteins used for immunofluorescence staining of PBMCs. 
Antibody/Protein Fluorochrome Clone 
Anti-human CD3 (Mo IgG1, κ) APC SK7 
Anti-human CD3 (Mo IgG1, κ) FITC UCHT1 
Anti-human CD4 (Mo IgG1, κ) APC RPA-T4 
Anti-human CD8a (Mo IgG1, κ) APC HIT8a 
Anti-human GATA-3 (Mo IgG2b, κ) PE 16E10A23 
Anti-human T-bet (Mo IgG1, κ) PE 4B10 
Annexin V FITC - 
Isotype control (Mo IgG1, κ) FITC MOPC-21 
Isotype control (Mo IgG1, κ)  APC MOPC-21 
Isotype control (Mo IgG1, κ) PE MOPC-21 
Isotype control (Mo IgG2b, κ) PE MPC-11 
 
 
Cells were stained in two steps, for extracellular markers in the first step (CD3, CD4, CD8, or 
corresponding isotype controls) and intracellular markers in the second step (T-bet, and GATA-
3, or corresponding isotype controls). For staining of CD3, CD4, and/or CD8, 1 x 106 cells 
were resuspended in 100 µL staining buffer (PBS, 0.5 % bovine serum albumin (BSA) w/v) 
with the relevant antibodies or corresponding isotype controls and were incubated at 4 °C for 
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30 minutes in the dark. Cells were then washed once in ice cold staining buffer (1500 g, 
5 minutes). In the second step of the staining protocol for GATA-3 and T-bet, the cells were 
fixed and permeabilised (Nuclear Factor Fixation and Permeabilisation Buffer Set, BioLegend) 
according to the manufacturers instructions. The cells were then resuspended in 100 µL of the 
permabilisation buffer with the relevant antibodies or corresponding isotype controls and were 
incubated at 4 °C for 30 minutes in the dark. After the incubation, the cells were washed twice 
in PBS/0.1 % BSA (1500 g, 5 minutes) and were finally resuspended in 300 µL PBS for flow 
cytometry analysis. Multi-colour flow cytometry (FACScalibur) was used to monitor the level 
of CFSE fluorescence in specific cellular populations and to monitor the expression of 
transcription factors in CD8+ populations. For the purposes of compensation, BD CalibriteTM 
beads and single colour controls for CFSE, FITC, PE, and APC were used to optimise 
detection. The proliferation index of the CFSE labelled PBMCs was determined by monitoring 
the percentage of cells in each generation as previously described31. 
5.2.5.3 Apoptosis analysis 
Following cell surface staining, PBMCs were washed once in Annexin V binding buffer 
(BioLegend) and 0.1 x 106 cells were resuspended in 100 µL of Annexin V binding buffer 
(BioLegend) with 5 µL of 1 mg/mL propidium iodide (PI) and the corresponding Annexin V-
FITC antibody. These cells were incubated for 15 minutes in the dark at room temperature after 
which the cell suspension was diluted in 400 µL of Annexin V binding buffer. The cells were 
then analysed immediately by flow cytometry.  
 
5.2.6   Haemoglobin quantification 
Levels of free haemoglobin in plasma samples and conditioned media samples were monitored 
by assessing absorbance at 414 nm (Synergy 2 Multi-Mode plate reader) as previously 
described32. Peaks at this wavelength are indicative of free haemoglobin. Red blood cell 
membranes were removed from the conditioned media samples prior to analysis by 
centrifugation at 16,000 g for 15 minutes. A haemoglobin calibration curve was prepared using 
haemoglobin (Sigma Aldrich, USA) at known concentrations and was analysed on GraphPad 
Prism software (ver. 6, USA). 
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5.2.7   Cytokine multiplex assay 
In this study, two multiplex assays were utilised. The first was the 27-plex human cytokine 
panel that assays for FGF basic, Eotaxin-1, G-CSF, GM-CSF, IFN-γ, IL-1β, IL-1ra, IL-2, IL-
4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12(p70), IL-13, IL-15, IL-17, IP-10, MCP-1, MIP-1α, 
MIP-1β, PDGF-BB, RANTES, TNF-α, and VEGF, and the second was the 21-plex human 
cytokine panel that assays for IL-1α, IL-2Ra, IL-3, IL-12(p40), IL-16, IL-18, CTACK, GRO-
α, HGF, IFN-α2, LIF, MCP-3, M-CSF, MIF, MIG, β-NGF, SCF, SCGF-β, SDF-1α, TNF-β, 
TRAIL (Bio-Plex Pro 27-plex and 21-plex, Bio-Rad). The assays were performed according to 
manufacturer’s instructions using an automated magnetic wash station (Bio-Plex Pro II, Bio-
Rad) for the washing steps. The assays were run on the Luminex® 200TM system (Bio-Rad) 
and fluorescence values were collected. The calibration curve for each cytokine was analysed 
with 5 parametric logistic curve regression using Bio-Plex manager software (ver. 5.0, Bio-
Rad, USA). Standard values were considered acceptable if the points fell within 80 - 120 % of 
the expected values. Conditioned media samples from A549-red blood cell culture and PBMC 
cultures were left undiluted for analysis. The conditioned media samples from the Jurkat 
cultures were concentrated 5x with centrifugal concentrators (3kD minimum cut off) for 
multiplex analysis. 
 
5.2.8   Statistical analysis 
Comparison of multiple treatment groups for haemoglobin concentration or flow cytometry 
data were statistically evaluated using a one-way ANOVA with correction for multiple 
comparisons (Tukey correction) to assess statistical significance. Data were statistically 
significant if p < 0.05. Graphing of results was performed using GraphPad Prism software (ver. 
6, USA). Flowing Software (ver. 2.5.1) was used to create data histograms and dot plots for 
flow cytometry data and for data analysis. Multi-plex cytokine data were presented as fold 
change of fluorescence and are presented as mean ± confidence interval (CI). Concentration 
values are presented as mean ± standard deviation (SD).  
Statistical analysis of raw fluorescence responses was performed using ‘R’ version 3.2.3 (2015-
12-10, R: A Language and Environment for Statistical Computing). Mixed-effects modelling 
was done using lmer33. The significance of interactions terms and interaction means and their 
associated standard errors were obtained using the Phia package34, for post-hoc analysis. 
Multiple test correction was done according to Holm’s method35. To analyse the fluorescence 
response, the following mixed-effects model, in R notation, was used: 
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Equation 5.1. Mixed-effects model for statistical analysis of cytokine data. 
log2ሺFIሻ~Cytokine ∗ Treatment ൅ ሺ1|kit: IDሻ 
 
The analysis was performed separately for red blood cells lysates and conditioned media 
samples. Where the log2 of fluorescence responses (Fl) was modelled using 2-way mixed 
effects ANOVA, (1) Cytokine (48 levels), and (2) Treatment (2 levels for red blood cell lysates: 
unprimed red blood cells, or primed red blood; 4 levels for conditioned media: none, PHA, 
unprimed red blood cells, or primed red blood cells) plus their interactions, together with one 
random term defined as (1|kit:ID), where ID represented subject identifier and where kit 
represented the 27-plex and 21-plex cytokine panels (2 levels). The random effects account for 
patient-to-patient variability and for differences with respect to kit groupings across the 2 
cytokine plates; it also accounted for the non-independence in the data due to multiple samples 
per subject. Results of the mixed-effects model validation is included in Appendix E. 
For the remainder of this chapter, the term ‘significant’ will be used to indicate a statistically 
significant result of p < 0.05 unless otherwise specified. 
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5.3    RESULTS 
 
5.3.1 Red blood cell purity 
Red blood cell purity was determined by calculating the depletion of white blood cells and 
platelets from whole blood to an enriched red blood cell population.  This enriched red blood 
cell population was produced through dextran sedimentation of red blood cells. The dextran 
sedimentation protocol utilised in this chapter was slightly different to the protocol outlined in 
Chapter 3 and Chapter 4. Here, dextran sedimentation occurred after the plasma was removed 
as opposed to sedimentation from complete whole blood. This small method change resulted 
in improved white blood cell depletion than previously seen in Chapter 4, Table 4.2 (mean: 
97 %, vs 83 %). The platelet depletion remained unchanged with a mean of 98% depletion. 
Thus, for every one million red blood cells there were approximately 28 white blood cells and 
2,700 platelets. 
 
Table 5.3. Purity assessment of enriched red blood cell (RBC) fractions (n = 12). 
RBC purity (%) White blood cell depletion (%) Platelet depletion (%) 
99.995 ± 0.004 97.2 ± 3.4 98.2 ± 3.8 
*Data are presented as mean ± SD 
  
 
5.3.2   Priming red blood cells with A549 cells 
For priming experiments, fresh red blood cells were collected and were incubated with or 
without a lung cancer cell line (A549 cells) for 3 days at 37 °C and 5 % CO2 to produce 
‘primed’ (pRBC) or ‘unprimed’ (upRBC) red blood cells. Proliferation of A549 cells in the 
presence or absence of red blood cells was determined and any changes in the cytokine profile 
of these primed or unprimed red blood cells were also investigated. 
5.3.2.1 A549 cell proliferation 
A549 cells were cultured under three conditions and following incubation the confluence of 
the A549 cells in each well was determined. There was no significant difference between the 
confluence of the A549 cells that were cultured alone or in the presence of red blood cells. 
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5.3.2.2 Conditioned media from A549 cells 
There was no significant difference in the concentration of cytokines in the conditioned media 
from A549 cells or A549 cells with red blood cells. In addition, there was no significant 
difference in the concentration of haemoglobin in the red blood cell conditioned media with or 
without A549 cells. The levels of haemolysis in the conditioned media for each sample 
corresponds to approximately 1 % of the original inoculation.  
5.3.2.3 Cytokine profile of red blood cell lysates 
Following incubation, the resulting upRBCs and pRBCs were collected and their lysates were 
analysed to establish the cytokine profile. The fold change of a representative selection of 
cytokines from the low prime group (red blood cells primed with A549 cells at 100:1 
respectively, pRBC-L) is presented in Figure 5.2; the data for the remaining cytokines can be 
found in Appendix F. For the upRBC group, the level of 17 cytokines in red blood cells changed 
following incubation, whilst 26 cytokines changed after incubation for the pRBC group 
(Appendix F). A significant increase in the level of eight cytokines in the pRBCs compared to 
upRBCs was observed. The significant changes between the upRBC and the pRBC group were 
observed for chemokines (IL-8, MCP-1 and GRO-α), growth factors (bFGF, M-CSF, and 
VEGF), and pro-inflammatory cytokines (IL-9, IL-12p70) (Figure 5.2). The largest observed 
increase in concentration in the red blood cells was bFGF, where, the concentration changed 
from a mean of 22 ± 18 pg/mL in the upRBCs, to 983 ± 414 pg/mL in the pRBCs. Similarly, 
the concentration of GRO-α increased from a mean of 6 ± 6 pg/mL in the unRBC group to 
259 ± 214 pg/mL in the pRBC group.  
The cytokine profile of the red blood cell from the high ratio prime group (red blood cells 
primed with A549 cells at 1000:1 respectively, pRBC-H) was very similar to the pRBC-L, 
however the differences between the primed and unprimed cells was less pronounced. As an 
example, GRO-α was 30 ± 28 fold higher with priming in the pRBC-L group, whilst it was 
only 20 ± 10 fold higher with priming in the pRBC-H group. This trend was also observed for 
IL-8, and MCS-F. 
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Figure 5.2. Summary of cytokines in the red blood cell lysates prior to incubation (T0) and 
of primed (pRBC) and unprimed (upRBC) red blood cells after incubation (T3, primed at 1:100 
for A549:RBCs) as measured by Bio-Plex and reported as fluorescence (100 million cells in 
1 mL PBS). Data are presented as mean fold change of fluorescence ± 95 % CI (n = 12), where 
● represents the fold change for unprimed red blood cells before and after incubation and ■ for 
primed cells before and after incubation, and ▲ represents the fold change in fluorescence 
between unprimed and primed red blood cells (T3). Data are statistically significantly different 
(*) if p < 0.05, (**) if p < 0.01, (***) if p < 0.001, (****) if p < 0.0001. 
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5.3.3   Red blood cell treatment of Jurkat cells 
In this study, proliferation of a leukemic T cell line (Jurkat cells) was monitored over 6 days 
with and without red blood cell treatment and was quantified by monitoring the dilution of 
cellular CFSE staining. Cytokine release from Jurkat cells during incubation was also 
monitored. 
5.3.3.1 T cell proliferation 
A reduction in CFSE staining was observed for the Jurkat cells that had been treated with 
upRBCs, and a further reduction was observed in the Jurkat cells that had been treated with 
pRBCs (Figure 5.3). This is representative of Jurkat cell proliferation that was stimulated in 
the presence of red blood cells. 
 
 
 
Figure 5.3. Histogram shows CFSE fluorescence loss in untreated Jurkat cells (none), 
Jurkat cells treated with unprimed red blood cells (+upRBC), or Jurkat cells treated with primed 
red blood cells (+pRBC) as measured by flow cytometry. A shift in the histogram peak to the 
left indicates Jurkat cell proliferation over 6 days at 37 °C and 5 % CO2. 
 
 
 
 
 
None 
+upRBC 
+pRBC 
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When treated with upRBCs, Jurkat cells proliferated significantly more than the untreated cells, 
with a mean fold increase of 2.4 (Figure 5.4a). In addition, Jurkat cells treated with pRBCs 
proliferated significantly more than the corresponding upRBCs (p < 0.0001) regardless of the 
RBC-A549 priming ratio (Figure 5.4a). Although the trends were the same, there were some 
differences between the groups. The red blood cells primed at a ratio of 1:100 (pRBC-L) 
produced a larger proliferative response in the Jurkat cells than the red blood cells primed at a 
ratio of 1:1000 (pRBC-H), with a mean fold change from the untreated control of 8.3 and 5.3 
respectively. This difference was highly statistically significant with a p-value of 0.0008. For 
this reason, subsequent proliferation experiments were conducted on the pRBC-L (1:100 
priming ratio of A549:RBC) group only. 
No increase in proliferation was observed for Jurkat cells treated with the culture media blank 
or with red blood cell conditioned media (Figure 5.4b). However, treatment with conditioned 
media from A549 cells and A549-red blood cell conditioned media resulted in significantly 
more proliferation than the untreated cells (p < 0.0001) with mean fold changes of 2.9 and 3.5 
respectively (Figure 5.4b). Of note, the addition of red blood cells to the A549 culture produced 
conditioned media that was significantly more stimulatory to the Jurkat cells than the 
conditioned media from A549 cells alone. 
An overall increase in Jurkat cell proliferation was observed with treatment of red blood cell 
fractions. The lysate or cytosol from red blood cells significantly increased proliferation by 
approximately 2-fold (Figure 5.4c). This was consistent for the lysates and cytosols isolated 
from both upRBCs and pRBCs and there was no difference between either of these groups. In 
addition, the increase observed for these conditions was consistent with the proliferation 
associated with intact, upRBCs, where each group resulted in a 2 to 2.5-fold increase in 
proliferation of the Jurkat cells (Figure 5.4a). Although lower proliferation was observed with 
red blood cell membrane treatment in comparison to red blood cell lysate and cytosol treatment 
(mean of 1.4-1.9 vs 2.2-2.6), the membranes stimulated the Jurkat cells to proliferate 
significantly more than the untreated controls (Figure 5.4c). In fact, the only difference between 
the upRBC and pRBC groups in the analysis of red blood cell fractions was observed with 
membrane treated Jurkat cells. Membranes isolated from pRBCs significantly promoted Jurkat 
cell proliferation when compared to the upRBC membranes (p = 0.0031).  
Chapter 5 – Modulation of RBC cytokine profile and the effect on immune cell activity 
149 
 
 
Figure 5.4. Graphical representation of Jurkat cell proliferation following treatment with 
(A) intact primed (pRBCs) or unprimed (upRBCs) cells which were primed at 1:100 (pRBC-
L) or 1:1000 (pRBC-H) for A549 cells:RBCs, (B) conditioned media from A549 cells, RBCs, 
or A549/RBC culture (cells primed at 1:100 for A549:RBCs), or (C) red blood cell lysate, 
cytosol, or membranes isolated from upRBCs and pRBCs (cells primed at 1:100 for 
A549:RBCs). Data are presented as fold change of loss of CFSE fluorescence from untreated 
Jurkat cells after 6 days in culture at 37 °C with 5 % CO2 (mean ± SD, n = 5). Data are 
statistically significantly different (*) if p < 0.05, (**) if p < 0.01, (***) if p < 0.001, (****) if 
p < 0.0001. 
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5.3.3.2 Cytokine prolife of Jurkat cell conditioned media 
The level of cytokines in the conditioned media from Jurkat cells in all culture conditions was 
evaluated using multiplex cytokine assays. The fold change of a representative selection of 
cytokines is presented in Figure 5.5; the data for the remaining cytokines can be found in 
Appendix G. In the pRBC group, the level of 22 cytokines increased, and none decreased 
(Appendix G) in comparison to the upRBC group. In the upRBC groups, secretion of only IL-
16 increased in comparison to the untreated group, and only IL-7 decreased. Of the 14 
cytokines that were significantly different between upRBC and pRBC treatment, all were 
higher in the pRBC group. Of those cytokines, there was an even distribution across the 
functional categories. Notably, of the five anti-inflammatory cytokines that are on the multiplex 
panels, the levels of four of them were significantly higher in the pRBC group when compared 
to the upRBC group (Appendix G). 
For the conditioned media from Jurkat treated with primed red blood cells, there were five 
cytokines with a mean fold increase from the untreated control of greater than 10 (IL-8, GRO-
α, MCP-1, RANTES, and VEGF). The concentration of each of these cytokines changed 
substantially (Figure 5.5). For example, the concentration of GRO-α was below the limit of the 
standard curve (< 7.3 pg/mL) for the upRBC group, but was present at 2443 ± 748 pg/mL 
(mean ± SD) in the conditioned media of the pRBC group. Similarly, IL-8 increased from a 
mean of 7 ± 3 pg/mL in the upRBC groups to 2317 ± 2420 in the pRBC group. Although the 
lysate concentration of these cytokines was also higher in the pRBC group compared to the 
upRBC group, these increased levels cannot only be attributed to red blood cell release or lysis. 
Primed red blood cells incubated alone in the same conditions released 3.5-fold less GRO-α 
than the Jurkat cells treated with the same primed cells. Likewise, primed red blood cells 
released 4-fold less IL-8 than primed red blood cell treatment group. 
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Figure 5.5. Summary of cytokines in Jurkat conditioned media as measured by Bio-Plex 
and reported as fluorescence. Data are presented as mean fold change from the untreated Jurkat 
control in fluorescence ± 95 % CI (n = 5), where ● represents the fold change for untreated 
Jurkat, ■ for Jurkat cells treated with unprimed red blood cells (upRBC), and ▲ for Jurkat cells 
treated with primed red blood cells (pRBC). Data are statistically significantly different from 
the untreated Jurkat control (*) if p < 0.05, (**) if p < 0.01, (***) if p < 0.001, (****) if 
p < 0.0001. 
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5.3.3.3 Concentration of haemoglobin in red blood cell conditioned media 
The concentration of haemoglobin in conditioned media from red blood cells and red blood 
cells incubated with Jurkat cells was quantified by monitoring the absorbance of the solutions 
at 414 nm. The concentration of haemoglobin in the conditioned media samples corresponds 
to the lysis of 68,000 to 375,000 red blood cells (Figure 5.6). With a starting inoculation of 
2.5 x 106, this corresponds to lysis of a minimum of 3 % and a maximum of 15 % of the total 
red blood cell number. In a comparison between upRBC and pRBC conditioned media samples, 
there is a trend towards more lysis in the upRBC samples. However, the only statistically 
significant difference was between upRBC-L and pRBC-L (primed at 1:100 with A549 cells) 
incubated with Jurkat cells for 6 days (Figure 5.6). 
 
 
Figure 5.6. Concentration of haemoglobin in the conditioned media of unprimed or primed 
red blood cells (2.5 x 106 red blood cells per condition) incubated alone or with Jurkat cells for 
6 days at 37 °C with 5 % CO2. Red blood cells were primed at 1:100 (pRBC-L) or 1:1000 
(pRBC-H) with A549 cells prior to incubation. Haemoglobin concentration was measured by 
absorbance at 414 nm. Data are presented as mean ± SD, n = 5, statistically significantly 
different (*) if p < 0.05. 
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5.3.4   Red blood cell treatment of peripheral blood mononuclear cells 
The effect of pRBCs and upRBCs on the activity and expression of peripheral blood 
mononuclear cells (PBMCs) was investigated. PBMCs were treated with red blood cells, and 
the level of proliferation, apoptosis, cytokine secretion and expression of transcription factors 
in T cells was quantified. 
5.3.4.1 T cell proliferation 
Proliferation of CD3+, CD4+, and CD8+ T cells was monitored by tracking CFSE dilution 
across 5 days in culture. Multiple peaks in the CFSE histograms indicate new cellular 
generations, and a shift in the CFSE peak to the left indicates dilution of CFSE and thus 
proliferation. Treatment with PHA-P and upRBCs stimulated increased proliferation compared 
to PBMCs treated with PHA-P alone. This result was consistent for CD3+, CD4+, and CD8+ 
cells (Figure 5.7). Treatment with pRBCs stimulated the generation of a number of additional 
peaks to the left of the original peak in each of the gated populations. Specifically, when treated 
with pRBCs, CD8+ T cells underwent more cell division cycles than the CD4+ cells (Figure 
5.7). 
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Figure 5.7. Histograms show CFSE fluorescence loss in PBMCs (peripheral blood 
mononuclear cells) treated with PHA-P (+ PHA), PHA-P and unprimed RBCs (+PHA 
+ upRBC), or PHA-P and primed RBCs (+PHA + pRBC). The histograms outline proliferation 
for CD3+ cells, CD4+ cells, and CD8+ cells as measured by flow cytometry. A shift in the 
histogram peaks to the left indicates cell proliferation over 5 days at 37 °C and 5 % CO2.
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T cell proliferation was quantified by recording the percentage of cells with a particular level 
of CFSE staining (gating parameters outlined in Figure 5.7). Treatment with PHA-P and 
pRBCs resulted in a significant increase in proliferation for CD3+ cells, CD4+ and CD8+ cells 
when compared to PBMCs treated with PHA-P alone (Figure 5.8). Between pRBC and upRBC 
treatment, there was a significant increase in CD8+ cell proliferation with pRBC treatment and 
there was an upward trend in cellular proliferation for CD3+ cells. This was not observed for 
CD4+ cells (Figure 5.8). 
 
 
Figure 5.8. Graphical representation of proliferation of PBMCs (peripheral blood 
mononuclear cells) following treatment with nothing (PBMC), with PHA-P (PBMC + PHA), 
with PHA-P and unprimed red blood cells (PBMC + PHA + upRBC), or with PHA-P and 
primed red blood cells (PBMC + PHA + pRBC) after 5 days in culture at 37 °C with 5 % CO2 
A B 
C 
Chapter 5 – Modulation of RBC cytokine profile and the effect on immune cell activity 
156 
 
(mean ± SD, n = 6). Figures represent proliferation of (A) CD3+ cells, (B) CD4+ cells, and (C) 
CD8+ cells from a PBMC population as fold change of proliferation index from loss of CFSE 
fluorescence (MFI). Data are statistically significantly different (*) if p < 0.05, (**) if p < 0.01, 
(***) if p < 0.001. 
 
 
5.3.4.2 Proportion of CD4+ and CD8+ cells 
Monitoring the proportion of CD4+ cells and CD8+ cells in a CD3+ T cell population revealed 
that treatment only significantly affected the proportion of CD8+ cells, whilst the proportion 
of CD4+ cells remained largely unchanged.  Inclusion of red blood cells and PHA-P in the 
PBMC culture (upRBCs or pRBCs) resulted in significantly more CD8+ cells than the 
untreated comparison (Figure 5.9). 
 
 
Figure 5.9. Percentage of (A) CD4+ cells or (B) CD8+ cells, in a CD3+ population of 
PBMCs (peripheral blood mononuclear cells) following treatment with nothing (PBMC), with 
PHA-P (PBMC + PHA), with PHA-P and unprimed red blood cells (PBMC + PHA + upRBC), 
or with PHA-P and primed red blood cells (PBMC + PHA + pRBC) for 5 days in culture at 
37 °C and 5 % CO2. Data are statistically significantly (*) if p < 0.05, n = 7.  
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Chapter 5 – Modulation of RBC cytokine profile and the effect on immune cell activity 
157 
 
5.3.4.3 Apoptosis 
Apoptosis of PBMCs was measured by Annexin V/PI co-staining and flow cytometry analysis. 
It was demonstrated that red blood cells were protective against PHA-P induced apoptosis of 
PBMCs. This protection was evident for both CD4+ and CD8+ cells (Figure 5.10). The 
proportion of live cells (Annexin V-/PI-) was significantly lower in PBMCs treated with PHA-
P when compared to untreated PBMCs (Figure 5.10).  Both pRBCs and upRBCs appeared to 
have a protective capacity on PHA-P treated PBMCs, and the proportion of live cells in these 
groups was consistent with that of untreated PBMCs (Figure 5.10). 
 
 
Figure 5.10. Percentage of Annexin V-/PI- cells in (A) CD4+ populations or (B) CD8+ 
populations from PBMCs (peripheral blood mononuclear cells) treated with nothing (PBMC), 
PHA-P (PBMC + PHA), PHA-P and unprimed red blood cells (PBMC + PHA + upRBC), and 
PHA-P and primed red blood cells (PBMC + PHA + pRBC) for 5 days at 37 °C and 5 % CO2 
(mean ± SD, n = 5). Data are statistically significantly different from PBMCs treated with 
PHA-P (*) if p < 0.05, (**) if p < 0.01. 
 
The proportion of early and late apoptotic cells (Annexin V+/PI-, and Annexin V+/PI+) 
increased with PHA-P treatment for both CD4+ and CD8+ cells (Figure 5.11). The numbers of 
early and late apoptotic cells were reduced in the presence of red blood cells and were at similar 
levels to the unstimulated PBMCs.  
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Figure 5.11. Dot plots of Annexin V and PI staining of CD4+ and CD8+ cells from PBMCs 
treated with (A) nothing, (B) PHA-P, (C) PHA-P and unprimed red blood cells (upRBCs), and 
(D) PHA-P and primed red blood cells (pRBCs) for 5 days at 37 °C with 5 % CO2. 
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5.3.4.4 Expression of transcription factors 
The expression of two transcription factors (GATA-3 and T-bet) in a CD8+ population were 
quantified using flow cytometry. PHA-P treatment of PBMCs stimulated a significantly higher 
expression of both transcription factors (Figure 5.12). Treatment with both PHA-P and upRBCs 
suppressed the expression of each transcription factor and there was no significant difference 
between those treated with the upRBC group and the untreated PBMCs (Figure 5.12). This 
suppression was not observed for the PBMCs treated with PHA-P and pRBCs. Instead, the 
level of expression of GATA-3 and T-bet were closer to the levels reported for the PHA-P 
treated samples (Figure 5.12). When compared to the PHA-P sample, the mean fold change in 
GATA-3 expression was 0.47 for the upRBC treatment and 0.84 for the pRBC treatment. 
Similarly, the mean fold change in T-bet expression was 0.37 for the upRBC treatment and 
0.71 for the pRBC treatment. Of note, although there was significantly less expression of T-
bet in the pRBC group, there was a clear increase in expression when compared to the upRBC 
group (Figure 5.12). The same trend was observed for GATA-3 expression. 
 
 
 
Figure 5.12. Expression of transcription factors in CD8+ population of PBMCs (peripheral 
blood mononuclear cells) treated with ● nothing, ■ PHA-P, ▲ PHA-P and unprimed red blood 
cells (upRBCs), or ▼ PHA-P and primed red blood cells (pRBCs), for 5 days at 37 °C and 5 % 
CO2 (mean ± min/max, n = 7). Data are presented as fold change from PBMCs treated with 
PHA-P in expression of (A) GATA-3 and (B) T-bet. Data are statistically significantly different 
from ■ PBMCs treated with PHA-P (*) if p < 0.05. 
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5.3.4.5 Cytokine profile of PBMC conditioned media 
The cytokines in the conditioned media of PBMCs from all cultures conditions were quantified 
using Bio-Plex assays. The fold change of a representative selection of cytokines is presented 
in Figure 5.13; the data for the remaining cytokines can be found in Appendix H. Treatment 
with PHA-P significantly stimulated increased secretion of 33 cytokines. Treatment with 
upRBCs resulted in five significantly altered cytokines when compared to the PHA-P treated 
control, whilst eight cytokines changed significantly in the pRBC group.  
Treating PBMCs with pRBCs altered the secretion profile in comparison to treatment with 
upRBCs. Between the two conditions, significant differences were observed for three 
cytokines. Of those cytokines, one was IL-5, a pro-inflammatory cytokine, one was MCP-3, a 
chemokine, and one was IL-2, a cytokine with multiple functions (Appendix H). IL-5 was 
significantly higher (p < 0.0001) in the conditioned media of the pRBC group when compared 
the upRBC group (Figure 5.13). A number of cytokines followed this same trend but were not 
statistically significant including IL-4, IL13, IL-17, and G-CSF. Of the cytokines with a 
significant difference between red blood cell treatment and PHA-P stimulation alone, all were 
higher in the pRBC group (Figure 5.13).  
The increase in concentration observed following treatment with red blood cells (upRBCs or 
pRBCs) could not be wholly attributed to red blood cell release or lysis, regardless of the red 
blood cell lysate concentration following priming. As an example, PBMCs treated with PHA-
P alone released 153 ± 67 pg/mL of IL-17 into the conditioned media. This was significantly 
lower than the amount released from PBMCs treated with red blood cells (Figure 5.13). For 
example, upRBCs incubated alone under the same conditions released 7.5 ± 1.1 pg/mL of IL-
17, and the PBMCs treated with the upRBCs released 645 ± 268 pg/mL of IL-17. Similarly, 
the pRBC equivalent released 7.0 ± 5.1 pg/mL of IL-17 when incubated alone, or 
891 ± 282 pg/mL of IL-17 when PBMCs were treated with the primed red blood cells. The 
amount released by red blood cells alone does not explain the observed increase. 
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Figure 5.13. Summary of cytokines in PBMC (peripheral blood mononuclear cells) 
conditioned media as measured by Bio-Plex and reported as fluorescence ± 95 % CI (n = 7). 
Data are presented as mean fold change from ■ PBMC treated with PHA-P, to ● untreated 
PBMCs, ▲ for PBMCs treated with PHA-P and unprimed red blood cells (upRBC), and ▼ for 
PBMCs treated with PHA-P and primed red blood cells (pRBC). Fold change from PBMCs 
treated with PHA-P and upRBCs to PBMCs treated with PHA-P and pRBCs represented by ○ 
(open circle). Data are statistically significantly different from PBMCs treated with PHA-P (*) 
if p < 0.05, (**) if p < 0.01, (***) if p < 0.001, (****) if p < 0.0001. 
  
Chapter 5 – Modulation of RBC cytokine profile and the effect on immune cell activity 
162 
 
5.3.4.6 Concentration of haemoglobin in red blood cell conditioned media 
Haemoglobin levels in the conditioned media from red blood cells and red blood cells 
incubated with PBMCs was quantified by monitoring the absorbance at 414 nm. The 
concentration of haemoglobin in the pRBC conditioned media samples was significantly lower 
than upRBC samples (Figure 5.14). This was true for both red blood cells incubated alone or 
red blood cells incubated in the presence of PBMCs (Figure 5.14). The concentration of 
measured haemoglobin corresponded to the lysis of 1,375,000 cells for the upRBC group and 
153,000 cells for the pRBC group. This represents 9 % and 1 % of the starting inoculation for 
the upRBC and pRBC groups respectively. 
 
 
Figure 5.14. Concentration of haemoglobin in the conditioned media of unprimed (upRBC) 
or primed (pRBC) red blood cells (15 x 106 red blood cells per condition) incubated alone or 
with PBMCs (peripheral blood mononuclear cells) and PHA-P for 5 days at 37 °C with 
5 % CO2. Red blood cells were primed at 1:100 with A549 cells prior to incubation. 
Haemoglobin concentration was measured by absorbance at 414 nm. Data are presented as 
mean ± SD, n = 7, statistically significantly different (*) if p < 0.05, (**) if p < 0.01. 
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5.4   DISCUSSION 
 
The previous chapters of this thesis identified that a range of inflammatory cytokines, growth 
factors, and chemokines are associated with red blood cells isolated from healthy individuals. 
These red blood cells were also observed to bind and release these cytokines, and this activity 
was modulated under certain conditions. The aim of this study was to investigate a cellular 
interaction mechanism of modulating this response. Specifically, the effect of interaction with 
a cancer cell line to modulate the binding and release of cytokines from red blood cells was 
investigated. The role of red blood cells in the activity of immune cells has been reported in 
the literature4,9,12 and a small number of papers have outlined how red blood cells can become 
dysregulated in an inflammatory condition or following long term storage16,18,19. This 
dysregulation was illustrated through the altered effect of red blood cells on corresponding 
immune cell populations. In the light of these reports, this study was designed to model the 
communication between proliferating tumour cells and red blood cells in vivo and any resulting 
dysregulation in red blood cells. As observed in this chapter, priming red blood cells with a 
cancer cell line had an altered cytokine profile (Figure 5.2). These primed cells (pRBCs) also 
had an increased capacity to stimulate proliferation of a leukemic T cell line (Jurkat cells) and 
freshly isolated peripheral blood mononuclear cells (PBMCs) (Figure 5.4 and Figure 5.8) and 
this proliferation was biased towards the stimulation of CD8+ cytotoxic T cells (Figure 5.9). 
Unprimed red blood cells (upRBCs) attenuated the PHA-P mediated expression of 
transcription factors in the CD8+ population, however pRBCs did not produce the same 
attenuation (Figure 5.12). In addition, pRBCs stimulated the secretion of higher levels of IL-4, 
IL-5, and IL-13 from PBMCs (Figure 5.13). The results of this study support the hypothesis 
that red blood cells play an important role in immune cell regulation, and that this role can be 
dysregulated in response to interactions with biological stimuli.  
 
5.4.1   Red blood cell priming with A549 cells 
Angiogenesis and modification of the immune response are well-known factors in the 
progression of non-small cell lung carcinomas (NSCLC)21,36. With angiogenesis and vessel 
formation in tumours, red blood cells can contact and directly interact with cancer cells through 
vasculogenic mimicry30. It was hypothesised that this cell-to-cell contact would alter the 
cytokine profile of the corresponding red blood cells. To test this hypothesis, red blood cells 
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were incubated for three days with or without an adherent NSCLC line (A549 cells) and the 
resulting cytokine profile of the red blood cells was evaluated.  
In the determination of the ratio of red blood cells to endothelial cells, the rate of red blood cell 
flow through capillaries was investigated. The literature determines that a 1 cm long capillary 
would have approximately 350 red blood cells moving at 0.9 mm/sec, therefore, approximately 
2300 red blood cells would pass through this vessel in 1 minute27. This equates to just under 
10 million red blood cells in 72 hours. If this number was used in vitro with 1.8 million A549 
cells, the ratio would be approximately 1:6. It is difficult to obtain data on how many times a 
given red blood cell will pass over the same point over their 120-day lifespan. A key 
consideration in the experimental setup was to use sufficient red blood cells to enable the 
subsequent detection of cytokines. The final experimental design used two ratios, 1:100 and 
1:1000, which ensured that there were sufficient red blood cells and assumed repeat transit of 
red blood cells between 20 and 2000 times. 
5.4.1.1 Cytokine profile 
This study identified that red blood cells incubated with a NSCLC cell line (A549 cells) were 
loaded with inflammatory cytokines as a result of the incubation. The levels of eight cytokines 
were significantly higher in these primed cells including IL-8, bFGF, and VEGF (Figure 5.2). 
These cytokines have been implicated as important in the progression of NSCLC. Zhao et al. 
reported that NSCLC cells express various cytokines that promote tumour growth and 
angiogenesis, including VEGF and bFGF37 and both of these cytokines have been correlated 
with poor patient prognosis38. Intracellular bFGF promotes NSCLC tumour growth and 
stimulates secretion of VEGF39. The red blood cells primed with cancer cells in this study also 
contained significantly higher levels of three chemokines, IL-8, GRO-α and MCP-1 (Figure 
5.2). Similarly, these have also been implicated in tumour growth and angiogenesis40–42. 
Although IL-10 was not significantly increased in this study, there was an upward trend in the 
lysate concentration of pRBC when compared to upRBC (Figure 5.2). IL-10 is discussed as a 
source of immunosuppressive activity from A549 cells43 and is a TH2 cytokine that supports 
an immunosuppressive environment and improves the metastatic potential of lung cancer 
cells44. These results demonstrate that following cell-to-cell contact, red blood cells could be 
primed with a group of pro-tumorigenic proteins. As reported in Chapter 4, red blood cells have 
a capacity to bind and release a wide variety of cytokines depending on availability. Shen et al. 
investigated the role of DARC on red blood cells on cytokine binding in a model of prostate 
cancer45. Similar to the study outlined in this chapter, they identified increased binding of IL-
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8 and GRO-α in the presence of red blood cells, but unlike this study, the concentration of 
VEGF was unchanged. Although in each study the red blood cells were being primed by a 
secondary cell line, the final cytokine profile was slightly different. Following these results, it 
is not unreasonable to hypothesise that other cell lines with different secretion profiles would 
result in altered red blood cell cytokine profiles. However, further investigation is required to 
confirm this. 
It is likely that the increase of cytokines observed in the red blood cell lysates was a result of 
decreased feedback inhibition. In the cancer cell culture where no red blood cells were present, 
the secretion of cytokines would be inhibited once the optimal extracellular concentration had 
been reached. However, with red blood cells present and continuously binding cytokines out 
the conditioned media, it is likely that the cancer cells would continue to produce and secrete 
cytokines to maintain optimal cytokine levels in the conditioned media, and thus the red blood 
cell levels would also continue to increase. In support of this, there were no significant 
differences in cytokine levels in the conditioned media of the A549 cells alone, or A549 cells 
incubated with red blood cells. 
In situ, red blood cells are continuously moving throughout blood vessels and interact directly 
with a variety of cell types along the way. Blood is pumped through the whole body every 
minute, on average, and red blood cells remain in the circulation for 120 days46. The speed of 
blood flow varies inversely with the total cross-sectional area of the blood vessels, therefore as 
the cross-sectional area of the vessels increases, such as in capillaries, the velocity of flow 
decreases47. Blood flow is slowest in the capillaries, which enables time for exchange of gases 
and nutrients. With each cycle, the red blood cells are being repeatedly exposed to 
inflammatory signals whilst in motion. Although the results of this experiment were interesting 
and may indicate that red blood cells are primed in vivo, it cannot be said to represent a perfect 
model of biological interactions with red blood cells. In this set of experiments, the cancer cells 
were adherent to the bottom of the flask and the red blood cells were added in suspension to 
the media in the flask in static culture conditions. Over the three-day incubation period, the red 
blood cells settled to the bottom of the flask and did not move during this time. Agitation of 
the culture flasks to achieve a homogenous suspension of cells was not performed in this study 
as red blood cells are typically quite fragile following collection, thus there was a risk that this 
agitation over an extended period of time may result in excessive haemolysis. Haemolysis 
would raise two key issues, the first being that haemolysis would reduce the yield of red blood 
cells and would alter the ratio of red blood cells to the adherent cell line. Secondly, as indicated 
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by the previous chapters of this thesis, haemolysis would result in a release of a variety of 
cytokines into the conditioned media. This release of cytokines would likely have an effect on 
the release of cytokines from the adherent cell line (due to feedback inhibition) and on the 
resulting cytokine profile of the remaining red blood cells. The study outlined in this chapter 
was a preliminary experiment to identify if red blood cells could be primed by biological 
stimuli, however further studies in this area may benefit from investigation into shaking or 
movement during the process of red blood cell priming. 
Oonishi et al. reported that prostaglandin E1 and E2 production was stimulated in red blood 
cells in a model of mechanical stress in microcirculation47. There is no literature at this point 
as to what effect the shearing forces of the red blood cells moving through blood vessels would 
have had on their capacity to bind and release cytokines, but it is likely that the incorporation 
of movement and pressure changes would influence the cytokine profile of the red blood cells. 
The aim of this study was not designed to perfectly assess the role of red blood cells in cancer. 
Instead, the cancer cell line was used as a model to test whether red blood cells could be 
changed and dysregulated following interactions with biological stimuli. Comprehensive 
analysis of the role of red blood cells in cancer progression would require analysis of clinical 
samples or animal models. 
 
5.4.2   Effect of primed cells on T cell proliferation and survival 
T cell proliferation is typically used as a model of immune cell activation. Upon presentation 
with an antigen or a stimulatory signal, T cells undergo clonal expansion and cell 
differentiation48. Apoptosis of these cells is a crucial process to maintain homeostasis following 
immune stimulation49. In this study, the effect of red blood cells on the proliferation and 
survival of T cells was evaluated. Most literature in this area has been focused on T cells, 
although a handful of papers have also looked at B cells and dendritic cells. The experiments 
in this chapter were performed on a leukemic T cell line (Jurkat cells) and on a mixed cell 
population of freshly isolated PBMCs. Analysis of this complex cell population was done to 
more closely model what may be occurring in vivo. However, in such models, it is difficult to 
elucidate the role and effect of the different cell types engaged in crosstalk. As such, where 
cytokines are the primary analytes, there would be value in the analysis of isolated lymphocyte 
populations in contact with red blood cells. Transcriptomics would be an alternative method, 
which may prove useful in the analysis of mixed populations such as PBMCs after stimulation 
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with red blood cells. Prior to RNA extraction the mixed population could be rapidly and gently 
separated using magnetic-activated cell sorting, which is available from a number of suppliers. 
5.4.2.1 Jurkat cell proliferation: treatment with intact red blood cells 
Jurkat cells are a leukemic T cell line that are frequently used to model T cell activity. Increased 
proliferation of these cells is used as an indication of stimulation with an immunogenic agent. 
This study demonstrated that upRBCs stimulated the proliferation of Jurkat cells by 
approximately 2-fold (Figure 5.4). Of the few publications investigating the effect of healthy 
red blood cells on T cell proliferation, one looked at the effect on Jurkat cells9. This study 
observed an approximately 5-fold increase in the proliferation of Jurkat cells in the presence of 
naïve red blood cells. The differences between the two studies here may be an artefact of red 
blood cell storage prior to analysis. In the study described in this chapter, the red blood cells 
were stored at 37 °C for three days before analysis, whereas in the published study, the red 
blood cells were stored at 4 °C for a non-specified period of time. Long term storage at 4 °C 
has been demonstrated to affect the capacity of red blood cells to stimulate proliferation of T 
cells19,50, as such, short term storage at 4 °C or otherwise may have also had an effect on the 
level of T cell proliferation following treatment with those red blood cells.  
Jurkat cells treated with red blood cells primed with cancer cells (pRBC) proliferated 
significantly more than the upRBC group (Figure 5.4). A549 cells were incubated with two 
different concentrations of red blood cells (low and high) to produce two groups of primed 
cells (pRBC-L, or pRBC-H respectively). Both groups of primed cells stimulated increased 
proliferation of the Jurkat cells, however, this effect was most pronounced in the pRBC-L 
group. This group stimulated 8.3-fold more proliferation than the untreated controls, whilst the 
pRBC-H groups stimulated only 5.3-fold more proliferation than the untreated controls (Figure 
5.4). It is unclear as to why the pRBC-L group was more immunogenic than the pRBC-H group, 
but it may be a result of the concentration of available soluble factors secreted from the A549 
cells being diluted across more red blood cells or simply an artefact of the static culture 
conditions. Fonseca et al. demonstrated that the activity of red blood cells was reliant upon 
them being intact and in direct contact with the immune cells14. Whilst the red blood cells were 
being primed by the cancer cells, they were left to settle to the bottom of the flask, and thus 
were in constant contact with the A549 cells. In the pRBC-H group, the layer of red blood cells 
was much more substantial than in the pRBC-L group and so the amount of direct contact 
between the cells may be have reduced. In turn, this may have reduced the immunogenic 
potential of these red blood cells. Following these data, the pRBC-L group was chosen as the 
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optimal group for stimulating T cell proliferation through cancer cell priming. All of the 
following T cell experiments were performed on the pRBC-L primed group only. 
5.4.2.2 Jurkat cell proliferation: treatment with red blood cell lysate, cytosols, or 
membranes 
Jurkat cells treated with red blood cell components including lysates, cytosols, or membranes 
did stimulate increased proliferation (Figure 5.4), with no significant difference observed 
between the upRBC and pRBC groups for the lysate and cytosol samples. However, this was 
not the case for the red blood cell membranes. The membranes isolated from pRBCs stimulated 
the Jurkat cells to proliferate significantly more than the membranes of the upRBCs with a 
mean fold change of 1.9 and 1.4 respectively (Figure 5.4). These results demonstrate that 
priming red blood cells with cancer cells resulted in a modification of the red blood cell 
membrane that made the membranes more immunogenic. This result is not surprising, as some 
inflammatory cytokines are known to bind to specific receptors on the red blood cell 
membrane51,52 and upon lysis both sides of the membrane would be available for binding, 
which may have resulted in an increase in non-specific binding. 
5.4.2.3 Jurkat cell proliferation: treatment with red blood cell conditioned media 
The conditioned media from A549 cells alone stimulated the Jurkat cells to proliferate 
significantly more than the media blank control with a fold change of 3.5 compared to 1.2-fold 
for the media control (Figure 5.4). Of note, the conditioned media from the red blood cells and 
the A549 cells incubated together stimulated the Jurkat cells to proliferate significantly more 
(3.5-fold) than the conditioned media of either component alone (2.9-fold for A549 cells, 1.5-
fold for red blood cells) (Figure 5.4). It has been previously demonstrated that the immunogenic 
activity of naïve red blood cells was mediated by soluble protein factors and that these factors 
were present in the non-vesicle fraction of the red blood cell conditioned media9. The increase 
in proliferation observed with the conditioned media in this study was a result of a change in 
one or more soluble factors and this change was dependent upon the inclusion of red blood 
cells in the culture. Together, the results of these experiments support the observation that a 
soluble factor may be mediating the stimulatory activity of red blood cells.   
Antunes et al. reported that conditioned media from red blood cells alone stimulated the Jurkat 
cells to proliferate as much as the intact red blood cells9, however, this result was not replicated 
in the study outlined in this chapter. No significant difference was observed between treatment 
with red blood cell conditioned media and the media control (Figure 5.4). There are a few 
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differences between the studies that may explain why no further proliferation was observed. In 
the study outlined by Antunes et al., they used 6x more red blood cells to produce the 
conditioned media and the red blood cells were incubated in a serum-free media. In contrast, 
in this study the red blood cell conditioned media was produced in a culture media that 
contained 10 % FBS. This high level of FBS and the low level of red blood cells is likely that 
reason that no difference was observed between the red blood cell conditioned media and the 
corresponding media blank.  
5.4.2.4 Jurkat cell cytokine release: treatment with intact red blood cells 
The level of cytokines in Jurkat conditioned media was increased following treatment with 
pRBCs compared to upRBCs, with 14 cytokines present at significantly higher levels in the 
pRBC group (Section 5.3.3.2). Unstimulated Jurkat cells secrete minimal inflammatory 
cytokines (Figure 5.5). Treatment with red blood cells was sufficient to stimulate the cells to 
secrete a number of cytokines. As observed with Jurkat cell proliferation, treatment with 
pRBCs produced a different profile than upRBCs. This demonstrates that the red blood cells 
were functionally altered as a result of priming. Whilst the results of the Jurkat cells are 
interesting, they are limited in their ability to model normal immune activity. Inactivated, these 
cells typically do not secrete many cytokines, and when they are activated, the signalling 
pathways become dysregulated53. For this reason, more biologically relevant analyses were 
performed using fresh peripheral blood mononuclear cells. 
5.4.2.5 PBMC proliferation: treatment with intact red blood cells 
In a mixed cell model, proliferation of T cells (CD3+) and subsets of T cells (CD4+ and CD8+ 
cells) were evaluated using CFSE staining. A small number of papers have investigated the 
effect of red blood cell treatment on the proliferation of cells in a PBMC population. In these 
papers, a consistent increase in proliferation of PBMCs following treatment with naïve red 
blood cells has been reported9,10,12–15. However, as there are so few papers reporting the 
proliferation of fresh T cells treated with red blood cells, there is no uniform set of methods 
that are used. As such, comparison of results between the papers was challenging.  
In the study outlined in this chapter, cell proliferation was significantly increased with pRBC 
treatment for CD3+, CD4+, and CD8+ cells (Figure 5.8). Treatment with pRBCs was 
demonstrated to stimulate an increase in the proliferation of CD8+ cells but not CD4+ cells 
(Figure 5.8). In a CD3+ population, the number of CD4+ cells, unlike CD8+ cells, did not 
change with phytohemagglutinin (PHA-P) stimulation or with PHA-P stimulation and red 
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blood cell treatment (Figure 5.9). The number of CD8+ cells increased significantly with red 
blood cell treatment (Figure 5.9). This increase in the number of cytotoxic T cells (CD8+ cells) 
following red blood cell treatment has been reported previously in both PBMC cultures and 
purified CD3+ cultures11,12. It is not clear if the reason for this selective expansion of CD8+ 
cells in vitro is simply a result of a faster doubling time than CD4+ cells or if it was true 
preferential expansion. These results were obtained in an in vitro model, which comes with its 
own limitations. In this study, the proportion of red blood cells to lymphocytes was 1:10, which 
is well out of the range of the normal ratio (1:3000). However, this was not viable for an in 
vitro study. In addition, the experiments were performed over a restricted time frame (5 days), 
which may have limited the overall CD4+ cell proliferation. Patients receiving multiple red 
blood cell transfusions, a similar preferential expansion of CD8+ cells has been observed54,55. 
In one study, participants receiving multiple transfusions for sickle cell anaemia or haemophilia 
had significantly higher levels of CD8+ T cells than the non-transfused controls54. It has been 
suggested that this preferential CD8+ cell proliferation may be one of the reasons for the 
immunosuppression that is observed following red blood cell transfusions8, however more 
work is required to investigate this hypothesis. In addition, the cause and effect of the increased 
proliferation of the CD8+ cells with primed red blood cell treatment of PBMCs observed in 
this study warrants further investigation. 
5.4.2.6 PBMC survival and apoptosis: treatment with intact red blood cells 
PHA-P is a stimulant for PBMC proliferation, however treatment with PHA-P also stimulates 
apoptosis in those same cells. In this study, the number of apoptotic and live cells was 
determined by assessing Annexin V staining of T cell subsets. The percentage of live cells 
dropped significantly from a mean of 73 % or 81 % for CD4+ and CD8+ cells respectively in 
the untreated group, to 46 % in the PHA-P stimulated group for both CD4+ and CD8+ cells 
(Figure 5.10). Treatment with red blood cells (either upRBCs or pRBCs) protected the CD4+ 
and CD8+ cells from PHA-P induced apoptosis (Figure 5.10). This protective activity of red 
blood cells on PBMCs has been well documented in the literature9,12,15. It has been shown that 
this promotion of cell survival in response to red blood cells is reliant on direct cell to cell 
contact and is specific to T cells and is independent of monocyte activity14. 
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5.4.3   T cell activation 
In order to further elucidate if there was any shift towards either a TC1 (immuno-potentiating) 
or TC2 (immunosuppressive) profile following upRBC or pRBC treatment, the expression of 
two transcription factors and the cytokine secretion prolife of PBMCs was assessed. 
5.4.3.1 Expression of transcription factors 
The expression of the transcription factors GATA-3 and T-bet are typically analysed in 
conjunction with cytokine expression to determine the differentiation of CD8+ T cells into a 
TC1 or TC2 subtype. Upregulation of T-bet is indicative of a TC1 profile, and upregulation of 
GATA-3 is indicative of a TC2 profile. This is the first report on the expression of GATA-3 
and T-bet in a CD8+ T cell population following treatment with red blood cells. Contrary to 
expectation, these results did not illustrate differentiation of CD8+ cells into one subtype or 
another, but instead documented the overall activation of these cells. Stimulation with PHA-P 
alone promoted the expression of both GATA-3 and T-bet in CD8+ T cells in comparison to 
the unstimulated control (Figure 5.12). Treatment with upRBCs in conjunction with PHA-P 
supressed this expression of both transcription factors such that it resembled the expression of 
the unstimulated PBMCs. However, this suppression was not observed with pRBC treatment. 
These cells were not able to suppress this expression to the same extent as the upRBCs, and as 
such it resulted in a very similar profile to stimulation with PHA-P alone (Figure 5.12).  
Upregulation of GATA-3 expression in CD8+ cells has been put forward as a potential 
biomarker for immune dysfunction56,57. T-bet expression in CD8+ cells drives differentiation 
into effector cells58 and is associated with an immune response to viral infection59. The 
attenuation in the expression of these transcription factors following treatment with upRBCs 
suggests a role for red blood cells in regulating immune activation and differentiation. This 
role, however, was dysregulated following red blood cell priming with cancer cells. Buttari et 
al. demonstrated that red blood cells from carotid atherosclerosis patients were also 
dysregulated and were no longer able to promote maturation of dendritic cells16. The results of 
the study outlined in this chapter provide further evidence that that red blood cells can be 
functionally altered in their ability to interact with immune cells. 
5.4.3.2 Cytokine release 
Cytokine release from CD8+ T cells in combination with other markers can be indicative of a 
shift towards a specific differentiation subtype. Secretion of INF-γ or IL-12 is correlated to a 
TC1 subtype, and secretion of IL-4, IL-5, and/or IL-13 is correlated to a TC2 subtype of CD8+ 
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T cells. In this study, the secretion of TC1 cytokines was low and the levels did not change 
significantly between the upRBC and pRBC groups. TC2 cytokines on the other hand, did 
change with treatment (Figure 5.13). The level of IL-4, IL-5, and IL-13 was released at higher 
concentrations from the PBMCs treated with pRBCs, than those treated with upRBCs (Figure 
5.13). Of those three, only IL-5 was significantly different in the pRBC group compared to the 
upRBC group. However, there is a clear overall trend towards a TC2 cytokine profile. Of the 
publications reporting the effect of red blood cells on T cells, most did not investigate cytokine 
release, but one study that did, reported a significant increase in the concentration of IFN-γ 
released from freshly isolated lymphocytes treated with red blood cells when compared to the 
PHA activated lymphocytes15. This result was replicated in this current study with an increase 
of IFN-γ following red blood cell treatment and was observed with both upRBC and pRBC 
with a mean fold change of approximately 4-fold (Figure 5.13). 
The concentration of haemoglobin in the PBMC conditioned media from the pRBC treated 
group was significantly lower than the upRBC group (Figure 5.14). This indicates that by 
priming the red blood cells, they were more resistant to haemolysis. The Gardos channel on 
red blood cells is responsible for maintaining cell volume and is regulated by cytokine binding 
to the Duffy antigen receptor for chemokines (DARC)60. A number of the cytokines that bound 
in high concentrations to the red blood cells after priming are also responsible for regulating 
this channel (including IL-8, RANTES)60. High levels of these cytokines or high expression of 
DARC is correlated with increased dehydration in red blood cells61. This may be the 
mechanism behind the lower level of haemolysis observed in the primed red blood cell group. 
By binding high levels of the relevant cytokines, the Gardos channel would have been activated 
and the cells would have been dehydrated. Gardos channel activation in red blood cells has 
been shown to be protective against haemolysis62. In saying that, the focus of this study was 
on the relationship between cytokines and red blood cells, as such, only the 48 cytokines on 
the multi-plex panel was analysed. The cytokines on these kits are unlikely to cover all of the 
changes that may have occurred to the red blood cells as a result of priming. Although this 
hypothesis fits the observed results, it does not rule out interactions with other molecules or 
factors that were not investigated. In this study, the secretion profile from a mixed cell 
population (PBMCs) was evaluated. As such, the exact cellular source of these cytokines could 
not be determined. Future experiments are required to determine the source of the cytokines 
and thus the differentiation status of the relevant cells. This can be accomplished by more 
comprehensive flow cytometry analysis or analysis of gene expression.   
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5.4.4    Biological significance and therapeutic potential 
The results of this chapter demonstrate that red blood cells can be manipulated to alter their 
cytokine profile and their influence on T cells. Similar dysregulation of red blood cell activity 
has been demonstrated in disease (carotid atherosclerosis)15, following surgery18, or following 
haemodialysis63. Further investigation around what causes this dysregulation in vivo and what 
role it may play in disease may be valuable in disease research. The experiments in this chapter 
were not designed to perfectly model the role of red blood cells in NCSLC. However, the results 
of these experiments do suggest that if there is interaction between the red blood cells and the 
cancer cells there may be some downstream immunological effects in vivo. In order to validate 
this, red blood cells isolated from NSCLC clinical samples will need to be collected and 
analysed to elucidate if their interaction with immune cells are altered in comparison to healthy 
controls. NSCLC currently has a poor prognosis and a low median survival time64. Thus, 
further understanding about the biology of the condition may be valuable in identifying 
therapeutic targets or developing earlier diagnostics. This study also identified that the cytokine 
profile of red blood cells changed significantly with exposure to NSCLC cells. Analysis of the 
cytokine profile of red blood cells isolated from patients may by useful for the identification of 
disease specific biomarkers. 
Since red blood cells are considered to be inert, they have been advocated as optimal biological 
carriers of antigens or drugs for cancer immunotherapy65,66. Loading red blood cells with 
tumour specific antigens has been demonstrated to stimulate an extended T cell response in 
mice65. The results of this chapter demonstrated that, without the addition of antigens or drugs, 
red blood cells can be modified to become more immunogenic or to selectively activate 
populations of immune cells. These results were achieved by priming red blood cells with a 
cancer cell line, however priming red blood cells with other cell types such as mesenchymal 
stem cells may create different immunogenic profiles. As such, primed red blood cells could 
be valuable in the future as for personalised immunotherapies.   
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5.5   CONCLUSION 
 
The results of this chapter can be summarised as follows: 
 Red blood cells were ‘primed’ following co-incubation with a NSCLC cell line, which 
was illustrated by a change in the red blood cell cytokine profile. 
 ‘Unprimed’ red blood cells played a role in stimulating the proliferation of leukemic 
and freshly isolated T cells. 
 Red blood cells primed with a NSCLC cell line resulted in enhanced proliferation of 
leukemic T cells and fresh CD8+ T cells, decreased protection against PHA driven 
activation of T cells, and altered the secretion profile of peripheral blood mononuclear 
cells. 
Red blood cells isolated from healthy individuals are able to modulate immune cells by 
promoting T cell proliferation, protecting these same cells from apoptosis, and suppressing 
stimulant-driven activation of CD8+ T cells. These results support the hypothesis that red blood 
cells play a key role in modulating the immune system in vivo. In addition to that, this study 
highlights that red blood cells and their interactions with the immune system are malleable. A 
dysregulation in red blood cell activity has been suggested in disease, and has now been 
observed through intentional alteration of the cells and their cytokine profile by exposing them 
to a NSCLC cell line. In the presence of these altered red blood cells, T cells were stimulated 
to proliferate to a greater degree, were no longer protected from stimulant-driven activation, 
and were driven to release a variety of cancer-related cytokines. This study identifies the 
potential for red blood cell involvement in disease or in their use as disease biomarkers. A 
further step would be the investigation of primed red blood cells as potential vehicles for 
immunotherapies. 
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DISCUSSION AND CONCLUSIONS 
 
 
 
This chapter discusses the results of this thesis in the wider context of red blood cell biology, 
diagnostics, and the potential for cytokine priming to enable new red blood cell based 
therapeutics. This chapter also outlines the conclusions and future work required to further 
explore these areas. 
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6.1   DISCUSSION 
 
The overall hypothesis of this thesis was that through interaction with cytokines, red blood 
cells play a role in inflammation and act as a buffer for inflammatory mediators. In support of 
this hypothesis, the results of this thesis demonstrated that red blood cells are a major reservoir 
in whole blood for at least 31 cytokines, chemokines, and growth factors (Figure 6.1). This 
included the identification of enzymatically active macrophage migration inhibitory factor 
(MIF) in red blood cell lysates at concentrations 1000-fold higher than the typical plasma level. 
In addition, red blood cells were found to bind both recombinant cytokines and cytokines 
released from cancer cells, and the resulting primed red blood cells were able to modulate the 
activity of T cells (Figure 6.1). These results support the primary hypothesis and demonstrate 
a need for further investigation into this activity. At this point in 2016, literature in this field of 
research is starkly lacking, but the implications are likely to be crucial in understanding disease 
processes such as the occurrence and progression of anaemia, or in optimising red blood cell 
therapeutics such as red blood cell storage and transfusion. Without further, more in depth 
research, it is difficult to make any definitive conclusions about what these results will mean 
in disease. But, in light of this thesis, what is clear is that the discussion around red blood cells 
is in dire need of change. The therapeutic use of blood transfusion has been routine for one 
hundred years and the literature is replete with examples of adverse events, inflammatory 
responses, and elevated plasma cytokines. Despite the wealth of literature documenting altered 
plasma cytokine levels after transfusion, this thesis appears to be the first study to report the 
quantification of cytokines in red blood cells. 
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Figure 6.1. Schematic of the interaction between cytokines and red blood cells as identified 
in this thesis. 
 
 
6.1.1   Red blood cell processing 
There is substantial variation in the methods used to isolate and process red blood cells. The 
majority of reports isolate these cells by centrifugation and removal of the plasma and the buffy 
coat1,2, or by centrifugation of whole blood over a density gradient such as Ficoll-Paque or 
Lymphoprep3,4. Although these methods are rapid and straightforward, they do not remove 
granulocytes which make up approximately 50 % of the total white blood cells in blood nor are 
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platelets completely removed from these cell pellets5,6. Contamination of red blood cell 
populations with white blood cells and platelets however, is rarely discussed as a limitation in 
red blood cell research as depletion of these populations is infrequently quantified and reported, 
if at all. In addition to this, there is considerable variability in the reported length of time 
between blood collection and sample processing. As an example, red blood cells can be 
classified as ‘fresh’ even up to 14 days of storage7, whilst other studies classify ‘fresh’ as cells 
processed immediately following collection8. These variations in processing times can have 
significant effects on the integrity of the sample9. The chosen method in this study, dextran 
sedimentation, is primarily used in the literature to isolate neutrophils from red blood cells as 
most other isolation methods do not sufficiently separate these two cellular components5. This 
method was initially chosen as it depletes most white blood cells (with greater than 80 % 
depletion) and most platelets (with greater than 95 % depletion) from the red blood cell pellet, 
and that it is also a very simple method that can be used to isolate cells from large volumes of 
blood with minimal manipulation10–12. It now appears that this method may have been more 
beneficial than initially recognised. Conventional red blood cell isolation methods such as 
centrifugation typically include extensive washing of the cells in an isotonic buffer13,14 and the 
justification for this is to ensure the removal of plasma proteins and to improve the purity of 
the red blood cells15. In proteomic analyses of red blood cells, this processing can be 
particularly rigorous. For example, in a report on the analysis of the proteome of red blood cell 
membranes, the isolated cells were centrifuged, filtered, washed four times in an isotonic 
buffer, and finally the cells were lysed and the resulting membranes were washed another four 
or five times14. This processing method may be optimal for the identification of transmembrane 
or structural proteins, but in the identification of proteins bound to the surface of the cell 
membrane this is unlikely to be effective.  
Amongst all of the proteomic analyses of red blood cells, no studies have yet been able to 
identify the presence of cytokines as reported in this thesis. There are likely to be a number of 
reasons for this such as issues with the dynamic range of the proteins; the abundance of these 
cytokines is approximately 100 million-fold lower than the abundance of haemoglobin in red 
blood cells. However, this issue is not likely helped by the vigorous washing procedures 
typically done during sample preparation. As identified in the literature, at least some of the 
cytokines associated with red blood cells are bound to receptors on the surface of the cells16,17. 
It is likely that excessive processing of the cells would result in the removal of some, if not all, 
of the bound cytokines, consequently further reducing their relative abundance. This is 
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observed in platelets, wherein excessive washing or vigorous processing techniques have been 
shown to promote their degranulation and subsequently an increase in the secreted detectable 
cytokine levels18. Although the platelet literature is clear on the effects of processing, the only 
other enucleate cells in humans, red blood cells, are not described as signalling cells and are 
regarded as transcriptionally and translationally inert and incapable of secretory activity. In the 
proteomics literature on red blood cells, they are treated as bags of protein that can be washed 
and purified without altering the proteome. The focus of red blood cell proteomics studies 
appears to have been on the technical challenge of identifying proteins against the 
overwhelming background of haemoglobin rather than elucidating a biological role of red 
blood cells beyond gas exchange. In contrast to the typical proteomic methods, dextran 
sedimentation is a very gentle process and does not require extensive washing. In this 
procedure, the red blood cells were left to slowly sediment over 30 minutes to 1 hour in the 
presence of high molecular weight dextran after which the purified red blood cells were 
collected and were washed once in phosphate buffered saline. Thus, the integrity of the binding 
partners on the surface of the red blood cells (such as cytokines) are likely to be protected more 
than other techniques would enable. In future studies, optimised blood fractionation methods, 
such as dextran sedimentation, will be crucial to achieve consistent and reliable analysis of 
cytokines in red blood cells. 
 
6.1.2   Transfusion of red blood cells 
Washing red blood cells appears to have some therapeutic benefit in transfusion medicine. The 
Australian Red Cross Service offers washed red blood cells for specific indications including 
patients with allergic reactions or in response to severe reactions with unwashed red blood cell 
packs. In fact, washing red blood cells following storage appears to be correlated with reduced 
incidence of adverse events and in some cases, improved outcomes such as in mice with 
haemorrhagic shock19. One of the benefits of this procedure is the depletion of inflammatory 
proteins from the blood pack19. This depletion is achieved by both removal of the storage media 
which contains inflammatory proteins19, and also likely by the removal of loosely bound 
cytokines from the surface of red blood cells. Cholette et al. reported that children undergoing 
cardiac surgery had reduced post-operative inflammation with transfusion of washed red blood 
cells compared to transfusion of unwashed cells20. This effect was represented by resulting 
lower serum levels of inflammatory cytokines and a change in trend towards reduced 
mortality20. However, there appears to be a delicate balance required in the amount of washing 
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needed to achieve this therapeutic benefit. Excessive washing increases red blood cell osmotic 
fragility and can lead to increased haemolysis following transfusion which can cause 
downstream adverse effects21–23. What is not well understood, in light of this thesis, is the 
mechanism behind these results. The reduction in resulting serum levels of inflammatory 
cytokines observed with washed red blood cell transfusion may be a result of depleting the 
blood pack of these same cytokines and so attenuating any inflammatory response to the 
transfusion. But it may also be that the process of washing the red blood cells actually deplete 
the cells of cytokines. This may then enable them to bind more cytokines upon transfusion, 
thus resulting in an overall reduction in the levels of circulating inflammatory molecules. 
Analysis of the cytokine profile and the activity of red blood cells is required to determine the 
mechanisms behind the effect of storing, washing, and transfusing red blood cells. 
Overall, the literature on red blood cell transfusions, the storage lesion, and optimising storage 
parameters has very little agreement24. One reason for this may be that the entire area of red 
blood cell interactions with cytokines has been underappreciated until this point, particularly 
in the field of transfusion medicine. Whilst there is some literature that has evaluated the 
cytokine load of the red blood cell storage medium over time25–27, there is no literature that 
thoroughly investigates the cytokine load of red blood cells in these conditions. The results of 
this study demonstrate that red blood cells are capable of both binding and releasing at least 31 
different cytokines, chemokines, and growth factors in high concentrations (Chapter 4). Thus, 
even if no significant increase in cytokine concentration in the storage media is observed, the 
red blood cells may still be involved in a continual process of binding and releasing cytokines 
to maintain a particular extracellular cytokine load, the process of which may result in 
potentially detrimental cellular alterations. This activity was observed during the priming of 
red blood cells with the lung cancer cell line in Chapter 5 of this thesis. Although there were 
no significant differences in the concentration of cytokines in the conditioned media from the 
lung cancer cells with or without red blood cells, the red blood cells themselves bound high 
quantities of bFGF, IL-8, and VEGF amongst others (Figure 5.2). Thus, if the cytokine analysis 
was isolated to the conditioned media alone, the conclusions would indicate that there was no 
significant effect of red blood cells. When in fact, the cytokine profile of these cells was 
significantly altered and their effect on T cell activity was also significantly modulated. Any 
cytokine changes that are likely occurring in the red blood cells during storage may be 
responsible, at least in part, for the progression of this ‘storage lesion’. By ignoring the red 
blood cells in the analysis of cytokines in the storage lesion, the issues presented by stored red 
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blood cells may never be totally resolved. The study in this thesis revealed significant changes 
in the red blood cell cytokine profile within 72 hours, but red blood cells are currently being 
stored for weeks before transfusion. An ideal study of stored red blood cells would, at the very 
least, quantify cytokines in red blood cells over a time course to establish whether significant 
changes occur and when. 
 
6.1.3   Red blood cells in disease 
The results of this thesis have significant implications in the field of diagnostics. This study 
identified that red blood cells are a major reservoir of a range of cytokines, chemokines, and 
growth factors. For the 31 cytokines with a higher red blood cell concentration than plasma, 
the range was 3.6 to 3970-fold higher in red blood cells than plasma with a median fold increase 
of 11.3 (Table 4.3). With the quantification of these inflammatory molecules in serum or 
plasma becoming progressively more common in clinical research28–30, the implications of their 
identification in red blood cells is two-fold. The first is that accurate and reproducible 
quantification of these cytokines can be complicated by red blood cells during processing. As 
indicated in Chapter 4, even undetectable levels of haemolysis (0.125 %) can be sufficient to 
release interfering concentrations of analytes such as IL-16 into the plasma or serum. In 
addition, Schnabel et al. reported that the coagulation that occurs in the production of serum 
can stimulate the release of the chemokine MCP-1 from red blood cells31. Thus, the presence 
of these cytokines needs to be considered when developing optimised methods for the isolation 
of plasma and serum. The second implication of this discovery is in the field of biomarker 
identification. As demonstrated in this thesis, the cytokine profile of red blood cells can change 
in response to their environment through binding and releasing of these molecules. As such, 
red blood cells have been described as a buffer for inflammatory molecules in blood. If this is 
true in vivo, then these cells are likely to have a different cytokine profile in patients with 
chronic inflammatory conditions. As identified by Profumo et al. and Yu et al., the red blood 
cells isolated from patients with atherosclerosis32 or following hip arthroplasty33 were 
dysfunctional in how they modulated T cell activity. Similar dysfunction was observed in the 
study outlined in Chapter 5, where the dysfunction was also coupled with a significantly altered 
red blood cell cytokine profile. The hypothesis is that these two factors are linked, and that 
altered cytokine profiles would also be observed in patients who have chronic inflammatory 
conditions. If this hypothesis is correct, then the analysis of red blood cells may be useful in 
diagnostics and in monitoring these conditions.  
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Anaemia of chronic inflammation is a well-known condition that occurs as a complication in 
many chronic inflammatory diseases including auto-immune diseases and infection34,35. The 
pathogenesis of this condition is poorly understood, and thus far there are no adequate 
treatments for it36. At this point, the recommended therapy is the management of the underlying 
inflammatory condition36. The reduced number of red blood cells observed in this anaemic 
condition may well contribute to a dysregulated red blood cell buffering system, and as such, 
the chronic inflammation may be closely related to the eventuation or progression of the 
anaemia. Chronic inflammation can be damaging to the normal function of cells. A recent study 
identified that chronic exposure of the pro-inflammatory cytokine, IL-1, on haematopoietic 
stem cells severely restricted the cellular capacity to self-renew, but the self-renewal was 
restored upon cessation of IL-1 exposure37. In Chapter 4 of this thesis, IL-1α and IL-1β were 
both demonstrated to be bound by red blood cells. Thus, red blood cells may be a mechanism 
for managing this over-exposure of IL-1 molecules in vivo, and the dysregulation of which 
could have detrimental down-stream effects. 
An example of attenuation of this cytokine binding has been observed with the knockout of 
one specific receptor on red blood cells, the Duffy antigen receptor for chemokines (DARC). 
Interference with this chemokine sink system has been shown to be involved in the 
pathogenesis of some inflammatory conditions including prostate cancer38 and graft rejection39. 
Shen et al. demonstrated that mice lacking DARC had increased prostate cancer tumour growth 
and tumour vessel density when compared to DARC positive mice38. Notably the concentration 
of pro-angiogenic chemokines - that are known ligands for DARC - were significantly higher 
in the tumour of DARC negative mice38. With these results, the authors concluded that the 
chemokine binding activity of red blood cells was directly related to tumour management by 
clearing the tumour of pro-angiogenic chemokines and thus restricting angiogenesis. The 
binding and release of a much wider population of cytokines, chemokines, and growth factors 
were identified as part of this thesis, as such, interference with the red blood cell binding 
activity is likely to have even more widespread effects. 
 
6.1.4   Red blood cells: the new immunotherapy? 
Immunotherapies are designed to stimulate the host immune system to attack a tumour or 
disease. The use of these therapies in cancer treatment have been under investigation for many 
years, and more recently, red blood cells have been advocated as an optimal vehicle for the 
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delivery of these drugs or antigens40,41. These cells have been proposed due to the relatively 
extensive understanding about their biocompatibility, the mechanisms of cell clearance 
following transfusion, and the observed extended therapeutic effects40. Banz et al. reported that 
red blood cell ghosts, loaded with a T-cell specific antigen, substantially prevented tumour 
growth and they demonstrated that the engulfment of antigens in red blood cells promoted an 
extended and more efficacious response than treatment with the free antigen40.  
In the investigation into priming red blood cells with a lung cancer cell line in Chapter 5, it was 
demonstrated that these primed red blood cells were altered in such a way that they stimulated 
increased T cell proliferation compared to naïve red blood cells. Whilst the results of this thesis 
established that the red blood cells primed with a lung cancer cell line (A549 cells) may be 
more immunosuppressive than immunogenic, the potential for using this priming platform in 
immunotherapy development is still valid. If these red blood cells can be induced to promote 
an immunosuppressive T cell response, then reason would suggest that, with appropriate 
priming, the opposite would also be possible wherein an immunogenic T cell response is 
promoted. In order to determine the benefits or limitations of using primed red blood cells as a 
therapeutic, substantial further research is still required. In support of this continued 
investigation, these primed red blood cells likely retain the same beneficial features of red 
blood cells ghosts loaded with antigens. For example, like ghosts, these cells are likely to be 
biocompatible, will be cleared regularly from the system, and are capable of binding and 
releasing the relevant proteins. The difference, however, lies in that these red blood cells are 
still biologically functional, wherein the intact primed red blood cells stimulated a stronger 
response in the T cells than the membranes alone (Figure 5.4) and have undergone less 
manipulation during sample processing. The cancer cells used in the priming experiments in 
Chapter 5 were grown in serum containing media. Further studies on red blood cell priming 
with cancer cells grown under altered conditions would be beneficial to determine whether 
conditions such as serum starvation, hypoxia, hyperoxia, or pressure produce immunogenic red 
blood cells. 
There are numerous reports on the use of cytokines as antigens in immunotherapies for cancer. 
These studies have highlighted the use of cytokines such as IL-2, IL-15, and IL-21 in 
stimulating T cell responses with promising results in cancer models and in clinical trials42,43. 
The focus of the research in this thesis was on primarily on the relationship between red blood 
cells and a group of 48 commonly studied cytokines, including key players in inflammation, 
immune cell recruitment, and regeneration. As such, the cytokine profile of these primed red 
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blood cells was deduced and conclusions regarding T cell activity was drawn solely on the 
analysis of these cytokines. However, the results of the interaction between red blood cells and 
the cancer cell line was likely more complex than an exchange of cytokines. The level of 
oxidative stress in the red blood cells may have changed and the transfer of cancer specific 
antigens to the red blood cells may have also occurred. Thus, it is reasonable to hypothesise 
that additional factors could have been partly responsible for the observed changes in T cell 
proliferation and activation. This transfer of immunogenic material, whether they be cytokines 
or antigens, is key to the development of an immunotherapy. Priming red blood cells with other 
cell types may produce a different cytokine profile and immunogenic response to what was 
observed in this study which may be prove to be more or less beneficial as a therapeutic. 
The therapeutic benefit of primed red blood cells is unlikely to be isolated to stimulating the 
immune response in cancer. These cells may also be beneficial in extending the therapeutic 
benefit of anti-inflammatory cells such as mesenchymal stem cells (MSCs). In recent years, 
much of the therapeutic benefit of MSCs has been attributed to their secretome44,45. These cells 
have been shown to secrete an array of anti-inflammatory molecules46,47 and have been 
demonstrated to be efficacious a range of conditions44,45,48. However, the issue with treating an 
inflammatory condition with a proteinaceous solution such as conditioned media is the 
potentially low half-life upon treatment40,45. Priming red blood cells with mesenchymal stem 
cells or with their conditioned media, may produce a similar, but slow-release, therapeutic 
benefit compared to treating with the conditioned media alone. Investigation into what changes, 
if any, are observed in red blood cells primed with other cell types or with cell-free solutions 
(such as conditioned media) is likely to provide some insight into the use of these cells as 
therapies designed to modulate the immune response. 
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6.2   CONCLUSIONS AND FUTURE DIRECTIONS 
 
The results and investigations outlined in this thesis are novel and highlight a burgeoning area 
of interest. The quantification of 48 cytokines, chemokines, and growth factors in red blood 
cells using multi-plex cytokine technology has never before been reported. These results 
illustrate that red blood cells are more complex than generally accepted, and that there is value 
from a research and clinical perspective in their analysis. It also demonstrated that they are an 
important, signalling component of whole blood and are involved in the function of the immune 
system as summarised in Figure 6.1.  
The investigation into the interactions between red blood cells and cytokines is very much in 
its infancy, and as a result, there are many pathways that future investigations could take. The 
majority of these investigations could be categorised under three primary topics. 
1. Improved understanding of the molecular interactions between red blood cells and 
cytokines 
2. Investigation into the profile and function of these cells in disease cohorts for use in 
diagnostics 
3. Development and optimisation of red blood cell based therapeutics  
The results of this thesis have outlined the starting ground for investigation into these areas of 
red blood cell research and as such have led to more questions than originally anticipated. The 
aim of the study was to investigate and quantify the concentration of a large group of cytokines 
with a focus on the modulation of these proteins and the implications of this modulation on 
immune cells. With this focus, elucidating the molecular processes behind the binding and 
release of these cytokines from red blood cells was not within the scope of this study. Thus, it 
would be of interest in future studies to more closely assess these molecular interactions. This 
could include the identification of where these cytokines localise after binding (intracellularly 
or on the cell membrane), and, if they bind to the cell membrane, then investigation into 
whether this involves binding to a specific receptor or if it is non-specific binding to membrane 
components. DARC is known to function as a promiscuous receptor for multiple chemokines 
such as IL-8 and RANTES. These chemokines have different specific receptors on other cell 
types, which lend weight to the hypothesis that red blood cells function as an independent sink 
for cytokines. Based on this hypothesis, the other cytokines identified in red blood cells in this 
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thesis probably bind via different receptors to those on non-red blood cells. As identified in 
this study, preliminary investigations demonstrated a role of proteases in the binding and 
release of these cytokines from red blood cells by using a cocktail of protease inhibitors to 
modulate this activity. Investigation into the activity of individual enzyme inhibitors could be 
useful in delineating which enzymes play a part in cytokine binding and release and may 
provide further understanding to this process. This thesis covered the analysis of 48 cytokines, 
chemokines, and growth factors, which are the most commonly analysed inflammatory proteins 
in blood. However, outside of these groups there are many more cytokines that may also be 
associated with red blood cells. In addition, the process of binding and release of cytokines 
from red blood cells is likely to involve other known proteins acting in newly described roles 
as chaperones. Future research into red blood cell signalling will benefit from investigation 
into which other proteins are present and may play a role in the inflammatory process. To 
achieve this, non-specific proteomics methods such as mass spectrometry will be required. This 
approach will need to be coupled with gentle red blood cell isolation methods to avoid washing 
away the target molecules. Collection of blood from a much larger cohort of healthy individuals 
would enable the investigation into whether there are normal ranges for these cytokines in red 
blood cells and to determine any trends correlated with specific demographics such as age, 
gender, race, or blood type. In addition to this, expanding the analysis of blood in disease 
groups from plasma or serum to the inclusion of red blood cells, may provide further 
understanding to the disease processes and inflammatory state of the patient. Value in this 
analysis is likely to come from time course sampling with quantification of red blood cell 
cytokine levels and also from investigation into the interactions between these cells and other 
cells types such as T cells or dendritic cells as has already been demonstrated in 
atherosclerosis32. This investigation into red blood cells in disease cohorts may also be valuable 
in the area of biomarker discovery. In order to further understand the effect and impact of the 
storage lesion of stored red blood cells, investigation into the cytokine profile of these cells at 
different times during storage may prove to be important. Finally, the investigations of this 
thesis identified that red blood cells could be primed with a cell line to alter its cytokine profile 
and its interaction with CD8+ T cells. These results could lead to the development of red blood 
cell-based therapeutics, however substantial research in this area is still required. This could 
include evaluating the effect of priming red blood cells with other cell types to see if a different 
T cell, or other immune cell response could be promoted. Identification of promising in vitro 
results would also need to be supported by investigation into the safety and efficacy of these 
primed cells in animal models of inflammation.   
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A  
--------------------------------------------------------------------------- 
 
A.1   ETHICS APPROVAL 
A.1.1   Macquarie University 
Ethics committee: Macquarie University Human Ethics Review Committee (Human 
Research) 
 
Ethics approval number: 5201100827 
 
Date of ethics approval: 01 May 2014 - 30 May 2016 
 
 
 
A.1.2   Northern Sydney Local Health District  
Ethics committee: Northern Sydney Coast Human Research Ethics Committee of Northern 
Sydney Local Health District and Central Coast Local Health District  
 
Ethics approval number: 1201-046M 
 
Date of ethics approval: 02 December 2016 - present 
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APPENDIX 
B  
--------------------------------------------------------------------------- 
 
B.1   METHODS 
B.1.1   Blood collection 
This study was approved by the Macquarie University Human Research Ethics Committee 
(5201100827) and by the Northern Sydney Coast Human Research Ethics Committee of 
NSLHD and CCLHD (1201-046M). Written informed consent was obtained from all 
participants before enrolment.  
Whole blood was collected from healthy volunteers by venepuncture (n ≥ 4). Blood was 
combined with EDTA (ethylenediaminetetraacetic acid) for anticoagulation (K2EDTA 
vacutainers, Becton Dickinson). Blood and blood components were isolated and aliquoted at 
room temperature within four hours of collection. All samples were subjected to three freeze-
thaw cycles at -80 °C to ensure complete cellular lysis before protein analysis. Samples were 
stored at -80 °C until analysis. 
 
B.1.2   Red blood cell isolation 
Red blood cells were isolated and frozen immediately for analysis. Concentration and purity of 
red blood cells were determined using a haematology analyser (Coulter AcT Diff, Beckman 
Coulter) or by flow cytometry (FACSAria III, Becton Dickinson).  
B.1.2.1 Dextran sedimentation 
Whole blood was added to dextran solution (6 % w/v dextran in 0.15 M sodium chloride) at a 
2:1 ratio (blood:dextran). This solution was gently mixed and left upright for 60 minutes at 
23 °C for red blood cell sedimentation. After sedimentation, two layers formed and were 
isolated and transferred to individual tubes. The lower, red blood cell dense layer, was washed 
twice in phosphate buffered saline (PBS, 500 g, 5 minutes) and the remaining red blood cell 
pellet was isolated. Relative purity of cells was determined using a haematology analyser 
(Coulter AcT Diff, Beckman Coulter) and the cells were then frozen at -80 °C. 
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B.1.2.2  Fluorescence activated cell sorting (FACS) 
Whole blood was diluted ten times in a wash buffer (PBS + 2 % FBS (fetal bovine serum)). A 
50 µL aliquot of the cell suspension was then washed twice in FACS wash buffer by 
centrifugation (1000 g, 5 minutes). The resulting cell pellet was resuspended in 50 µL FACS 
wash buffer with 5 µL of CD45-FITC (Table B.1). This solution was incubated in the dark at 
room temperature for 15 minutes. After incubation, the cells were washed twice in the wash 
buffer (1000 g, 5 minutes). Cells were resuspended up to 500 µL the wash buffer for sorting. 
Red blood cells were sorted using a FACSAria III flow cytometer with four lasers and cell 
separation by negative staining. Red blood cells and white blood cells were gated from platelets 
according to size using forward scatter and side scatter. Red blood cells were then gated from 
white blood cells according to lack of CD45 fluorescence. This final gated population (red 
blood cells) was then sorted into an individual collection tube. Purity of the population was 
determined by analysing the collected population for CD45 fluorescence on the flow cytometer. 
Cells were then pelleted and frozen at -80 °C. 
 
Table B.1. Monoclonal antibody used for FACS sorting of red blood cells. 
Antibody Fluorochrome Clone 
Mouse anti-human CD45 FITC HI30 
 
 
B.1.3   Enzyme-linked Immunosorbent Assay (ELISA) 
Concentrations of MIF were measured using a MIF ELISA (R&D Systems, USA), which was 
run according to manufacturer’s instructions. The absorbance data for the MIF ELISA were 
collected with a Synergy 2 plate reader (BioTek) at 450 nm with absorbance correction at 
570 nm. The calibration curve was analysed using a log/log curve fit using GraphPad Prism 
software (ver. 6, USA). 
 
B.1.4   Statistical analysis 
Data were evaluated using two-tailed, paired t-tests to assess statistical significance between 
groups with significance levels of p < 0.05. Statistical analysis and graphing of results was 
performed using GraphPad Prism software (ver. 6, USA). Concentration values are presented 
as mean ± standard deviation (SD).  
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B.2   RESULTS 
B.2.1    Red blood cell purity 
Purity of the red blood cell populations was determined by counting the levels of remaining 
white blood cells using a haematology analyser for dextran sorted cells or using flow cytometry 
for the FACS sorted cells. The purity of the red blood cell populations was slightly higher in 
the red blood cells sorted with FACS (Table B.2). 
 
Table B.2.  Purity of red blood cell populations according to isolation technique. 
Isolation technique RBC purity (%)* WBC depletion (%)* 
Dextran 99.97 ± 0.01 79.0 ± 5.1 
FACS ≥ 99.99 ≥ 90 
*Data are presented as mean ± standard deviation (n ≥ 4) 
 
 
B.2.2    MIF concentration according to isolation technique 
The average concentration of MIF in red blood cells was significantly lower in the cells that 
were sorted by FACS (Figure B.1) compared to when the cells were separated by dextran 
sedimentation. Dextran sedimentation yielded a total concentration that was approximately 5 
times higher than that observed in FACS sorted cells. Although there is a substantial 
discrepancy in concentrations, that appears to be dependent on the isolation method, these 
levels are still much higher than what is seen in other blood components including plasma, 
white blood cells, and platelets (Chapter 3, Table 3.3).  
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Figure B.1.  Concentration of MIF in red blood cells purified using dextran sedimentation 
and fluorescence activated cell sorting (FACS). Concentration is normalised to their relative 
contribution to one millilitre of whole blood. Data are presented as mean ± SD, n ≥ 4, 
statistically significant (*) if p < 0.05. 
 
 
B.3   DISCUSSION 
These results demonstrate that the amount of MIF that is measured in red blood cell populations 
is dependent on the method of cell recovery. Although each method tested here resulted in 
similar purities (Table B.2), the MIF levels differed extensively (Figure B.1). Differences in 
white blood cell contamination of the fractions would account for less than 1 % of the observed 
concentration (Chapter 3, Table 3.3), indicating that the impurities were not the contributing 
factor. Likewise, the time from collection to sample storage was less than 3 hours for both 
methods which would enable the same duration of time for cell-to-cell interactions to occur, 
indicating that this is also not a factor. Prior experimentation (data not shown here) 
demonstrated that the presence of dextran does not alter to the level of MIF measured. 
The chief difference between the two populations is how extensively they were processed. The 
dextran sedimentation method is relatively gentle and involves minimal washing steps. With 
the FACS method, the cells undergo a number of washing steps and are sent at high speed 
through the flow cytometer for cell sorting. It is the hypothesis that this extensive washing and 
manipulation of the red blood cells in the FACS method depleted the cells of MIF.  
Cell activation is a common complication in blood processing, and care needs to be taken to 
avoid activation of white blood cells and platelets1. The results of this study suggest that this 
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may also be the case for red blood cells. For the purposes of continued red blood cell analysis 
in this thesis, dextran sedimentation was chosen as the preferred cell isolation method. This is 
because the method was reproducible, large volumes of blood could be processed at once, and 
it was relatively gentle on the cells.  
Aside from highlighting the complications in isolating and analysing pure red blood cell 
populations, the results of this study may be used to further understand the mechanics of red 
blood cells. As outlined in Chapter 3, red blood cells may be able to bind extracellular MIF 
(Figure 3.4). If the cells were depleted of MIF (for example by FACS or extensive washing) 
their secretion and binding activities may be altered. If the cells that were collected from 
healthy individuals were in fact already saturated with MIF, it follows that MIF depletion from 
red blood cells may enable the cells to bind more of this protein. If this is the case, then red 
blood cells could be used as a therapeutic to remove excess circulating levels of MIF in diseases 
that are associated with high levels of the protein such as sepsis2.  
 
  
B.4   REFERENCES 
1. Zimmermann, R. et al. Sample preparation technique and white cell content influence 
the detectable levels of growth factors in platelet concentrates. Vox Sang 85, 283–289 
(2003). 
2. Al-Abed, Y. et al. ISO-1 binding to the tautomerase active site of MIF inhibits its pro-
inflammatory activity and increases survival in severe sepsis. J Biol Chem 280, 36541–
36544 (2005). 
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APPENDIX 
C  
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Figure C.1.  Summary of pro-inflammatory cytokines released from red blood cells into 
PBS over 24 hours and in the corresponding red blood cell lysate at 37 °C with or without 
protease inhibitors (PI) as measured by Bio-Plex and reported as fluorescence (100 million 
cells in 1 mL PBS). Data are presented as mean fold change after addition of PI ± 95% CI, 
where  represents fold change in conditioned media of PI treatment compared to the no PI 
control, and  represents fold change in fluorescence in lysate of red blood cells treated with 
PI compared to the no PI control (n = 6). 
 
 
 
 
 
 
Figure C.2. Summary of anti-inflammatory cytokines released from red blood cells into 
PBS over 24 hours and in the corresponding red blood cell lysate at 37 °C with or without 
protease inhibitors (PI) as measured by Bio-Plex and reported as fluorescence (100 million 
cells in 1 mL PBS). Data are presented as mean fold change after addition of PI ± 95% CI, 
where  represents fold change in conditioned media of PI treatment compared to the no PI 
control, and  represents fold change in fluorescence in lysate of red blood cells treated with 
PI compared to the no PI control (n = 6). 
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Figure C.3. Summary of chemokines released from red blood cells into PBS over 24 hours 
and in the corresponding red blood cell lysate at 37 °C with or without protease inhibitors (PI) 
as measured by Bio-Plex and reported as fluorescence (100 million cells in 1 mL PBS). Data 
are presented as mean fold change after addition of PI ± 95% CI, where  represents fold 
change in conditioned media of PI treatment compared to the no PI control, and  represents 
fold change in fluorescence in lysate of red blood cells treated with PI compared to the no PI 
control (n = 6). 
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Figure C.4. Summary of growth factors released from red blood cells into PBS over 24 
hours and in the corresponding red blood cell lysate at 37 °C with or without protease inhibitors 
(PI) as measured by Bio-Plex and reported as fluorescence (100 million cells in 1 mL PBS). 
Data are presented as mean fold change after addition of PI ± 95% CI, where  represents fold 
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change in conditioned media of PI treatment compared to the no PI control, and  represents 
fold change in fluorescence in lysate of red blood cells treated with PI compared to the no PI 
control (n = 6). 
 
 
 
 
 
 
Figure C.5. Summary of cytokines with multiple functions released from red blood cells 
into PBS over 24 hours and in the corresponding red blood cell lysate at 37 °C with or without 
protease inhibitors (PI) as measured by Bio-Plex and reported as fluorescence (100 million 
cells in 1 mL PBS). Data are presented as mean fold change after addition of PI ± 95% CI, 
where  represents fold change in conditioned media of PI treatment compared to the no PI 
control, and  represents fold change in fluorescence in lysate of red blood cells treated with 
PI compared to the no PI control (n = 6). 
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APPENDIX 
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Figure D.1. Summary of pro-inflammatory cytokines in red blood cell lysate after 
incubation into PBS over 24 hours at 37 °C with or without recombinant protein and protease 
inhibitors (PI) as measured by Bio-Plex and reported as fluorescence (100 million red blood 
cells in 1 mL PBS). Data are presented as fold change after addition of recombinant protein ± 
95% CI, where  represents fold change in cytokine profile of lysate with exogenous 
recombinant protein compared to control, and  represents fold change in cytokine profile of 
lysate with PI, with addition of exogenous recombinant protein compared to control (n = 5). 
 
 
 
 
 
 
Figure D.2. Summary of anti-inflammatory cytokines in red blood cell lysate after 
incubation into PBS over 24 hours at 37 °C with or without recombinant protein and protease 
inhibitors (PI) as measured by Bio-Plex and reported as fluorescence (100 million red blood 
cells in 1 mL PBS). Data are presented as fold change after addition of recombinant protein ± 
95% CI, where  represents fold change in cytokine profile of lysate with exogenous 
recombinant protein compared to control, and  represents fold change in cytokine profile of 
lysate with PI, with addition of exogenous recombinant protein compared to control (n = 5). 
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Figure D.3. Summary of chemokines in red blood cell lysate after incubation into PBS over 
24 hours at 37 °C with or without recombinant protein and protease inhibitors (PI) as measured 
by Bio-Plex and reported as fluorescence (100 million red blood cells in 1 mL PBS). Data are 
presented as fold change after addition of recombinant protein ± 95% CI, where  represents 
fold change in cytokine profile of lysate with exogenous recombinant protein compared to 
control, and  represents fold change in cytokine profile of lysate with PI, with addition of 
exogenous recombinant protein compared to control (n = 5). 
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Figure D.4. Summary of growth factors in red blood cell lysate after incubation into PBS 
over 24 hours at 37 °C with or without recombinant protein and protease inhibitors (PI) as 
measured by Bio-Plex and reported as fluorescence (100 million red blood cells in 1 mL PBS). 
Data are presented as fold change after addition of recombinant protein ± 95% CI, where  
represents fold change in cytokine profile of lysate with exogenous recombinant protein 
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compared to control, and  represents fold change in cytokine profile of lysate with PI, with 
addition of exogenous recombinant protein compared to control (n = 5). 
 
 
 
 
 
Figure D.5. Summary of cytokines with multiple factors in red blood cell lysate after 
incubation into PBS over 24 hours at 37 °C with or without recombinant protein and protease 
inhibitors (PI) as measured by Bio-Plex and reported as fluorescence (100 million red blood 
cells in 1 mL PBS). Data are presented as fold change after addition of recombinant protein ± 
95% CI, where  represents fold change in cytokine profile of lysate with exogenous 
recombinant protein compared to control, and  represents fold change in cytokine profile of 
lysate with PI, with addition of exogenous recombinant protein compared to control (n = 5).
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APPENDIX 
E  
---------------------------------------------------------------------------  
 
 
E.1  METHODS 
E.1.1  Statistics analysis of multiplex Luminex® data 
Statistical analysis of raw fluorescence responses was performed using ‘R’ version 3.2.3 (2015-
12-10, R: A Language and Environment for Statistical Computing). Mixed-effects modelling 
was done using lmer1. The significance of interactions terms and interaction means and their 
associated standard errors were obtained using the Phia package2, for post-hoc analysis. 
Multiple test correction was done according to Holm’s method3. To analyse the fluorescence 
response, the following mixed-effects model, in R notation, was used: 
 
Equation E.1 Mixed-effects model for statistical analysis of cytokine data. 
log2ሺFIሻ~Cytokine ∗ Treatment ൅ ሺ1|kit: IDሻ 
 
The analysis was performed separately for red blood cells lysates and conditioned media 
samples. Where the log2 of fluorescence responses (Fl) was modelled using 2-way mixed 
effects ANOVA, (1) Cytokine (48 levels), and (2) Treatment (2 levels for red blood cell lysates: 
unprimed red blood cells, or primed red blood; 4 levels for conditioned media: none, PHA, 
unprimed red blood cells, or primed red blood cells) plus their interactions, together with one 
random term defined as (1|kit:ID), where ID represented subject identifier and where kit 
represented the 27-plex and 21-plex cytokine panels (2 levels). The random effects account for 
patient-to-patient variability and for differences with respect to kit groupings across the 2 
cytokine plates, it also accounted for the non-independence in the data due to multiple samples 
per subject. Goodness-of-fit of the model for the data was determined by visual analysis of the 
residuals on a Q-Q plot and deviation of the mean from zero on a box plot.
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E.2   RESULTS AND DISCUSSION 
To validate the model for use with this dataset, a visual inspection of the residuals was 
completed. The following plots demonstrate that the data were normally distributed and there 
was minimal deviation from zero (Figure E.1). Similarly, the Q-Q plots demonstrate that the 
data is linear and the model is a good fit with small residuals (Figure E.2). This data 
demonstrates that the model used in this analysis was appropriate for the dataset. The goodness-
of-fit for the model used in the red blood cell lysate analysis had a similar profile to the plots 
observed here. Thus, the models in this study were appropriate for the datasets. 
 
Figure E.1. Box plots of the residuals and distribution of cytokine data from the PBMC 
conditioned media as measured by Bio-Plex and reported as fluorescence ± 95 % CI (n = 7).
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Figure E.2. Q-q-plots testing for normality of residuals from the cytokine data in the PBMC 
conditioned media as measured by Bio-Plex and reported as fluorescence (n = 7). 
 
E.3  REFERENCES 
1. Bates, D., Mächler, M., Bolker, B. M. & Walker, S. C. Fitting linear mixed-effects 
models using lme4. J Stat Softw 67, 1–51 (2014). 
2. Rosario-Martinez, H. De. Phia: post-hoc interaction analysis. R Package version 01-3 
(2015). 
3. Holm, S. A simple sequentially rejective multiple test procedure. Scand J Stat 6, 65–70 
(1979). 
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APPENDIX 
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Figure F.1. Summary of pro-inflammatory cytokines in the red blood cell lysates prior to 
incubation (T0) and of primed (pRBC) and unprimed (upRBC) red blood cells after incubation 
(T3) as measured by Bio-Plex and reported as fluorescence (100 million cells in 1 mL PBS). 
Data are presented as mean fold change of fluorescence ± 95 % CI (n = 12), where ● represents 
the fold change for unprimed red blood cells before and after incubation and ■ for primed cells 
before and after incubation, and ▲ represents the fold change in fluorescence between 
unprimed and primed red blood cells (T3). Data are statistically significant different (*) if 
p < 0.05, (**) if p < 0.01, (***) if p < 0.001, (****) if p < 0.0001. 
 
 
 
 
 
Figure F.2. Summary of anti-inflammatory cytokines in the red blood cell lysates prior to 
incubation (T0) and of primed (pRBC) and unprimed (upRBC) red blood cells after incubation 
(T3) as measured by Bio-Plex and reported as fluorescence (100 million cells in 1 mL PBS). 
Data are presented as mean fold change of fluorescence ± 95 % CI (n = 12), where ● represents 
the fold change for unprimed red blood cells before and after incubation and ■ for primed cells 
before and after incubation, and ▲ represents the fold change in fluorescence between 
unprimed and primed red blood cells (T3). Data are statistically significant different (*) if 
p < 0.05, (**) if p < 0.01, (***) if p < 0.001, (****) if p < 0.0001. 
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Figure F.3. Summary of chemokines in the red blood cell lysates prior to incubation (T0) 
and of primed (pRBC) and unprimed (upRBC) red blood cells after incubation (T3) as 
measured by Bio-Plex and reported as fluorescence (100 million cells in 1 mL PBS). Data are 
presented as mean fold change of fluorescence ± 95 % CI (n = 12), where ● represents the fold 
change for unprimed red blood cells before and after incubation and ■ for primed cells before 
and after incubation, and ▲ represents the fold change in fluorescence between unprimed and 
primed red blood cells (T3). Data are statistically significant different (*) if p < 0.05, (**) if 
p < 0.01, (***) if p < 0.001, (****) if p < 0.0001. 
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Figure F.4. Summary of growth factors in the red blood cell lysates prior to incubation 
(T0) and of primed (pRBC) and unprimed (upRBC) red blood cells after incubation (T3) as 
measured by Bio-Plex and reported as fluorescence (100 million cells in 1 mL PBS). Data are 
presented as mean fold change of fluorescence ± 95 % CI (n = 12), where ● represents the fold 
change for unprimed red blood cells before and after incubation and ■ for primed cells before 
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and after incubation, and ▲ represents the fold change in fluorescence between unprimed and 
primed red blood cells (T3). Data are statistically significant different (*) if p < 0.05, (**) if 
p < 0.01, (***) if p < 0.001, (****) if p < 0.0001. 
 
 
 
 
 
Figure F.5. Summary of cytokines with multiple functions in the red blood cell lysates 
prior to incubation (T0) and of primed (pRBC) and unprimed (upRBC) red blood cells after 
incubation (T3) as measured by Bio-Plex and reported as fluorescence (100 million cells in 
1 mL PBS). Data are presented as mean fold change of fluorescence ± 95 % CI (n = 12), where 
● represents the fold change for unprimed red blood cells before and after incubation and ■ for 
primed cells before and after incubation, and ▲ represents the fold change in fluorescence 
between unprimed and primed red blood cells (T3). Data are statistically significant different 
(*) if p < 0.05, (**) if p < 0.01, (***) if p < 0.001, (****) if p < 0.0001.
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APPENDIX 
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Figure G.1. Summary of pro-inflammatory cytokines in Jurkat conditioned media as 
measured by Bio-Plex and reported as fluorescence. Data are presented as mean fold change 
from the untreated Jurkat control in fluorescence ± 95 % CI (n = 5), where ● represents the 
fold change for untreated Jurkat, ■ for Jurkat cells treated with unprimed red blood cells 
(upRBC), and ▲ for Jurkat cells treated with primed red blood cells (pRBC). Data are 
statistically significant different from the untreated Jurkat control (*) if p < 0.05, (**) if 
p < 0.01, (***) if p < 0.001, (****) if p < 0.0001. 
 
 
 
 
 
 
Figure G.2. Summary of anti-inflammatory cytokines in Jurkat conditioned media as 
measured by Bio-Plex and reported as fluorescence. Data are presented as mean fold change 
from the untreated Jurkat control in fluorescence ± 95 % CI (n = 5), where ● represents the 
fold change for untreated Jurkat, ■ for Jurkat cells treated with unprimed red blood cells 
(upRBC), and ▲ for Jurkat cells treated with primed red blood cells (pRBC). Data are 
statistically significant different from the untreated Jurkat control (*) if p < 0.05, (**) if 
p < 0.01, (***) if p < 0.001, (****) if p < 0.0001. 
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Figure G.3. Summary of chemokines in Jurkat conditioned media as measured by Bio-Plex 
and reported as fluorescence. Data are presented as mean fold change from the untreated Jurkat 
control in fluorescence ± 95 % CI (n = 5), where ● represents the fold change for untreated 
Jurkat, ■ for Jurkat cells treated with unprimed red blood cells (upRBC), and ▲ for Jurkat cells 
treated with primed red blood cells (pRBC). Data are statistically significant different from the 
untreated Jurkat control (*) if p < 0.05, (**) if p < 0.01, (***) if p < 0.001, (****) if p < 0.0001. 
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Figure G.4. Summary of growth factors in Jurkat conditioned media as measured by Bio-
Plex and reported as fluorescence. Data are presented as mean fold change from the untreated 
Jurkat control in fluorescence ± 95 % CI (n = 5), where ● represents the fold change for 
untreated Jurkat, ■ for Jurkat cells treated with unprimed red blood cells (upRBC), and ▲ for 
Jurkat cells treated with primed red blood cells (pRBC). Data are statistically significant 
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different from the untreated Jurkat control (*) if p < 0.05, (**) if p < 0.01, (***) if p < 0.001, 
(****) if p < 0.0001. 
 
 
 
 
 
Figure G.5. Summary of cytokines with multiple functions in Jurkat conditioned media as 
measured by Bio-Plex and reported as fluorescence. Data are presented as mean fold change 
from the untreated Jurkat control in fluorescence ± 95 % CI (n = 5), where ● represents the 
fold change for untreated Jurkat, ■ for Jurkat cells treated with unprimed red blood cells 
(upRBC), and ▲ for Jurkat cells treated with primed red blood cells (pRBC). Data are 
statistically significant different from the untreated Jurkat control (*) if p < 0.05, (**) if 
p < 0.01, (***) if p < 0.001, (****) if p < 0.0001. 
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APPENDIX 
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Figure H.1. Summary of pro-inflammatory cytokines in PBMC (peripheral blood 
mononuclear cells) conditioned media as measured by Bio-Plex and reported as 
fluorescence ± 95 % CI (n = 7). Data are presented as mean fold change from ■ PBMC treated 
with PHA-P, to ● untreated PBMCs, ▲ for PBMCs treated with PHA-P and unprimed red 
blood cells (upRBC), and ▼ for PBMCs treated with PHA-P and primed red blood cells 
(pRBC). Fold change from PBMCs treated with PHA-P and upRBCs to PBMCs treated with 
PHA-P and pRBCs represented by ○ (open circle). Data are statistically significant different 
from PBMCs treated with PHA-P (*) if p < 0.05, (**) if p < 0.01, (***) if p < 0.001, (****) if 
p < 0.0001. 
 
 
 
 
Figure H.2. Summary of anti-inflammatory cytokines in PBMC (peripheral blood 
mononuclear cells) conditioned media as measured by Bio-Plex and reported as 
fluorescence ± 95 % CI (n = 7). Data are presented as mean fold change from ■ PBMC treated 
with PHA-P, to ● untreated PBMCs, ▲ for PBMCs treated with PHA-P and unprimed red 
blood cells (upRBC), and ▼ for PBMCs treated with PHA-P and primed red blood cells 
(pRBC). Fold change from PBMCs treated with PHA-P and upRBCs to PBMCs treated with 
PHA-P and pRBCs represented by ○ (open circle). Data are statistically significant different 
from PBMCs treated with PHA-P (*) if p < 0.05, (**) if p < 0.01, (***) if p < 0.001, (****) if 
p < 0.0001. 
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Figure H.3. Summary of chemokines in PBMC (peripheral blood mononuclear cells) 
conditioned media as measured by Bio-Plex and reported as fluorescence ± 95 % CI (n = 7). 
Data are presented as mean fold change from ■ PBMC treated with PHA-P, to ● untreated 
PBMCs, ▲ for PBMCs treated with PHA-P and unprimed red blood cells (upRBC), and ▼ for 
PBMCs treated with PHA-P and primed red blood cells (pRBC). Fold change from PBMCs 
treated with PHA-P and upRBCs to PBMCs treated with PHA-P and pRBCs represented by ○ 
(open circle). Data are statistically significant different from PBMCs treated with PHA-P (*) 
if p < 0.05, (**) if p < 0.01, (***) if p < 0.001, (****) if p < 0.0001. 
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Figure H.4. Summary of growth factors in PBMC (peripheral blood mononuclear cells) 
conditioned media as measured by Bio-Plex and reported as fluorescence ± 95 % CI (n = 7). 
Data are presented as mean fold change from ■ PBMC treated with PHA-P, to ● untreated 
PBMCs, ▲ for PBMCs treated with PHA-P and unprimed red blood cells (upRBC), and ▼ for 
PBMCs treated with PHA-P and primed red blood cells (pRBC). Fold change from PBMCs 
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treated with PHA-P and upRBCs to PBMCs treated with PHA-P and pRBCs represented by ○ 
(open circle). Data are statistically significant different from PBMCs treated with PHA-P (*) 
if p < 0.05, (**) if p < 0.01, (***) if p < 0.001, (****) if p < 0.0001. 
 
 
 
 
 
Figure H.5. Summary of cytokines with multiple functions in PBMC (peripheral blood 
mononuclear cells) conditioned media as measured by Bio-Plex and reported as 
fluorescence ± 95 % CI (n = 7). Data are presented as mean fold change from ■ PBMC treated 
with PHA-P, to ● untreated PBMCs, ▲ for PBMCs treated with PHA-P and unprimed red 
blood cells (upRBC), and ▼ for PBMCs treated with PHA-P and primed red blood cells 
(pRBC). Fold change from PBMCs treated with PHA-P and upRBCs to PBMCs treated with 
PHA-P and pRBCs represented by ○ (open circle). Data are statistically significant different 
from PBMCs treated with PHA-P (*) if p < 0.05, (**) if p < 0.01, (***) if p < 0.001, (****) if 
p < 0.0001 
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APPENDIX 
I  
--------------------------------------------------------------------------- 
 
The data in this thesis have been included in three patent applications as outlined below.  
 
Title of patent Date of filing Status 
Blood preparation and profiling October 2015 PCT 
Therapeutic methods using erythrocytes December 2015 PCT 
Blood profiling with protease inhibitors December 2016 Provisional 
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